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Abstract 
 
Exploring the genetic basis of monogenic disorders imparts fundamental insights 
into human molecular biology. Moreover, cataloguing and describing pathogenic 
mutations offers new genetic tests to diagnose and identify mutation carriers 
worldwide. Sometimes, reaching a genetic diagnosis provides long sought-after 
answers for patients and their families. Likewise, comprehending the genetic and 
clinical spectrum of rare disorders aids clinicians in managing their patients. 
Further, clinical knowledge obtained from genetic studies allows clinicians to 
anticipate and screen for potential complications.  
Founder populations experience higher burdens of certain Mendelian 
disorders and thereby provide unique circumstances to conduct genetic studies. 
Several founder populations exist in the Canadian province of Newfoundland & 
Labrador. These have proven instrumental for genetic discoveries. My thesis 
investigated the genetic basis of three Mendelian disorders in families from 
Newfoundland. These disorders include retinitis pigmentosa, Weill-Marchesani 
Syndrome and hereditary colorectal cancer.  
First, whole exome sequencing and linkage analyses were employed to 
investigate retinitis pigmentosa in a large kindred living on the Great Northern 
Peninsula of Newfoundland. This identified a linked region on chromosome 2 
(logarithm of the odds 4.89 [θ = 0]) encompassing a novel pathogenic 25 kb deletion 
(c.845-1450del; p.Ala282_His483del) in MERTK, which segregated in the family. The 
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molecular features and clinical manifestations of the deletion were characterized 
and study findings were explained to family members.  
Next, Weill-Marchesani Syndrome was investigated in a Newfoundland 
family using whole exome sequencing and homozygosity mapping. This identified a 
novel homozygous pathogenic missense variant (c.3068G>A, p.C1023Y) in 
ADAMTS17. Transfection of ADAMTS17 p.C1023Y expression plasmids into 
HEK293T cells revealed significantly reduced secretion of ADAMTS17 into the 
extracellular matrix. The clinical and molecular consequences of the variant were 
characterized and the family members were counselled.  
Finally, candidate gene screening of GALNT12 in a cohort of 479 colorectal 
cancer cases from Newfoundland identified eight rare variants (p.Asp303Asp; 
p.Arg297Trp; p.His101Gln; p.Ile142Thr; p.Glu239Gln; p.Thr286Met; p.Val290Phe; 
c.732-8G>T), which were overrepresented in cases compared to controls (N=400) 
(P=0.0381). Six of eight variants showed reduced GALNT12 enzyme activity, 
providing supportive evidence of a role for this gene in colorectal cancer. In 
summary, each study above imparted novel insights into genetic disorders in 
Newfoundland. 
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Foreword 
 
"Nature is nowhere accustomed more openly to display her secret 
mysteries than in cases where she shows traces of her workings 
apart from the beaten path; nor is there any better way to advance 
the proper practice of medicine than to give our minds to the 
discovery of the usual law of Nature by careful investigation of 
cases of rarer forms of disease. For it has been found, in almost all 
things, that what they contain of useful or applicable is hardly 
perceived unless we are deprived of them, or they become 
deranged in some way." 
Sir William Harvey as translated by Sir Archibald Garrod (1928) 
 
 “There are many of us to whom a scientific research appeals in 
proportion to its practical utility, and others for whom a discovery 
loses much of its charm when applied to practical uses. So, too, I 
take it, there have always been, and always will be, many members 
of our profession to whom the study of those common diseases 
which are of so great practical importance, and to cope with which 
is the daily task of the medical man, make the strongest appeal, 
whereas for others, who form but a small minority, the 
investigation of rare maladies has a special attraction.” 
Sir Archibald Garrod (1928) 
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Chapter 1.  Overview: Mendelian Genetics and Unique Aspects of the 
Newfoundland & Labrador Founder Populations 
 
1.1 Genetic Discovery  
 
For me, nothing is more exciting than pursuing a potential genetic discovery. These 
moments of enthusiasm sustained me during my M.D. and Ph.D. programs 
(Memorial University of Newfoundland). This thesis outlines genetic discoveries 
garnered from the investigation of three Mendelian disorders: retinitis pigmentosa 
(RP), Weill-Marchesani Syndrome (WMS) and hereditary predisposition for 
colorectal cancer (CRC). The aim of each research project was to apply modern 
genetic strategies to uncover novel genes and characterize variants implicated in 
unsolved Mendelian disorders in Newfoundland & Labrador (NL). The purpose of 
the endeavor was to reach a genetic diagnosis for NL families (and potentially others 
worldwide), while gaining insight into pathologic mechanisms underlying each 
disorder. 
In this general introductory section, I review the importance and purpose of 
Mendelian disease gene exploration and describe how technological advances have 
shifted the paradigm of genetic discovery. I then discuss the importance of genetic 
isolates for Mendelian discovery, before acquainting the reader with unique aspects 
of the NL population. Thereafter, each proceeding thesis chapter examines an 
independent research project investigating one of the three Mendelian disorders 
listed previously. Such studies expand our knowledge of the pathogenesis of these 
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disorders, further our understanding of the unique founder populations of NL and 
provide answers to family members. 
Such studies would not be possible without the generosity and kindness of all 
research study participants, who contributed their personal and family histories, as 
well as their biological heritage. Certainly, these gifts are what drive genetic 
discoveries. Given such substantial contributions, an emergent question becomes – 
what are Mendelian disorders, and why do we study them? 
1.2 Study of Mendelian Disorders  
 
Mendelian disorders are phenotypes caused by genetic aberration and germline 
transmission of a single altered gene product or locus (i.e. monogenic inheritance). 
These alterations cause observable or measurable phenotypes. Studying Mendelian 
disorders provides fundamental clues into the pathophysiology of human diseases. 
Indeed, renowned clinician-scientist Sir Archibald Garrod (1857-1936) once said “…we find in rare diseases the keys to not a few dark places of physiology and 
pathology” (Garrod, 1928). Understanding basic science can unlock keys to many 
clinically impactful questions. 
Genetic discovery allows clinicans to diagnose Mendelian disorders based on 
genetic tests. Early genetic diagnoses can provide individuals with life-saving 
foreknowledge about potentially fatal conditions. For example, in Arrhythmogenic 
Right Ventricular Cardiomyopathy Type 5 (ARVC5), identifying mutation carriers is 
valuable; as individuals predisposed to sudden cardiac death can receive 
implantable cardioverter defibrillators (Hodgkinson et al., 2005).  
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Carrier identification is also important in the medical management of 
Mendelian disorders such as phenylketonuria, which is treatable by dietary 
restriction of phenylalanine (MacLeod & Ney, 2010). Likewise, identifying affected 
carriers for Mendelian conditions such as WMS can help recommend patients for 
screening of common complications such as thoracic anuerysms (see Section 3.1). 
Similarly, identifying individuals who carry pathogenic mutations for hereditary 
cancer predisposition can greatly reduce mortality of the disease by enrollment in 
tailored surveillence programs.  
Identifying non-carriers by genetic testing may also re-assure individuals that 
they do not possess a particular pathogenic mutation. Moreover, these individuals 
can avoid the tailored surveillance regimens of their affected family members. This 
practice not only reduces patient anxiety associated with these screening tests, it 
also reduces healthcare costs associated with unnecessary testing. Lastly, an 
important role for distinguishing between both carrier and non-carrier status exists 
for genetic counselling and family planning purposes. 
The ability to find new causal genes and then develop genetic testing for 
individuals suspected of harboring a Mendelian disorder is largely dependent on 
sequencing technology. Historically, rapid advances in these DNA sequencing 
technologies have greatly facilitated genetic discoveries for many Mendelian 
disorders. 
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1.3 Technology Drives Genetic Discoveries 
 
Historically, Sanger DNA sequencing and genetic mapping were critical tools for 
genetic discovery. For example, by 1983, genetic linkage analysis identified a critical 
disease interval for Huntington disease on chromosome 4 (Gusella et al., 1983), after 
which the trinucleotide repeat expansion of the gene HTT was discovered 
(MacDonald et al., 1993). By 1986, a positional cloning study identified the first gene 
(CYBB) for a Mendelian disorder (i.e. x-linked chronic granulomatous disease), 
without any prior isolation of the affected protein (Royer-Pokora et al., 1986). Later, 
the same method uncovered the role of CFTR in cystic fibrosis, which was the first 
gene for an autosomal recessive disorder (Riordan et al., 1989). The increasing 
sophistication of genetic mapping and sequencing strategies led to a dramatic rise in 
the number of genes mapped to online databases, which grew from approximately 
500 genes in early 1980 to nearly 3000 in 1993 (McKusick, 2007). 
By 1990, approval of the Human Genome Project provided three billion 
dollars over a 15 year period to assemble a human reference genome (International 
Human Genome Sequencing Consortium, 2001). This project eventually led to the 
development of massively parallel sequencing (MPS) or ‘next-generation’ DNA 
sequencing (Heather & Chain, 2016). Next-generation sequencing is a catchall term 
referring to technologies that are successors to Sanger DNA sequencing. These 
methods capture much larger volumes of sequence data compared with Sanger 
sequencing. For example, coverage of entire genomes at substantial read depth is 
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achieved with next-generation sequencing, as compared with Sanger, which 
captures only short 200-1000 base pair fragements of a single locus of the genome.  
Next-generation sequencing begins with capture of the target region by 
binding (i.e. hybridization) of probes to target regions of the genome. Target regions 
can include specific loci, the entire protein coding region of the genome (i.e. exome), 
or the entire genome. DNA in captured regions is then amplified by clonal 
amplification of DNA fragments, after which DNA sequencing commonly using 
reversible dye terminators allows for generation of vast quantities of data 
(Voelkerding et al., 2009) (Figure 1.1). Raw sequence data is then managed by 
variant annotation and filtering pipelines to identify novel disease-associated 
variants (Goh & Choi, 2012) (Figure 1.2). 
Ultimately, the first personal human genome was sequenced (i.e. genome of 
Craig Venter), at a cost of approximately 100 million dollars (Levy et al., 2007). Early 
on, next-generation DNA sequencing (i.e. whole exome and whole genome 
sequencing) was too expensive for use in research studies. Initial cost estimates for 
clinical genome sequencing were between 25 and 50 million dollars (Schwarze et al., 
2018). By 2004, the US National Human Genome Research Institute funded the ‘Advanced Sequencing Technology Awards’, which were a series of grants for 
technology companies to innovate cheaper sequencing methods, with the hope of 
reaching a ‘$1000 genome’ price range (Hayden, 2014). The cost of next-generation 
sequencing eventually dropped to 10 million dollars per genome, and eventually to 
several thousand dollars (Dewey et al., 2012). 
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Figure 1.1 Whole Exome Sequencing Using Reversible Dye Terminators. 
Reprinted from Voelkerding et al., (2009) with copyright permission. 
 
This figure shows the general process of whole exome sequencing using reversible chain 
terminators. Adaptor molecules anchor DNA fragments to a flow cell. Each DNA fragment 
multiplies by bridge amplification. Reversible dye terminators are sequentially added and 
exposed to a fluorophore as the DNA polymerase (POL) reaction proceeds in this 
sequencing-by-synthesis method. 
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Figure 1.2 DNA Sequencing and Data Management Pipeline for Whole Exome 
Sequencing. Reprinted from Goh & Choi (2012) with Copyright Permission 
under Creative Commons  Attribution Non-Commercial License.  
This figure shows whole exome capture and DNA sequencing on a next-generation DNA 
sequencing platform, the raw data is processed through a computational pipeline to first call 
base pairs, then map reads to the human reference genome, and finally trim reads based on 
quality thresholds. Next, variants and indels are identified and annotated based on known 
gene function and reported allele frequencies among other metrics, before filtering variants 
to identify a disease-associated variant.   
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Given the precipitous decrease in next-generation DNA sequencing costs, 
Mendelian discovery studies could begin pursing whole exome sequencing by 2008.  
By 2010, the first study to use whole exome sequencing to identify a novel 
disease-causing gene (DHODH) for a Mendelian disorder (Miller Syndrome) was 
published (Ng et al., 2010). In fact, another 13 novel gene discoveries for 
Mendelian discoveries were made in 2010 using next-generation sequencing 
(Rabbani et al., 2012). By 2011, a further 54 new candidate genes were identified 
for various Mendelian disorders, and by May 2012 -- over 100 new gene 
discoveries were made.   
It soon was clear that the dogma of genetic mapping and Sanger sequencing 
studies was giving way to a paradigm shift toward next-generation sequencing 
technology. The work of this thesis began in 2012, shortly after the first 
commercial (i.e. mass-produced) whole exome sequencers became accessible in 
Canada. An early national initiative called ‘The Finding of Rare Disease Genes’ 
(FORGE) Canada Consortium was funded to facilitate research studies into unsolved 
Mendelian disorders by providing the infrastructure and bioinformatic expertise 
necessary, which was not widely available in Canada at the time (Beaulieu et al., 
2014).  
This broad initiative encompassed 21 genetic centers across 10 provinces of 
Canada, involving approximately 95 clinical geneticists and 170 other FORGE 
members (i.e. pediatric subspecialists, molecular biologists, genetic researchers). 
With the increasing availability of whole genome sequencing data, new revelations 
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about the frequency of rare genetic variants soon emerged. The next section 
discusses how next-generation sequencing has influenced our ability to determine 
pathogenic mutations with confidence.  
1.4 Refinement of ‘Disease-causing Mutations’ in the Genomic Era 
 
The Human Gene Mutation Database (HGMD) is an online catalog of all genetic 
variants responsible for inherited diseases as well as disease-associated or 
functional polymorphisms (Stenson et al., 2017). At present, HMGD lists more than 
224,000 germline mutation entries, including missense, nonsense, splice variants, as 
well as structural changes (http://www.hgmd.cf.ac.uk/ac/index.php).  There are 
127,200 HMGD missense and nonsense variants described, with splicing variants 
accounting for 20,132 entries. Meanwhile, small deletions and small insertions 
account for 33,090 and 13,864 entries respectively (October 2018). Following 
widespread next-generation DNA sequencing initiatives, it soon became clear that 
higher standards were needed for variant interpretation, as genomes and exomes of 
healthy individuals showed an excessive number of previously reportedly disease-
causing mutations (Abouelhoda et al., 2016; Bell et al., 2011; MacArthur et al., 2014; 
Wang and Shen, 2014).  
For example, Xue and co-authors examined preliminary whole genome data 
from 179 individuals of the 1000 genomes pilot project (Xue et al., 2012). Among the 
179 healthy control genomes examined, there were 577 variants classified as ‘disease-causing mutations’ according to HGMD – indicating many of the healthy 
individuals carried alleles thought to be highly penetrant for Mendelian disorders. 
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There were also 191 apparently disease mutations in the homozygous state in these 
healthy controls. On average, between 40 and 110 disease causing mutations were 
carried by each individual, and 3 to 24 of these variants (per patient) were 
homozygous. These findings strongly suggested that numerous variants in HGMD 
were likely falsely reported as pathogenic mutations. This was in part due to HGMD 
reporting criteria, whereby a variant was determined to be disease causing based 
solely on what was published in the literature. It soon became clear that peer-
reviewed publication were not enough to define pathogenicity, and clinicians 
needed a system to describe pathogenic variants in more rigid terms.   
 This led the American College of Medical Genetics and Genomics (ACMG) to 
adopt a five-tier terminology system (i.e. pathogenic, likely pathogenic, variant of 
uncertain significance, likely benign and benign) to categorize our varied 
understanding of the effects of genetic variants, with the intention of avoiding false 
positives in clinical care (Richards et al., 2015).  
 Using this five-tiered framework, the strength of evidence supporting or 
refuting pathogenicity can be weighed. For example, Table 1.1 shows a list of criteria 
for assessing the pathogenicity of a variant. One of the strongest levels of evidence 
for pathogenicity (i.e. very strong pathogenic) occurs when there is a null variant in 
a gene known to cause a Mendelian disorder, and a loss of function mechanism has 
already been proven. It is intuitive to see how this would be very strong evidence to 
support pathogenicity. For the next level, that is, ‘strong’ support of pathogenicity, a 
number of pieces of evidence can be considered, including well-established in vitro 
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or animal studies that indicate damaging consequences to the gene or protein 
product. An alternative strong supporting criterion (PS4) occurs when the 
prevalence of a variant is significantly higher in cases compared to population 
controls.  
 Conversely, more ‘moderate’ evidence to suggest pathogenicity (i.e. PM5) 
would be an instance of a novel missense variant being found in a gene that has 
previously discovered disease causing missense variants; whereas weaker ‘supporting’ evidence (i.e. PP3) would be an instance where multiple in silico tools 
suggest a deleterious effect. There are separate criteria for defining variants as ‘benign’ also. Multiple pieces of evidence can then be used to classify a variant 
overall as either clinically pathogenic, likely pathogenic, uncertain significance, 
likely benign or benign (Table 1.2).  
           Although the ACMG scoring system is still rather primitive, it provides an 
initial point of agreement for what should be called pathogenic verses benign. 
Unfortunately, the ACMG guidelines do not take into account much of context and 
disease specific data that is present in the literature – particularly for well-studied 
disorders such as CRC. This led to the creation of several disease-specific expert 
panels which implement a more detailed ACMG-like scoring system that is more 
effective at determining variant pathogenicity (Thompson et al., 2014). 
The ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/) represents the 
culmination of an effort to score all potential disease causing variants using ACMG  
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Table 1.1 ACMG guidelines for assessing pathogenicity of a candidate variant 
using a multi-tiered evidence-based assessment scheme. Reprinted from 
Richards et al., (2015) with copyright permission. 
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Table 1.2 ACMG guidelines for stratifying variants into categories based on 
evidence assessments. Reprinted with permission from Richards et al., (2015).  
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guidelines and focus on the clinically actionable using the ACMG guidelines 
(Landrum et al., 2016).  ClinVar restricts entries to assertions based on the ACMG 
five tiered confidence system and uses only a limited pool of recognized data 
submitters (i.e. clinical testing laboratories, genetics clinics and researchers). 
According to ClinVar, there are 74,824 high confidence ‘pathogenic’ Mendelian 
variants, and 5,504 ‘likely pathogenic variants’. The next section emphasizes the 
global burden of Mendelian disorders, and key considerations in applying special 
populations (i.e. founder populations) for discovery of new genetic variants. 
1.5 The Burden of Mendelian Disorders  
 
The Online Mendelian Inheritance of Man (OMIM) is a vast repository of collective 
knowledge about Mendelian and complex traits (Amberger et al., 2015). OMIM 
periodically updates and synthesizes descriptions as new genes and phenotypes 
become available. As of October 2018, OMIM described an impressive 5,173 
phenotypes and 3,548 genes causing Mendelian traits or disorders  
(https://www.omim.org/statistics/geneMap). Approximately 300 new Mendelian 
phenotypes are described annually (Chong et al., 2015). Moreover, total OMIM 
entries have risen every month since the inception of the database in 1995. The 
dramatic rise in OMIM entries coincides with increasing sophistication of genetic 
mapping and gene discovery strategies.  
Given the observation that more than 17% of an estimated 20,000 human 
genes are now linked to a Mendelian trait or disorder, Mendelian genetics clearly 
affects a wide swath of our biology, and consequently, the human condition. Many 
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organ systems and physiological processes are impacted by Mendelian disorders. 
Broadly, these include ocular disorders (Rattner et al., 1999; Young, 2003), blood 
disorders (Sonati & Costa, 2008), connective tissue disorders (Tilstra and Byers, 
1994), metabolic disorders (Dipple & McCabe, 2000), neurological disorders (Huang 
et al., 2014), cardiovascular diseases (McBride and Garg, 2010), pulmonary 
disorders (Garcia and Raghu, 2004), renal diseases (Hildebrandt, 2010) and 
hereditary cancers (Nagy et al., 2004) among others.  
From both financial and emotional perspectives, there are high burdens 
associated with Mendelian disorders. In the United States for example, the lifetime 
healthcare cost for a person with a genetic disorder is approximately $5,000,000 
(Chong et al., 2015). Meanwhile, some families carry an unidentified gene mutation, 
and the uncertainty regarding if – or when – their genetic disease might strike 
another family member can be anxiety provoking. For other families, this problem 
can be exacerbated by failure to reach a clinical diagnosis in the first place. One 
retrospective study found that patients with mitochondrial disorders visited an 
average of eight clinicians before being diagnosed (Grier et al., 2018). Indeed, 
delayed diagnosis can be a significant source of emotional trauma, known as the “diagnostic odyssey” (Basel & McCarrier, 2017). 
Likewise, the demographic burden of Mendelian disorders is appreciable. 
Population studies demonstrate that genetic disorders occur in 5.32% of all live 
births by age 25 (Chong et al., 2015). In a landmark study, Baird et al. reviewed over 
one million (N=1,169,873) consecutive live births of the British Columbia Health 
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Surveillance Registry. Data was collected from more than 60 provincial health 
registries and encompassed a 25-year period from 1952-1983 (Baird et al., 1988). 
The authors reviewed medical records to assess burden of genetic disease in British 
Columbia, Canada. They found that Mendelian disorders occurred in 0.36% of live 
births: with autosomal dominant (0.014%), autosomal recessive (0.017%) and X-
linked (0.05%) disorders each represented. Moreover, this series does not include 
Mendelian disorders that were lethal in the embryonic stage, nor does it include 
late-onset adult monogenic disorders (i.e. hereditary cancers) diagnosed after age 
25 (Baird et al., 1988; Verma and Puri, 2015).  
Thus, Mendelian disorders are individually rare, but with a substantial 
collective burden. Additionally, geographic factors considerably influence the 
demographic burden of Mendelian disorders. In special cases, isolated founder 
populations may experience higher frequencies of certain Mendelian disorders, 
providing ideal research conditions for genetic discoveries. Such discoveries will 
help to end the diagnostic odyssey for future patients, and provide answers to 
families. 
1.6 Role of Founder Populations in Mendelian Discoveries 
 
Genetic diversity acts as a buffer against autosomal recessive disorders. Gene flow in 
and out of populations are important mechanisms for maintaining genetic diversity 
(Amos & Harwood, 1998). Geographic and/or cultural isolation can cause limited 
flow of genes into a population and thereby reduce genetic diversity. The ‘founder 
effect’ is a special circumstance whereby a small group of individuals (i.e. founders) 
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become geographically and/or culturally isolated from their larger and well-
established population – often owing to migration to a new region (Matute, 2013). 
The new founder population is vulnerable to genetic drift because of its relatively 
small size, and non-random sampling of alleles from the original population.  
Colonization of island populations can lead to founder effects, as geographic 
barriers restrict gene flow in and out of these populations. With a reduction in 
genetic diversity, conditions exist for a higher prevalence of rare disorders -- 
especially autosomal recessive disorders. Moreover, in isolated populations, higher 
rates of consanguinity and inbreeding can then also contribute to genetic 
homogeneity and reduced genetic diversity. Higher disease frequency facilitates 
gene discovery studies as it potentially allows recruitment of more study 
participants with pathogenic mutations on a reduced genetic background due to 
consanguinity.   
Well-recognized founder populations exist around the world and include 
populations of Finland (Norio et al., 1973), Iceland (Kristiansson et al., 2008), 
Quebec (Scriver, 2001), the Netherlands (Zeegers et al., 2004), Sardinia (Chiò et al., 
2011) and NL (Rahman et al., 2003). The province of NL harbors several founder 
populations owing to a unique settlement history and population expansion that has 
resulted in a cluster of genetically distinct isolates residing in geographically 
restricted areas. It is important to understand the structure of this unique 
population in order to design genetic studies.  
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1.7 The Newfoundland & Labrador Founder Populations: Colonization & 
Population Expansion 
 
The province of NL is part of Atlantic Canada, and consists of two geographically 
distinct regions: the large landmass of Labrador (294,330 km2) on the easternmost 
portion of mainland Canada; and the island of Newfoundland (108,860 km2) -- the 
most eastern point of North America.  
Genetic evidence indicates that indigenous peoples arrived in Labrador from 
western Canada around 10,000 calibrated years before present (cal YBP), and 
subsequently migrated to Newfoundland across ice patches in the straight between 
Newfoundland and Labrador nearly 6,000 cal YBP (Duggan et al., 2017). At least 
three indigenous cultural groups (Maritime Archaic, Palaeoeskimo and Beothuk 
peoples) inhabited NL from around 8000 to 200 cal YBP. In 1497, Giovanni Caboto 
(known as “John Cabot”), working by commission of King Henry VII, found and 
claimed Newfoundland for England (Allen, 1992).  Thus began a period of prolonged 
European contact leading to the cultural extinction of the original indigenous 
groups. By the 17th century, only the Beothuk remained. Shanawdithit -- the last of 
the Beothuk peoples -- died in captivity in 1829 (Marshall, 1998). 
While the discovery of Newfoudland occurred in 1497, colonization of the 
island did not begin in earnest until the 1600s. Commercial fishing in the waters 
surrounding NL provided lucrative economic opportunities and was a primary 
driving force in the settlement of the island. Early settlement was therefore seasonal, 
as English and Irish fishermen resided in Newfoundland during the summer and 
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Figure 1.3 The Canadian Province of Newfoundland & Labrador is the most 
eastern point in North America. Reprinted from 
https://commons.wikimedia.org/wiki/File:Newfoundland_and_Labrador_in_C
anada_(modern).svg  and licensed by Allice Hunter under the Creative 
Commons Attribution-Share Alike 4.0 International license. 
 
In this figure, Canada is shaded light blue, while Newfoundland & Labrador is shaded 
dark blue. 
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returned home in the winter. The geographic distribution of most settlements 
around coastal parts of the island reflects this history. These small ‘outport’ 
communities were often geographically restricted from one another, with few roads, 
and many only accessible by boat.  
During this early settlement period, the population ebbed and flowed in an 
unplanned manner, with very slow rates of population growth, punctuated by larger 
expansions driven largely by immigration primarily from Dorset and Devon, 
England. Subsequently, permanent settlement increased while seasonal settlement 
began to decline. Permanent migration to NL reached a pinnacle between 1780 and 
1830 (Mannion, 1977). By 1803, the population of 19,034 would eventually expand 
to 220,249 in 1901 -- this time driven by immigration and natural population 
expansion. Immigants came from several founding populations including English, 
Irish, French and Spanish (Basque).  
 From 1901 onwards, Newfoundland consisted of numerous small outport 
communities separated by rugged coastlines. Within these small communities, 
cultural and religious factors (i.e. Protestant and Catholic denominations) played a 
role in mate selection, as individuals married within their denominations. 
Population expansion continued but with limited in-migration. The population 
increased to a modern day size of about 528,488. Remarkably, 95% of the present 
day population of NL trace their ancestry to either southeast England or southwest 
Ireland (Mannion, 1977) .   
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What we find in Newfoundland is a large number of small genetic isolates, 
with varying degrees of admixture and genetic diversity (Zhai et al., 2016).  
Additional factors provide optimal conditions for genetics research studies. First, 
vital statistics and marriage records from 1840 to 1949 are publically available.  
This, in addition to large family structure, greatly facilitates ancestry tracing and 
pedigree construction. The high incidence of particular Mendelian disorders and the 
recurrence of several founder mutations in nearby communities have played large 
roles in previous NL genetic discoveries. 
1.8 Reviewing Current Understanding of Mendelian Genetics in the 
Newfoundland & Labrador Founder Populations 
 
Extensive investigation of the genetic etiology of the NL population has 
demonstrated that outport communities of NL are genetically heterogeneous with 
numerous founder effects and higher inbreeding (Rahman et al., 2003; Zhai et al., 
2016). The willingness of the population to participate in genetic research studies 
has provided unique insights into the clinical manifestation and natural history of 
numerous genetic diseases, and has played an integral role in gene discovery -- most 
notably for Bardet-Biedl Syndrome (BBS) (i.e. BBS6 discovery), CRC (i.e. MSH2 
discovery) and ARVD5 (TMEM43 discovery). The following is a review of Mendelian 
disorders in the province of NL.  
 Inherited Blood Disorders 1.8.1
 
One of the earliest case reports describing a genetic disorder in NL was the 
characterization of a large family with severe congenital deficiency of factor XIII, 
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which was only the second family in Canada to be reported at the time (Hanna, 
1970). The prevalence of hemophilia A is also quite notable. Early on, clinicians 
recognized a very high incidence of X-linked factor VIII deficiency (i.e. hemophilia 
A), which clustered in communities on the northern shore of Newfoundland (i.e. 
Twillingate and New World Island). Early estimates suggested the incidence was 
130 times higher than reported elsewhere in North America at the time (Bear et al., 
1987). The prevalence was lated identified as 44 in 3,330 males -- the highest 
population density of hemophilia A reported in the world (Xie et al., 2002). 
Extensive genealogical and genetic studies of a multiplex pedigree consisting of 
1,630 family members across ten generations demonstrated the founder effect, 
caused by the pathogenic variant pathogenic variant (p.Val2016Ala) in the F8 gene.  
Founder effects are also observed for other less common blood disorders, 
including for α0‐thalassaemia. There are 11 NL families carrying a large 26 kb 
deletion in both HBA genes designated α0‐thalassaemia (‐‐BRIT) common in the 
British population; as well as another founder mutation (90.7 kb deletion) 
designated α0‐thalassaemia (--NFLD) (Eng et al., 2009).   
 Hereditary Ocular Disorders 1.8.2
 
Studies by Green and colleagues have established a high prevalence of monogenic 
ocular disorders in NL based on data from ocular genetics clinics in St. John’s and 
rural NL as well as by review of CNIB records and extensive pedigree analysis of 
famlilies (Green et al., 1986; Green & Johnson, 1983). Strikingly, monogenic 
disorders accounted for 30% of all provincially registered CNIB cases in 1986. The 
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largest proportion included RP or other rod-cone dystrophies, accounting for 31% of 
all ocular genetic disorders. Additionally, cone, cone-rod or macular dystrophies 
accounted for 22% of cases. Ocular albinism and oculocutaneous albinism each 
contributed an additional 9% of genetically determined CNIB cases, while congenital 
cataract disorders accounted for a further 6% among other lesser causes.  
While a comprehensive review of NL RP mutations has not been published, 
there are reports of a notable rod-cone dystrophy due to RLBP1 mutations called 
Newfoundland Rod-Cone Dystrophy (OMIM #607476). While RLBP1 mutations are 
typically a very rare cause of rod-cone dystrophies worldwide, there are six NL 
families carrying homozygous or compound heterozygous combinations of two 
pathogenic splice variants in RLBP1 (Eichers et al., 2002). Subsequently, four other 
RLBP1 mutations have been identified in a further four NL families (Green J, 
unpublished data), indicating significant diversity of mutations for this rare rod-
cone dystrophy.  
Meanwhile, among inherited macular dystrophies, Stargardt disease is a 
juvenile macular degeneration prominently seen in NL -- with 31 families identified 
since the 1970s. A founder mutation in ABCA4 (c.5714+5G>A) is the most common 
cause among 21 ABCA4 mutations identified in NL (Green et al., 2010).  Likewise, 
since the 1970s, X-linked ocular albinism has been prevalent along the central and 
northern coast and in central Newfoundland. Genealogical investigation of a six-
generation pedigree of 200 family members identified a founder mutation with a 
common ancestor living in Moreton’s Harbor ~178 years ago (Johnson et al., 1971). 
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Subsequent genetic studies of NL families were integral to early genetic mapping 
studies, which identified a critical interval for X-linked ocular albinism on 
chromosome Xp22.3 (Charles et al., 1993; Pearce et al., 1971), which facilitated a 
discovery implicating GPR143 in this disorder (Bassi et al., 1995). 
Finally, a number of cases of congenital iris atrophy (N=40), previously 
coined ‘peninsula pupil’ were identified on the Great Northern Peninsula of 
Newfoundland (Bosanquet and Johnson, 1981). Also, a large NL family with anterior 
segment disorders including Peter’s Anomaly is described (Green & Johnson, 1986), 
with subsequent genetic studies identifying a pathogenic variant in FOXE3 (Doucette 
et al., 2011). Founder effects causing achromatopsia are also seen in families with 
pathogenic CNGB3 (p.T383IfsX) and CNGA3 (p.L527R) variants,  and a family with 
Jalili syndrome (OMIM #217080) -- an extremely rare cone-rod dystrophy 
associated with amelogenesis imperfecta was also identified (Doucette et al., 2013). 
 Bardet-Biedl Syndrome 1.8.3
 
There is a significantly high incidence of BBS in NL (1 in 17,500) (Moore et al., 
2005).  Clinical characterization of this autosomal recessive syndromic retinopathy 
among NL BBS families has made significant contributions to our understanding of 
the cardinal manifestations of BBS (Green et al., 1989). Furthermore, analysis of 46 
BBS patients from 26 NL families provided strong evidence that BBS and Laurence-
Moon Syndrome were distinct entities (Moore et al., 2005). Significant genetic 
heterogeneity has been documented among NL BBS families (Figure 1.4). 
Consequently, NL founder families have played a significant role in early genetic 
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studies mapping the BBS loci. These include studies investigating the BBS1 locus 
(Young et al., 1999; Fan et al., 2004); the BBS3 locus with subsequent discovery of 
ARL6 mutations (Young et al., 1998; Fan et al., 2004b); the BBS5 locus and discovery 
of the BBS5 gene (Woods et al., 1999; Young et al., 1999; Li et al., 2004); and 
mapping the BBS6 locus with identification of MKKS as the first gene identified  for 
BBS (Katsanis et al., 1999). Moore and colleagues summarize clinical and genetic 
findings of NL founder BBS mutations in six large families homozygous for p.M390R 
in BBS1, three families homozygous for p.F94fsX103 in MKKS and two families 
homozygous for p.D143fsX157 in MKKS, among several other loci (Moore et al., 
2005) (Green J, unpublished data). 
 Connective Tissue and Muscular Disorders 1.8.4
 
There is a high prevalence of certain muscular and connective tissue disorders in NL.  
For example, a population-based study from 2006 to 2011 identified 28 families 
(36% of total cases) with family history of pulmonary fibrosis (Fernandez et al., 
2012). This relatively high proportion of familial pulmonary fibrosis (compared to 
only 0.5-20% of familial cases reported in other populations) clustered in 
communities along the eastern region of Newfoundland (i.e. Avalon Peninsula) 
(Figure 1.5). Moreover, Fernandez et al. (2012) identified several pathogenic TERT 
mutations (p.Phe883Cys, p.Arg631Gln and p.Arg865His) in 3/28 families (10.7%). 
In terms of muscular disorders, a very high prevalence of myotonic 
dystrophy has been seen in Labrador. For example, in 1978, the prevalence was 75 
per 100,000 – which was approximately 13x higher than reported elsewhere  
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Figure 1.4 The geographic distribution of BBS families and their respective 
haplotypes, around several communities in Newfoundland. Reprinted from 
Parfrey et al., (2002) with copyright permission. 
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Figure 1.5 The geographic distribution of FPF study families around 
Newfoundland. Reprinted from Fernandez et al., (2012) with copyright 
permission under creative commons license. 
 
 
30 
 
(Webb et al., 1978). Meanwhile, on the west coast of Newfoundland, one family with 
an exceptionally rare skeletal and connective tissue disorder, known as WMS, was 
reported (Johnson & Bosanquet, 1983). This family is the subject of a genetic 
investigation of this thesis.    
 Cardiovascular disorders 1.8.5
 
Studies of NL families have yielded significant insights into arrhythmogenic right 
ventricular dysplasia type 5 (ARVD5). For example, one large NL ARVD5 family was 
first described in the late 1980s (Marshall et al., 1988). Investigation of this 
extended pedigree of more than 200 individuals with ten alive and affected at this 
time identified an ARVD5 locus on chromosome 3p25 (Ahmad et al., 1998). 
Subsequently, Merner and colleagues fine mapped this locus in 14 additional NL 
ARVD5 families, identifying a 2.36 Mb critical interval. Thereafter, they discovered 
the causal role of TMEM43 in ARVD5 (Merner et al., 2008). This TMEM43 founder 
mutation (p.S358L) was found in all 15 NL ARVD5 families and has provided 
extensive clinical data, characterizing the natural history of p.S358L within the NL 
population (Hodgkinson et al., 2016, Hodgkinson et al., 2013). The TMEM43 p.S358L 
mutation has been independently replicated other places nationally and globally, 
including in Canada (Baskin et al., 2013) and Denmark (Christensen et al., 2011). 
Moreover, a common haplotype has been identified between some Danish, German 
and NL ARVD5 families, suggesting ancestral origins from within Europe (Milting et 
al., 2015).  
Finally, in terms of other hereditary cardiovascular disorders, familial 
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hyperlipoproteinemia has been reported in two large families with at least 39 
affected individuals clustering near Baie Verte, on the north coast of NL (Anjilvel, 
1973).  
 Neurological Disorders 1.8.6
 
Studies indicate extensive genetic heterogeneity and founder effects are present 
among neurological disorders in NL. There is a notably high prevalence (13.4 per 
100,000) of neuronal ceroid lipofuscinosis (NCL) in NL, compared with relatively 
low prevalence (0.15 to 0.78 per 100,000) seen in other populations (Moore et al., 
2008). Moreover, if considering the late infantile NCL subtype, NL reports the 
highest prevalence (9.0 per 100,000) in the world. Most of these families have been 
followed since the 1980s (Andermann et al., 1988), and characterization of their 
clinical manifestations has provided substantial insights into NCL.  
Most NCL families cluster around the northern Avalon Peninsula or the 
southern coast of Newfoundland (Figure 1.6). Substantial genetic heterogeneity and 
numerous NCL founder mutations have been identified in the NL population. For 
example, Moore et al., (2008) reviewed all NCL cases ascertained by adult and 
pediatric neurology clinics between 1960 and 2005. Among 54 patients from 32 
families, pathogenic mutations were found in TTP1 (CLN2), CLN3, DNAJC5 (CLN4), 
CLN5 and CLN6. A number of founder mutations were identified in TTP1, as two 
families were homozygous for p.Ser475TrpfsX13, five families were homozygous for 
p.Gly284Val and four families were homozygous for a splice variant (c.509-1G>C). 
Moreover, as many as seven additional families harbored compound heterozygous 
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alleles of the above, or other nonsense variants; including p.Lys104X and p.Ala208X. 
Finally, in CLN6, there were five families homozygous for p.Val91GlufsX42, with 
CLN3 and DNAJC5 causing a smaller proportion of cases – and highlighting the 
extensive genetic heterogeneity in the province. 
In terms of other neurological disorders within NL, the rate of pediatric idiopathic 
epilepsy (107 per 100,000 individuals) is approximately 3x higher than other 
developed countries (Mahoney et al., 2012). Among 88 NL families with pedigree 
data available, family history was present in many (n=55), with eight families 
demonstrating clear autosomal dominant inheritance. To date, the genetic etiology 
of only one family has been solved, with identification of a pathogenic mutation 
(p.Y388H) in SCN1A (Mahoney et al., 2009).  
Meanwhile, among hereditary spastic ataxias, NL families have significantly 
contributed to our understanding of these disorders. The first locus identified for an 
autosomal dominant spastic ataxia was the ‘SAX1’ locus on chromosome 12p13, 
which was found in 3 large NL families (Meijer et al., 2002). Later, these families 
were further clinically characterized and the locus fine mapped to a 1.9 Mb region 
(Grewal et al., 2004). Subsequently, candidate gene sequencing discovered VAMP1 
mutations in autosomal dominant spastic ataxia (Bourassa et al., 2012). The causal 
pathogenic mutation (c.340+2T>G) segregated in 50 affected individuals from four 
multiplex families living on the northern Avalon Peninsula of Newfoundland – 
demonstrating a founder effect.  
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Figure 1.6 The geographic distribution of NCL families in Newfoundland 
stratified by mutation status. Reprinted from Moore et al., (2008) with 
copyright permission. 
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Finally, investigation of NL families with hereditary sensory and autonomic 
neuropathy type II has yielded additional founder effects. This was demonstrated by 
mapping and identification of homozygous WNK1 c.594delA mutations in NL 
families (Lafreniere et al., 2004). Additionally, linkage analysis and homozygosity 
mapping in a family with congenital lack of pain sensation identified a nonsense 
mutation (p.Y328*) in SCN9A (Ahmad et al., 2007).  
 Inherited Renal Disorders 1.8.7
 
The incidence of monogenic renal disorders has been extensively studied in the NL 
population (O’Dea et al., 1998). Parfrey et al. (2002) comprehensively reviewed the 
clinical and epidemiological distribution of monogenic and complex kidney diseases 
across NL. Within a cohort of 669 patients who developed end stage renal disease 
between 1987 and 1993, they found that 8.5% of cases resulted from a monogenic 
disorder. Among the autosomal dominant disorders, the most common disorders 
were polycystic kidney disease (PKD) (4.5% of cases), Alport Syndrome (2.7% of 
cases) and Charcot-Marie Tooth syndrome (0.3% of cases). Meanwhile, among 
autosomal recessive disorders there were BBS (0.3% of cases); 2,8 
Dihydroxyadenine stone disease (0.3% of cases); hyperoxaluria (0.3% of cases); and 
autosomal recessive PKD (0.2% of cases).  
PKD is the most prominently studied inherited renal disorder in NL, with at 
least 17 families with autosomal dominant PKD (Figure 1.7) (Parfrey et al., 1990).  
Many of these families have been studied since the 1980s (Churchill et al., 1984). For 
example, a founder effect at the PKD1 locus was identified in 91 affected individuals 
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of four NL families living on the south coast of Newfoundland (Parfrey et al., 2002). 
Meanwhile, at least four other PKD1 mutations account for a further 54 affected 
individuals, from another four families -- demonstrating genetic heterogeneity for 
PKD1 in NL. Likewise, at least two families share a founder mutation in PKD2 
(c.1510del127), with another two families segregating different PKD2 mutations. 
Finally, linkage and haplotype analyses have demonstrated at least one NL family 
that appears to have trans-heterozygotes for PKD1 and PKD2 loci, suggesting bi-
lineal inheritance (Pei et al., 2001).  
 Hereditary Cancers 1.8.8
 
Hereditary cancer syndromes have important implications in NL. The genetics of 
CRC is comprehensively reviewed in Section 4.1, while NL population-related CRC 
studies are briefly described here. NL has the highest incidence of CRC in Canada 
(Canadian Cancer Society’s Advisory Committee on Cancer Statistics, 2015). 
Moreover, Green and colleagues observed the highest reported familial incidence of 
CRC in the world (Green et al., 2007).  
 In terms of Familial Adenomatous Polyposis (FAP), a study of 90 individuals 
from 5 families identified a founder mutation in APC originating from Twillingate 
island, NL (Spirio et al., 1999). Meanwhile, investigation of Hereditary Non-polyposis 
CRC (HNPCC) in NL families has yielded several important discoveries. Primarily, the 
investigation of an NL family dubbed ‘Family C’ was integral to the discovery of 
MSH2, the first gene identified for HNPCC (Fishel et al., 1993; Leach et al., 1993), and 
a common ancestor has been identified for many of these families. The founder  
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Figure 1.7 The geographic distribution of PKD families in Newfoundland with 
their respective haplotypes. Reprinted from Parfrey et al., (2002) with 
copyright permission. 
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mutation in Family C (c.942+3A>T) is found in 21 NL families with eight families 
known to share a common haplotype (Froggatt et al., 1999). The same mutation has 
also been found in the United Kingdom and the United States (Lynch et al., 2004). 
Anadditional MSH2 founder mutation, an exon 8 deletion, was identified in a number 
of NL families as well as another large family harboring a deletion of exons 4-16 
(Green J, personal communication). The clinical sequalae of these three MSH2 
mutatations have been extensively characterized (Stuckless et al., 2007). 
Population-based studies genetically screening NL patients have yielded 
important insights as well. For example, Woods et al. (2010) comprehensively 
screened all incident CRC cases (N=750 CRC patients, N=708 families) in the 
province who were ascertained over 5-year period from 1999 to 2003. This genetic 
screening identified 12 mutations in known CRC genes. An additional 0.9% of cases 
were ascribed to APC or biallelic MUTYH mutations. Critically, this study identified 
several Familial CRC Type X (FCCTX) families, or families with strong genetic 
predisposition of unknown etiology -- which remain a particularly important avenue 
for ongoing genetic research studies. The geographic distribution and common 
HNPCC with MMR mutations (now called Lynch Syndrome) in NL families are shown 
in Figure 1.8. Meanwhile, the geographic distribution of FCCTX families is shown in 
Figure 1.9.  
Finally, in terms of other hereditary cancer syndromes, the incidence of 
gastric cancer is high in NL as well -- which has been appreciated since the 1970s 
(Pfeiffer et al., 1973). The high incidence is partly explained by a recurrent CDH1 
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Figure 1.8 The geographic distribution of families with known Lynch 
Syndrome mutations in Newfoundland. Reprinted from Warden et al., (2013) 
with copyright permission. 
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Figure 1.9 The geographic distribution of FCCTX families in Newfoundland. 
Reprinted from Warden et al., (2013) with copyright permission. 
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founder mutation (c.2398delC) found in 23 gastric cancer and 16 breast cancer 
cases belonging to four families residing near the southeast coast and Avalon 
Peninsula (Kaurah et al., 2007). Lastly, Von Hippel-Lindau disease has been 
identified in at least one large family from NL (Green et al., 1986b). 
 Unsolved Mendelian Disorders in NL 1.8.9
 
Taken together, this broad overview of NL Mendelian genetics highlights the 
extensive genetic heterogeneity in the presence of multiple founder effects in NL. 
The willingness of this population to participate in genetic research studies has 
provided unique insights into the clinical manifestation and natural history of 
numerous rare diseases over the years, and has played an integral role in gene 
discovery; most notably for BBS (i.e. BBS6), CRC (i.e. MSH2) and ARVD5 (TMEM43). 
Studying NL families with unsolved genetic etiology is poised to yield new 
discoveries for disorders including RP, WMS, CRC/FCCTX and FPF; suggesting new 
insights are on the horizon. 
1.9 Thesis Aims 
 
The thesis aim was to explore three Mendelian disorders (arRP, WMS, CRC) in 
families of the NL founder populations by applying modern genetic strategies for the 
discovery of novel genes and/or genetic variants underying each disorder. 
Secondary aims were to characterize the clinical manifestation of these rare 
disorders, as well as the genetic variants uncovered. The purpose of this endeavor 
was to provide the families, and potentially others around the world, with a genetic 
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diagnosis, while gaining unique insights into the underlying molecular pathogenesis 
of these disorders.  
Three main methods were employed including a.) family-based studies using 
whole exome DNA sequencing with genetic linkage analysis or homozygosity 
mapping (arRP and WMS studies, respectively), and b.) cohort-based candidate gene 
approach using Sanger sequencing (CRC project). Following identification of 
candidate variants, the next objective was to assess and interpret variants for 
pathogenicity using control DNA sequencing, segregation analysis, bioinformatic 
prediction and functional assays where appropriate. Finally, the last objective was to 
synthesize the clinical and molecular genetic data in order to provide meaningful 
insights into these Mendelian disorders.  
1.10 Co-authorship Statement 
 
The following three chapters are independent and published research articles, 
written by me as the primary author. As a major contributor, I participated in data 
generation, interpretation and critical appraisal of data, and I made significant 
intellectual contributions to each project. I am grateful to a number of contributors 
and collaborators who provided their expertise during each of these projects. 
Individual contributions made by each co-author are described in the author 
contributions section of Chapters 2-4.   
 
42 
 
Chapter 2.  Discovery of a Novel Mutation for Retinitis Pigmentosa in a Large 
Kindred from Newfoundland Using Whole Exome Sequencing and Genetic 
Linkage Analysis. 
 
2.1 Background: Retinitis Pigmentosa 
 
During the visual process, light is detected within the retina, which is a complex 
tissue consisting of ten histological layers (Joselevitch, 2008) (Figure 2.1). Photons 
reach the inner limiting membrane and travel toward the outermost layer of the 
retina called the pigment epithelium (RPE). The photoreceptor layer lies above the 
RPE, and both play critical roles in the visual cycle. The photoreceptor cells (i.e. rods 
and cones) are highly specialized neuroepithelial cells within the photoreceptor 
layer that detect incoming photons, and there are more than 120 million rods and 
six million cones within the retina. Whereas rods are highly sensitive to photons (i.e. 
providing vision in low light conditions), the cones are less sensitive, but able to 
perceive color vision. The photo transduction cascade is the physiological process of 
vision that is responsible for detecting incoming photons (Arshavsky et al., 2002).  
Photoreceptor cells are structurally unique (Figure 2.2). These cells have 
outer segments, which contain layers of flattened disc-like membranes studded with 
a photopigment called rhodopsin. There are approximately 700-1000 of these discs 
per photoreceptor cell (Mayhew & Astle, 1997). Moreover, approximately 90% of 
the protein content in each disc is rhodopsin (Hargrave, 2001), which equates to 
approximately 150,000 rhodopsin molecules per disc, and 1.5 million molecules per  
 
43 
 
 
Figure 2.1 The histological and cellular structure of a healthy retina compared 
to changes seen in RP. Reprinted from Hartong et al., (2006) with copyright 
permission. 
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Figure 2.2 Structure of the retinal photoreceptors, demonstrating the 
membranous discs of the photoreceptor outer segments. Courtesy of 
Encyclopaedia Britannica, Inc., copyright 2012; used with permission. 
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retina. Rhodopsin consists of opsin and covalently bound 11-cis-retinal, which is a 
chromophore that is central to the photo transduction cascade. 
During the photo transduction cascade, photons travel to the photoreceptor 
layer and are absorbed by rhodopsin. This results in a conformational change of the 
11-cis-retinal chromophore, which isomerizes to all-trans retinal – creating 
conformational changes to the opsin molecule. This initiates a series of G-protein 
coupled signalling events leading to the photo transduction cascade. A 
conformational change of rhodopsin to metarhodopsin II activates a G-protein called 
transducin (Shichida & Morizumi, 2007). The exchange of guanosine triphosphate to 
the metarhodopsin-activated transducin α-subunit causes dissociation of the 
subunit from the transducin β and γ subunits. The activated transducin α-subunit 
then proceeds to activate cGMP phosphodiesterase (Fung et al., 1981). Normally, 
under dark conditions, cGMP molecules are bound to Na+ and Ca2+ channels on the 
disc membrane, which keep the channels open and the cells depolarized. Activation 
of cGMP phosphodiesterase during the photo transduction cascade hydrolyzes cGMG 
causing these channels to close and photoreceptors to hyperpolarize. The now-
activated photoreceptor cell then transmits stimulatory signals to the inner retinal 
membrane via bipolar cells, which relay signals to the optic nerve via retinal 
ganglion cells for visual perception (Euler et al., 2014).  
Ultimately, the isomerized all-trans retinal must be recycled back to 11-cis 
retinal in order for a new photon to re-initiate the cascade, while also preventing 
accumulation of phototoxic products. To accomplish this, a ‘bleach and recycling’ 
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pathway acts to convert all-trans retinal back to 11-cis retinal by a series of 
enzymatic reactions that occur within photoreceptor outer segments and the RPE 
(Figure 2.3). This complex and multi-step pathway demonstrates the important 
roles of the photoreceptor outer segments and the RPE. Communication between 
these two layers is critical, and the complex interplay between them is essential for 
maintaining healthy and properly functioning photoreceptors.  
The RPE plays a critical role in maintaining photoreceptor excitability and 
viability (Strauss, 2005). Several mechanisms contribute to this. First, secretion is an 
important process of the RPE that facilitates communication between 
photoreceptors and blood vessels. The RPE secretes a number of growth factors and 
other important molecules, including fibroblast growth factors, insulin-like growth 
factors, vascular endothelial growth factor and pigment epithelium derived factor 
(PEDF). PEDF is secreted from the apical surface of the RPE toward the 
photoreceptor cells. PEDF is a neurotrophic factor which prevents apoptosis and 
stabilizes photoreceptor cells (Cayouette et al., 1999). Furthermore, as previously 
mentioned, the photoreceptors are constantly exposed to phototoxic products and 
free radicals, which accumulate and cause damage in the absense of a properly 
functioning retina. The RPE also plays a critical role in light absorption, which 
improves image quality by absorbing scattered light. Melanosomes within the RPE 
are dynamic molecules which can migrate to the apical surface to absorb more 
photons under light conditions (Strauss, 2005). Likewise, Na+/K+-ATPases are 
important mediators of K+ transport to photoreceptors and glial cells. As well, the 
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Figure 2.3 The bleach and recycling pathway restores 11-cis retinal for use in 
the photoreceptor transduction cascade. Reprinted from (Wright et al., 2010) 
with Copyright Permission. 
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epithelial transport of water, ions, and retinal precursors such as vitamin A across 
the sub-retinal space is important in maintaining a healthy retina.  
 Lastly, phagocytosis is a key process performed by the RPE. Given the toxic 
accumulation of phototoxic products during the visual cycle, the photoreceptor 
outer segments must undergo continuous renewal – and are therefore shed into the 
sub-retinal space for further breakdown. Once shed, the outer segments traverse the 
subretinal space and must be phagocytosed by the RPE.  Meanwhile, new discs are 
formed at the proximal end (near the cell body), as older discs move distally toward 
the microvilli of the RPE. Phagocytosis occurs at the apical membranes of the RPE 
and involves three key protein mediators: CD36, MERTK and αVβ5 integrin. Whereas 
CD36 mediates internalization of photoreceptor outer segments, MERTK plays a 
critical role in signal transduction to activate phagocytosis. Meanwhile, αVβ5 integrin 
mediates the binding process. The importance of the MERTK receptor in 
phagocytosis is notable from studies of the Royal College of Surgeons (RCS) rat, 
which was the first animal model for inherited retinal degeneration (D’Cruz et al., 
2000). By ensuring adequate activation and signal transduction during phagocytosis, 
the photoreceptor outer segments can be cleared from the sub retinal space. Failure 
to phagocytize the outer segments causes a build-up of debris in the sub-retinal 
space, which hinders the flow of nutrients and leads to photoreceptor degeneration.  
Photoreceptor degeneration has been extensively studied in humans, given 
that blindness can substantially impair one’s quality of life. During the normal aging 
process, retinal photoreceptor density decreases by about 0.2% to 0.4% per year 
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(Panda-Jonas et al., 1995), which leads to a corresponding decrease in visual acuity. 
Inherited retinal dystrophies (IRDs) however, cause early vision loss and blindness. 
The IRDs constitute a large heterogeneous group of retinal disorders, united by their 
progressive degeneration of photoreceptors, variable clinical manifestations and 
monogenic patterns of inheritance. The more than 300 genes or loci known to cause 
IRDs, highlights the substantial complexity of the visual cycle; and the critical role 
that photoreceptors play in this process. 
  A broad array of molecular pathways has been implicated in hereditary 
retinal degeneration (Figure 2.4). While some mutations occur in genes in obvious 
pathways such as the visual cycle, a broad variety of processes impacted include 
more generalized cellular functions such as protein folding, extracellular matrix 
regulation and lipid metabolism (Wright et al., 2010). In fact, the pathway 
accounting for the largest proportion of IRDs involves ciliary trafficking. Meanwhile, 
the clinical pattern of visual problems associated with IRDs, along with 
electrophysiological findings can broadly sub-classify IRDs into cone-rod 
dystrophies, rod-cone dystrophies and inherited macular dystrophies.  
In rod-cone dystrophies, there is primarily a loss of rod photoreceptors 
followed by loss of cone photoreceptors.  As rods are concentrated in the mid-
periphery, visual field loss is often first noticed in the periphery, with sparing of the 
cone-rich macula, responsible for central vision, until the later stages. As rods are 
involved in low light responses, early onset of night-blindness occurs in rod-cone  
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Figure 2.4 The relative proportion of known genes causing photoreceptor 
death and their respective molecular pathways. Reprinted from Wright et al., 
(2010) with copyright permission. 
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dystrophies. Color vision and central visual fields and acuities may then be affected 
later on, as the disease progresses. 
RP is the most common IRD, and is essentially a rod-cone dystrophy. There 
are more than 1.5 million people worldwide living with RP. The progressive 
decrease in visual fields and acuities that accompany it and eventual blindness are a 
significant and incurable cause of disability.  The global prevalence of RP is 
approximately 1:4000 (Pagon, 1988). There is also geographic variability in RP, with 
one study in India estimating RP prevalence of 1:750 (Nangia et al., 2012). RP is a 
broad and heterogeneous disorder, united by a triad of clinical features: waxy pallor 
of the optic disc, attenuation of retinal blood vessels, and pigmentary aggregates 
visualized in the fundus, called bone spicules (Figure 2.5). 
Night blindness and loss of visual fields may occur early (typically by the 
second decade) with blindness probably as early as the 40th decade.  Based on 
accompanying clinical features, RP is sub-divided into syndromic and non-
syndromic forms. Syndromic RP includes conditions with extra-ocular 
manifestations. The syndromic forms of RP are well characterized, and include 
Usher Syndrome, Bassen-Kornzweig Syndrome, Refsum disease, Bardet-Biedl 
Syndrome, and Batten disease. Meanwhile non-syndromic RP involves only ocular 
features. The genetic and molecular pathogenesis of RP is broad and explained by a 
large number of genes resulting in autosomal dominant, autosomal recessive and X-
linked inheritance patterns (Figure 2.6). X-linked RP is the least common form of RP 
(5-15% of cases) and demonstrates the least heterogeneity, with pathogenic  
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Figure 2.5  Clinical manifestation of RP revealed by fundus appearance using 
ophthalmoscopy. The panel on the left shows a normal healthy fundus while 
the panel on the right shows characteristic features of RP. Reprinted from 
Hartong et al., (2006) with copyright permission. 
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Figure 2.6 Proportion of RP cases caused by known and unknown genes 
displayed for each respective mode of inheritance. Reprinted from Hartong et 
al., (2006) with copyright permission. 
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variants identified in RP2, RP6, RP23, RP24 and RPGR (70-80% of X-linked cases). 
Autosomal dominant RP (adRP) accounts for 30-40% of cases. There are more than 
22 genes identified where mutations cause adRP. The most common gene is RHO, 
encoding rhodopsin, and accounting for approximately 25% of adRP cases. The 
remaining identified adRP genes each account for small percentages (<5%), while a 
significant proportion (~50%) of adRP remains unsolved. Finally, autosomal 
recessive RP (arRP) accounts for the majority of cases of RP, with approximately 50-
60% of cases. A substantial number of genes (over 30 genes and loci) account for 
arRP. Usher Syndrome Type II (RP with hearing loss) accounts for a large fraction of 
arRP, and USH2A mutations account for approximately 17% of arRP. USH2A is an 
example of clinical heterogeneity, as it can cause both syndromic RP (Usher 
syndrome) and non-syndromic RP. Approximately 9% of arRP cases are accounted 
for by USH2A causing Usher Syndrome, while 8% of arRP cases is accounted for by 
USH2A, causing non-syndromic RP. The majority of strictly non-syndromic RP genes 
individually account for a small percentage of arRP (<5%), but collectively explain 
the largest percentage (Figure 2.6). Finally, the genetic etiology of up to 30% of non-
syndromic RP is unknown.  
 In humans, MERTK mutations are a rare cause of RP, accounting for 
approximately 1% of cases. Based on findings in the RCS rat, the first MERTK 
mutations found in humans were described by Gal et al., (2000). Gal and coauthors 
screened 328 DNA samples from IRD cases and identified three MERTK mutations in 
RP families. Since the initial discovery, there have been more than 33 pathogenic 
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missense, 12 nonsense, 12 splicing, 14 indels and 3 duplications (Audo et al., 2018). 
Furthermore, three large MERTK deletions have been reported in RP families 
(Mackay et al., 2010; Ostergaard et al., 2011; Siemiatkowska et al., 2011).  
 
2.2 Study Aims & Objectives 
 
In this study, we hypothesized the existence of a pathogenic variant segregating in a 
large family with non-syndromic arRP from Newfoundland. The study aim was to 
uncover this causal variant to provide a genetic diagnosis, and gain insight into the 
molecular pathogenesis of RP. The primary study objective, therefore, was to 
explore and interpret whole exome and genetic linkage data in this family. To prove 
causality, the next objective was to validate, and test segregation of candidate 
variants in the family. The final objective was to characterize the pathogenic variant, 
and perform a comprehensive clinical review to assist clinicians and researchers in 
understanding the manifestations of this rare disorder.  
2.3 Author Contributions 
 
The following is an original research article peer-reviewed and published in 
Investigative Ophthalmology & Visual Science (Evans et al., 2017). As first author of 
the study, I was responsible for interpretation of whole exome sequence data to 
identify the causal pathogenic variant in this family. I validated the candidate variant 
in DNA samples of family members using PCR and Sanger sequencing, and tested 
variant segregation in all family members. I reviewed and interpreted clinical data 
for family members and prepared the manuscript.  Gordon J. Johnson (GJJ) and Jane 
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S. Green (JSG) ascertained patients and clinical data. GJJ performed ophthalmic 
examinations, interpreted clinical findings, and provided referral to genetics in 
collaboration with JSG. Justin French (JF) performed funduscopy of patient VI-9. JSG 
conceived of the study, interviewed patients, interpreted molecular findings and 
assisted in manuscript revision. Generation of whole exome sequence and genetic 
linkage data was performed under the FORGE Canada framework. Kym M. Boycott 
(KMB) Jacek Majewski (JM), Somayyeh Fahiminiya (SF) and Jeremy 
Schwartzentruber (JS) supervised and assisted in whole exome sequencing analysis, 
and with result interpretation. Andrew D. Patterson (AP), Christian R. Marshall 
(CRM), Tara A. Paton (TAP) and Nicole M. Roslin (NMR) assisted in the generation of 
microarray data for linkage and copy number variant (CNV) analysis. Chandree L. 
Beaulieu (CLB) and Wen Qin (WQ) mapped the breakpoints of the MERTK deletion 
using primer walking. Michael O. Woods (MOW) participated in the study design, 
supervised the collection of molecular and genetic data, and assisted in manuscript 
revision. All authors read and approved the final manuscript.   
Co-authors were affiliated with the following institutions during the 
completion of this work. GJJ was affiliated with the Department of Surgery 
(Ophthalmology), Faculty of Medicine, Memorial University of Newfoundland, St. 
John’s, Newfoundland, Canada. JSG and MOW were affiliated with the Discipline of 
Genetics, Faculty of Medicine, Memorial University of Newfoundland, St. John’s, 
Newfoundland, Canada. JS and JM were jointly affiliated with the Department of 
Human Genetics, McGill University, Montreal, Quebec, Canada and McGill University 
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and Genome Quebec Innovation Centre, Montreal, Quebec, Canada. CLB, WQ, SF and 
KMB were affiliated with the Children’s Hospital of Eastern Ontario Research 
Institute, University of Ottawa, Ottawa, Ontario, Canada. TAP, NMR, CRM and AP 
were affiliated with the Program in Genetics and Genome Biology, The Center for 
Applied Genomics, The Hospital for Sick Children Research Institute, and Dalla Lana 
School of Public Health, University of Toronto, Toronto, Ontario, Canada. CF was 
affiliated with the Western Memorial Regional Clinic (Eye Care Centre), Corner 
Brook, Newfoundland, Canada. 
2.4 Abstract 
 
RP describes a complex group of inherited retinal dystrophies with almost 300 
reported genes and loci. We investigated the genetic etiology of autosomal recessive 
RP (arRP) in a large kindred with five affected family members, who reside on the 
island of Newfoundland, Canada. Genetic linkage analysis was performed on 12 
family members (Infinium HumanOmni2.5-8 BeadChip). Whole exome sequencing 
analysis (Illumina HiSeq) was performed on one affected individual. A custom 
pipeline was applied to call CNVs, annotate, and filter variants. FishingCNV was used 
to scan the exome for rare CNVs. Candidate CNVs subsequently were visualized from 
microarray data (CNVPartition v.3.1.6.). MERTK breakpoints were mapped and 
familial cosegregation was tested using Sanger Sequencing. We found strong 
evidence of linkage to a locus on chromosome 2 (logarithm of the odds [LOD] 4.89 
[θ = 0]), at an interval encompassing the MERTK gene. Whole exome sequencing did 
not uncover candidate point mutations in MERTK, or other known RP genes. 
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Subsequently, CNV analysis of the exome data and breakpoint mapping revealed a 
25,218 bp deletion of MERTK, encompassing exons 6 to 8, with breakpoints in 
introns 5 (chromosome 2:112,725,292) and 8 (chromosome 2:112,750,421). A 48 
bp insertion sequence was buried within the breakpoint; 18 bps shared homology 
to MIR4435-2HG and LINC00152, and 30 bp mapped to MERTK. The deletion 
cosegregated with arRP in the family. This study describes the molecular and clinical 
characterization of an arRP family segregating a novel 25 kb deletion of MERTK. 
These findings may assist clinicians in providing a diagnosis for other unsolved RP 
cases. 
2.5 Introduction 
 
RP is a broad term meant to describe a complex group of hereditary retinal 
dystrophies. These dystrophies are characterized by the progressive degeneration of 
photoreceptor cells and/or RPE, which typically leads to severe visual impairment 
or blindness by the fourth decade of life (Hartong et al., 2006). Symptoms of RP 
typically include early difficulty with night vision and dark adaptation, progressive 
loss of peripheral and/or central fields of vision, and declining visual acuity in the 
later stages. On examination of the fundus, RP often manifests with a triad of clinical 
features: a waxy pallor of the optic disc, attenuation of retinal blood vessels, and 
pathognomonic pigmentary aggregates called bone spicules (Hamel, 2006; Pruett, 
1983). There can be great variability in the clinical manifestation of RP, owing to the 
large number of causative genes and metabolic pathways affected (Hartong et al., 
2006). Moreover, carriers of pathogenic RP mutations sometimes display phenotypic 
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variability within families, a phenomenon likely due to a combination of genetic 
modifiers and environmental influences (Chang et al., 2011; Leroy et al., 2007; 
Passerini et al., 2007). Depending on the causal gene or mutation(s), patients with 
RP can experience onset of visual symptoms in a range from early childhood to mid-
adulthood, with the progression and severity of disease influenced by the particular 
molecular pathways involved. The genetic etiology of inherited retinal dystrophies is 
complex, with nearly 300 genes and loci currently reported 
(RetNet, http:www.sph.uth.tmec.edu/RetNet/; in the public domain). (Daiger et al., 
2013). The investigative approaches to uncovering these causal genes have been 
well-described (Siemiatkowska et al., 2014). Mutations of the MERTK gene explain 
approximately 1% of cases of autosomal recessive RP (arRP) (Tschernutter et al., 
2006). Pathologic mutations of this gene were first described in the RCS rat (D’Cruz 
et al., 2000) and subsequently in human RP patients (Gal et al., 2000). 
MERTK has an essential role in maintaining retinal photoreceptor viability by 
facilitating phagocytosis of shed photoreceptor outer segments (Qingxian et al., 
2010; Strick and Vollrath, 2010). In humans, MERTK mutations are a well-
documented cause of arRP (Brea-Fernández et al., 2008; Coppieters et al., 2014; 
Ebermann et al., 2007; McHenry et al., 2004; Shahzadi et al., 2010; Srilekha et al., 
2015; Tada et al., 2006; Thompson et al., 2002). RP often displays a phenotype 
involving early onset of symptoms (night blindness) within the first decade of life 
and a rapid progression and severity of disease. Mutations of MERTK occur along the 
entire length of the gene (Jinda et al., 2016). Several point mutations and small 
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indels in MERTK have been described, in addition to three large exonic deletions. 
These deletions include a 91 kb deletion encompassing exons 1 to 7 (Mackay et al., 
2010), a 9.86 kb deletion of exon 8 (Ostergaard et al., 2011) and a 1.73 kb deletion of 
exon 15 with a complex re-arrangement (Siemiatkowska et al., 2011). 
We present findings of a fourth exonic deletion of MERTK; a 25 kb deletion 
encompassing exons 6 to 8, which was identified using whole exome data 
supplemented by CNV and linkage analyses. The deletion segregates in a large 
consanguineous arRP family with five affected individuals, who live on the island of 
Newfoundland, Canada (Figure 2.7). Affected individuals have an early-onset form of 
RP that affects peripheral and central fields of vision, and leads to a rapid decline in 
visual acuities and eventual blindness.
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Figure 2.7 A large arRP family from Newfoundland, Canada, segregating the 25 kb (c.845-1450del; 
p.Ala282_His483del) deletion of MERTK. Reprinted from (Evans et al., 2017) with copyright permission under 
creative commons licensing. Shaded symbols indicate clinically manifested RP. Screening for the deletion 
shows deletion carriers (wt/del), affected homozygotes (del/del), and wild-type non-carriers (wt/wt).  
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2.6 Materials and Methods 
 Patient Recruitment 2.6.1
 
Following ethical approval (HIC# 11.060), family members gave informed consent in 
adherence with tenets of the Declaration of Helsinki for participation in a research 
study. Genomic DNA was extracted from peripheral leukocytes using standard 
protocols for whole blood DNA extraction. The family was enrolled in the Finding of 
Rare Disease Genes in Canada (FORGE Canada) Consortium study.  
 Genotyping and Linkage Analysis 2.6.2
 
Genomic DNA samples of 12 family members (Figure 2.7; individuals IV-10, V-4, V-7, 
V-8, V-10, V-12, V-13, VI-2, VI-3, VI-8, VI-9, VI-10) were genotyped for 2,379,855 
SNPs, using the Infinium HumanOmni2.5-8 v1.0 BeadChip (Illumina, Inc., San Diego, 
CA, USA) according to the manufacturer's protocols at The Centre for Applied Genomics (Toronto, Canada). Briefly, 200 ng of DNA (4 μL at 50 ng/μL) was 
independently amplified, labeled, and hybridized to BeadChip microarrays and then 
scanned with default settings using Illumina iScan. Analysis and intrachip 
normalization of the resulting image files was performed using Illumina's 
GenomeStudio Genotyping Module software (v.2011) with default parameters. 
Genotype calls were generated using the Illumina-provided genotype cluster 
definitions file (HumanOmni2.5-8v1_C.egt) with a Gencall cutoff of 0.15. The 
CNVPartition v.3.1.6 module in GenomeStudio was used for CNV and (copy number 
neutral) loss of heterozygosity analysis with default parameters.  
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Following quality control and filtering protocols, 17,718 SNPs across the 
autosomes and X chromosome were suitable for linkage analysis. We assumed a 
recessive model of inheritance with a disease allele frequency of 0.1 and penetrance 
of 0.2, 0.2, and 99% for 0, 1, and 2 copies of the disease-causing allele, respectively. 
This corresponds to a disease prevalence of approximately 1%. A multipoint linkage 
analysis then was performed using a two-stage approach. First, the pedigree was 
broken down into two subpedigrees and then analyzed using an exact multipoint 
calculation. Subsequently, regions showing evidence of linkage were further 
analyzed using approximate methods and the full pedigree.  
 Whole Exome Analysis and FishingCNV 2.6.3
 
The genomic DNA of one affected patient (Figure 2.7; individual VI-9) was chosen for 
whole exome sequencing analysis. Whole exome capture and high-throughput 
sequencing was performed at the McGill University and Genome Québec Innovation 
Centre (Montréal, Canada). The Agilent SureSelect (Agilent Technologies, Santa 
Clara, CA, USA) 50 Mb All Exon Kit (V3) was used for target exome enrichment, and 
high-throughput sequencing was achieved using the Illumina HiSeq platform. An in-
house annotation pipeline was applied to call and annotate sequence variants as 
previously described for other FORGE projects (Fahiminiya et al., 2014). Candidate 
homozygous variants were reviewed manually for evidence of pathogenicity. CNVs 
were identified in the whole exome dataset using FishingCNV (Shi and Majewski, 
2013). Briefly, this program compares exon-level read counts in a test sample 
against a population of control samples (from FORGE) to establish rare CNVs. Exon-
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level read counts were determined using GATK (v1.0) depth of coverage for 
individual VI-9, with comparison against 150 in-house control exomes. These 
exomes consisted of DNA samples that were sequenced during other rare disease 
gene projects carried out by FORGE, using the same target exome enrichment and 
sequencing protocols as per individual VI-9. 
 Breakpoint Analysis and Carrier Screening 2.6.4
 
Following the identification of a candidate CNV in MERTK, the genomic position of 
the deletion breakpoints were mapped using primer walking. Primer sequences 
were designed using Primer3 (Untergasser et al., 2012). The primer sequences used 
to identify deletion breakpoints are as follows: Forward 1 primer 
(ACCTTCATCCTCACCACACC), Reverse 1 primer (TCAATTCCACAGCAGACACC), 
Forward 2 primer (CCTGCCCTCATCCATAAAGA), and Reverse 2 primer 
(GACACTGAAGCAGGGAGGTC). A PCR protocol was developed to capture deletion-
specific amplicons in patients carrying the MERTK deletion (Appendix A: Supporting 
Materials for arRP Study). Twenty family members were screened by this custom 
PCR protocol, to distinguish noncarriers from heterozygous and homozygous 
deletion carriers (Supp Figure 2). To mitigate the possibility of PCR reactions 
yielding false-negative results, we repeated each reaction in triplicate for every 
individual tested. Sequence chromatograms for deletion carriers were inspected 
visually for alignment to regions of MERTK according to the GRCh38.p3 human 
reference genome.  
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2.7 Results 
 
Affected patients of this family were initially seen by GJJ and JSG in 1983, after 
referral to an Ocular Genetics clinic. Referrals initially were received for three 
separate families; however, genealogical analysis later revealed a shared and 
complex ancestry (Figure 2.7).  Individual V-11 (Figure 2.7) was first seen in 1975 at 
age 28 with central vision loss. Visual acuities were 20/120 in both eyes at age 29, 
and by age 30, vision was reduced to hand movements only. At age 35, posterior 
capsular cataracts developed in the left eye, and funduscopy revealed pigmentary 
clumping, but no pallor of the optic discs or attenuation of retinal blood vessels. At 
36, his fundus had a beaten-bronze appearance, with granular gray and whitish 
flecks in the midperiphery. Many bone spicules also were seen in the periphery. 
Individual VI-10 (Figure 2.7) reported that he was always night blind. At age 11 
(1984), he had temporal constriction of the left visual field and a full field of vision in 
the right eye. Visual acuities were 20/20 in both eyes, and he had a color vision 
defect with 10/20 errors using the Ishihara test. His fundus had an albinoid 
appearance, with a marked decrease in chorioretinal pigmentation, and no bone 
spicules were found on examination. The following year at age 12, visual acuities 
decreased to 20/25 in both eyes, and his fundus had a salt and pepper appearance. 
Findings suggestive of delayed dark adaptation and nyctalopia were noted at this 
time. At age 16, visual acuities in both eyes further decreased to 20/40, and he 
reported difficulties in school, having trouble seeing the blackboard. At this time, his 
color vision continued to deteriorate, such that he scored 19/20 errors on the 
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Ishihara test, and had strong red-green and blue-yellow defects, seeing only one 
plate using the Hardy, Rand, and Rittler Pseudoisochromatic plate test. By age 19, he 
had a large central scotoma in both eyes, with peripheral vision only (nasally). By 
age 37, he had central scotomas to 30° to 40° in both eyes, and visual acuities were 
confined to hand movements only. The fundus displayed extensive chorioretinal 
degeneration. Alternating exotropia was noted. Individual VI: 3 (Figure 2.7) first 
experienced a decrease in central vision at age 7. The defect rapidly progressed, 
such that by age 12 the patient was enrolled at a school for the blind. Visual acuities 
continued to decrease, and color vision deficits were noted, as well as decreased 
night vision. The patient reported being sensitive to light for as long as he could 
remember. In 1980, at the age of 30, the patient had typical changes of RP, with 
macular degeneration as well. Visual acuities were reduced to hand movements only 
in the right eye, and light perception in the left. At age 35, fundi showed dense bone 
spicules at the equator, with an atrophic area in the mid periphery with grayish 
spots. At the macula, there was a small atrophic area with the appearance of 
choroidal sclerosis. Optic discs had a gray pallor and retinal blood vessels were 
narrowed. Visual acuities further decreased to light perception in both eyes. The 
patient had a marked exotropia, mainly of the left eye, which did alternate at times. 
Individual VI-9 (Figure 2.7) was first seen in 1986 (age 14) as his younger brother 
(VI-10) already was experiencing symptoms. At this time, VI-9 had 20/20 visual 
acuities in both eyes, and decreased chorioretinal pigmentation and stippling was 
noticed on funduscopic examination. He stopped playing hockey at age 15 due to 
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deteriorating vision, and reported he was always night blind. By age 17, uncorrected 
visual acuities were 20/80 in the right eye and 20/40 in the left. He had difficulties 
with classes and left school by grade 12. At age 20, he had developed a significant 
loss of central vision, such that only peripheral islands of vision (nasally) remained. 
Visual acuity was reduced to counting fingers only by age 30, and the patient 
subsequently lost all vision. Funduscopic surveillance of this patient at age 44 
highlights the classic features of RP, including bone spicules, attenuation of retinal 
vessels, and pallor of the optic disc (Figure 2.8). A summary of the clinical findings of 
this family is provided in (Appendix A, Supplementary Tables & Figures, Supp Table 
1). A genetic linkage analysis of 12 family members (Figure 2.7: individuals IV-10, V-
4, V-7, V-8, V-10, V-12, V-13, VI-2, VI-3, VI-8, VI-9, VI-10) was performed to search 
for evidence of a disease-susceptibility locus in the family. Owing to the large size of 
the pedigree, we first performed an exact multipoint linkage analysis of 
subpedigrees, which revealed six regions on five chromosomes displaying logarithm 
of the odds (LOD) scores above 1.5 (Appendix A, Supplementary Tables & Figures). 
A maximum LOD score of 3.71 (θ = 0) was observed on chromosome 2 
encompassing markers rs7584136 and rs10177102 (chromosome 2:105833093-
121145352). An approximate linkage analysis of these chromosomes subsequently 
was performed using the full pedigree, which increased the maximal LOD score to 
4.89 (θ = 0), indicating strong evidence of linkage at chromosome 2: 107493123-
117426163 (Appendix A, Supp Figure 3, Supp Table 3). The region covered markers 
rs4676093 and rs4525709 (chromosome 2: 107493123 - 117426163), a 7.5 cM (10  
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Figure 2.8 Fundus imaging of RP patient (VI-9), showing characteristic 
features of RP, including bone spicules, attenuation of retinal blood vessels, 
and pallor of the optic disc, with significant atrophy of the retina. (A, B) 
Patient's left eye. (C, D) Patient's right eye. Reprinted from Evans et al., (2017) 
with Copyright Permission under creative commons licensing. 
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Mb) interval that includes the MERTK gene.  
Next, we sequenced the exome of one affected patient (Fig. 1; individual VI-
9), to screen for point mutations, small indels, and CNVs. In filtering the whole 
exome data, we included variants with minor allele frequency <5% and excluded 
variation that was synonymous or in untranslated regions (UTRs). This strategy 
produced 541 candidate variants; 32 of which were homozygous. Each homozygous 
variant then was assessed for evidence of pathogenicity by reviewing protein 
function, predicted mutation consequences, and evolutionary conservation scores. 
None of the 32 variants was in genes known to cause RP, in the interval with 
maximal LOD score, or appeared functionally relevant to an ocular phenotype (data 
not shown). Therefore, our exome filtering strategy did not produce any obvious 
candidate point mutations.  
To screen the exome for candidate CNVs, we next applied FishingCNV. This 
program yielded 9 candidate CNVs after Holm-Bonferroni correction (P < 0.05). 
These candidates included amplifications or deletions in ZFHX3, MERTK, 
AAK1, SMARCAL1, CCDC7, GIT2, NAALAD2, ZNF658, and FGGY (Appendix, Supp Table 
4). Among these, the CNV in MERTK was the only candidate functionally relevant to an ocular phenotype and also situated in a linked interval of LOD ≥ 1. This was a 
significant finding, given that aberrations of MERTK are known to cause RP, and this 
locus had the strongest evidence of linkage in the family, demonstrating a significant 
LOD score of (4.89 [θ = 0]). The CNV in MERTK is a large 25 kb deletion spanning 
chromosome 2:112725714-112740570 and encompassing exons 6, 7, and 8. It is a 
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novel deletion, which to our knowledge, is not reported in the literature or online 
databases. Thus, we identified a strong candidate deletion for arRP in this family; a 
novel in-frame deletion of 25 kb in the MERTK gene (c.845-1450del; 
p.Ala282_His483del), which removes 201 amino acids from the encoded protein, 
corresponding to two fibronectin type-III domains.  
To further investigate this mutation, we screened other family members for 
the deletion, by re-examining microarray data generated during the linkage analysis. 
This corroborated a heterozygous MERTK deletion in obligate carriers (Figure 2.7: 
individuals IV-10, V-4, V-13), and a homozygous deletion in the affected individuals 
with RP (Figure 2.7; V-10, VI-3, VI-9, VI-10), and no unaffected individuals were 
homozygous for the deletion. We then proceeded to map the breakpoints of the 
segregating MERTK deletion using primer walking. The 5′ breakpoint is located in 
intron 5 (chromosome 2:112,725,292), while the 3′ deletion breakpoint is in intron 
8 (chromosome 2:112,750,421). The sequence surrounding the 5′ breakpoint maps 
to an L2B repeat of the LINE-2 family, while the 3′ breakpoint maps to a MER21A 
repeat sequence. The deletion spans a total of 25,218 base pairs according to the 
GRCh38.p3 human reference genome.  
We next optimized a custom PCR protocol to validate the MERTK deletion and 
screen additional family members, by amplifying deletion-specific fragments 
(Appendix A Supplementary Methods). In brief, the PCR protocol is able to 
differentiate DNA samples with wild-type breakpoint sequences from heterozygous 
or homozygous deletion carriers (Appendix Supp Figure 2), and, therefore, may 
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prove useful for others who wish to screen for this deletion in unsolved arRP 
families. A total of 20 family members were screened and validated in this manner. 
As expected, the deletion was homozygous in affected individuals and heterozygous 
in obligate carriers (Figure 2.7), thereby replicating our previous findings. Screening 
identified a total of 8 carriers in the family, who did not have a phenotype similar to 
their homozygous affected cousins, and were not routinely followed by 
ophthalmology.  
Interestingly, Sanger sequencing of the deletion-specific PCR amplicons 
revealed a 48 bp insertion sequence within the deletion breakpoints (Figure 2.9). A 
Basic Local Alignment Search Tool (BLAST) search of this sequence 
(ATTACTAGGTGAAGCACAGTGGAGCACATGGCTTGGTATAGGAGACCC), showed that 
the terminal 30 bp (GTGGAGCACATGGCTTGGTATAGGAGACCC) have a 97% identity 
to intron 5 of MERTK. The remaining proximal 18 bp of the insertion 
(ATTACTAGGTGAAGCACA) mapped with 100% identity to intronic regions 
of MIR4435-2HG and LINC00152 (Figure 2.10). MIR4435-2HG is a microRNA 
approximately 700 kb upstream of MERTK, while LINC00152 is a long noncoding 
RNA on the opposite arm of chromosome 2.  
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Figure 2.9 Novel 25 kb deletion of MERTK detected in WES data (A) and validated using Sanger 
sequencing (B). Validation of the deletion breakpoints (B) revealed a 48 bp insertion sequence in 
this affected family member. Reprinted from Evans et al., (2017) with copyright permission  
under creative commons licensing. 
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Figure 2.10 Diagrammatic representation of 25 kb MERTK (c.845-1450del, p.Ala282_His483del); an 
in-frame deletion encompassing exons 6 to 8, with a 48 bp insertion sequence at the breakpoints. 
Red font, the 5′ and 3′ breakpoints of the deletion; green font, 18 bp of insertion with homology 
to MIR4435-2HG; blue font, 30 bp region of homology to intron 5 of MERTK. Reprinted from Evans et 
al., (2017) with copyright permission under creative commons licensing.  
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2.8 Discussion 
 
This study provided compelling evidence for the discovery of a novel 25 kb deletion 
of MERTK causing arRP in this large family from the island of Newfoundland. We 
discuss our rationale for these findings below. First, we observed strong evidence of 
linkage disequilibrium at an interval that encompasses MERTK (LOD 4.89 [θ = 0]). 
Meanwhile, our whole exome filtering strategy did not uncover strong candidate 
mutations in known or putative RP genes. Subsequently, CNV analysis then 
uncovered a large exonic deletion of MERTK within the interval with the strongest 
linkage signal. Analysis of genotype data and a custom PCR protocol corroborated 
the segregation of this deletion in a pattern typical of autosomal recessive 
inheritance. Moreover, deletion of exon 8 is known to cause RP (Mackay et al., 2010) 
and the deletion identified here encompasses exons 6 to 8. The large size of our 
study family provides important insights into the clinical manifestation of arRP 
caused by MERTK mutations.  
The family is characterized by an early onset form of RP. Affected individuals 
all reported decreased or absent night vision early in life, and subsequently 
experienced a rapidly progressive deterioration of central and peripheral vision. 
Most individuals were blind by their 20th to 30th year. Deterioration of color vision 
also was noted in these patients, and funduscopy revealed classic changes of RP, 
with some variability in the detection of bone spicules (Appendix Supp Table 1). 
Indeed, other patients with MERTK mutations often experience earlier onset of 
symptoms compared to other forms of arRP.  
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This family segregates only the fourth exonic deletion of MERTK to be 
reported to our knowledge. The 25 kb deletion (c.845-1450del; 
p.Ala282_His483del), encompasses exons 6 to 8 and overlaps portions of two 
other MERTK deletions reported in the literature: one encompassing exons 1 to 7 
(91 kb) (Ostergaard et al., 2011) and the other a deletion of exon 8 (9.86 kb) 
(Mackay et al., 2010). 
Interestingly, some clinical overlap is seen in each of these families 
carrying MERTK deletions. For example, patients carrying the 91 kb deletion 
encompassing exons 1 to 7 also experienced onset of symptoms in the first decade of 
life, which led to deterioration of central and peripheral vision; a finding that also 
was seen in our patients. As well, authors of that study noted interindividual 
variation within their family with respect to retinal vessel attenuation and optic disc 
pallor. Interindividual variation is seen within our family as well, as individual V-11 
(Figure 2.7) did not display any obvious attenuation of retinal vessels or pallor of the 
optic disc, while these features were prominent in individual VI-3. It remains unclear 
if these observations are due to differences in disease manifestation or 
thoroughness of surveillance. We also observed variability between two affected 
individuals of the same sibship (Figure 2.7: individuals VI-10, VI-9). Individual VI-10, 
the younger brother, appeared to have a more severe onset and progression of 
disease, as he began noticing decreased peripheral vision by age 11. Meanwhile, his 
older brother did not clinically manifest symptoms until age 14. Moreover, 
individual VI-3, a more distant relative, manifested symptoms at age 7 and 
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experienced significant visual deterioration such that he was registered at a school 
for the blind by age 12. Thus, the phenotype seen in our family is one that is severe 
and early in onset, with first reported decline in visual acuities often by the second 
decade, ranging from age 7 to age 30.  In patients segregating the MERTK exon 8 
deletion (Mackay et al., 2010), the authors noted macular involvement, as the 
proband of their study had central vision deficits by age 13. Additionally, affected 
family members of their study experienced progressive color vision defects. For 
example, the proband of their study failed a color vision test with 24/24 errors at 
age 26, while the younger sibling, who also was affected, began experiencing mild 
generalized dyschromatopsia by age 8. Early color vision deficits also were noted in 
our study, as individual VI-10 experienced significant deficits at age 11 (10/20 
errors), which markedly progressed by age 16 (19/20 errors). Moreover, individual 
IV-3 of our study also had early color vision deficits, documented at age 12, 
suggestive of early rod and cone involvement.  
A peculiar finding of this study was the discovery of a 48 bp insertion 
sequence buried within the deletion breakpoint. In patients with the previously 
reported exon 8 deletion of MERTK, the authors uncovered a complete AluY element 
insertion, leading them to hypothesize nonhomologous recombination between two 
AluY elements as the mechanism of the deletion. Intrigued by those findings, we 
performed a BLAST search of our 48 bp insertion sequence, but did not find 
homology to Alu elements. We did, however, find homology to three intronic regions 
on chromosome 2. Shown in Figure 2.10, 30 bps of the insertion sequence map to a 
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stretch of intron 5, which is deleted in these patients, and appears to be the reverse 
complement compared to wild-type intron 5 reference sequences. The remaining 18 
bp portion of the insertion sequence maps to two other intronic loci on chromosome 
2: MIR4435-2HG and LINC00152. One possible explanation for these findings could 
be the insertion of a transposable element buried within one of these genes. The 
etiology of these exonic MERTK deletions appears complex, given that the third 
reported MERTK deletion is a removal of exon 15 (1732 bp), with a duplication and 
inversion event (Siemiatkowska et al., 2011) with no mechanism postulated for 
those findings.  
The deletion uncovered in this study (c.845-1450del; p.Ala282_His483del) 
removes 201 amino acids from encoded MERTK protein, corresponding to the 
removal of two fibronectin type-III domains. These domains function in the 
extracellular region of the protein, and together with the immunoglobulin domains, 
define MERTK within the TAM receptor tyrosine kinase family (Lemke, 2013). This 
deletion does not disrupt the reading frame, given that the 484th amino acid is 
retained as a glycine, rendering nonsense-mediated decay unlikely. It is likely, 
however, that the removal of the fibronectin domains could structurally alter the 
extracellular region of the MERTK protein, impairing its ability to bind GAS6 ligands. 
Binding of GAS6 ligands to MERTK is functionally important, as it is known to 
stimulate phagocytosis (Hall et al., 2001; Qingxian et al., 2010), and loss of this 
ability could lead to the observed accumulation of photoreceptor outer segment 
debris in the sub-retinal space.  
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This study highlights the importance of using alternative methods to screen 
arRP patients who have early onset and severe forms of RP. MERTK currently is 
believed to account for 1% of arRP cases; however, these numbers were estimated 
using a sequencing study that screened a cohort of 96 arRP cases (Tschernutter et 
al., 2006). Therefore, it remains possible that the true proportion of arRP caused 
by MERTK mutations may differ when taking potentially undetected CNVs into 
account. Therefore, investigators should consider screening this gene for larger 
deletions in unsolved arRP families. The identification of novel pathogenic 
mutations and structural alterations remains an important process, particularly for 
the MERTK gene, as ongoing clinical trials continue to highlight the potential for the 
future application of gene therapy (Ghazi et al., 2016), which will first require 
patients to have a genetic diagnosis.  
We concluded that the discovery of this 25 kb MERTK deletion, abolishing 
exons 6 to 8, is a novel cause of arRP which ultimately leads to an early onset and 
rapid progression of visual symptoms seen in this family. We provided an optimized 
PCR protocol (Appendix A, Supplementary Methods) that others might use to detect 
this deletion in unsolved arRP families. The clinical histories provided here are of 
benefit to clinicians and investigators in understanding the clinical manifestation 
of MERTK deletions, and this is one of the largest families segregating 
a MERTK deletion currently reported in the literature. Moving forward, we 
encourage others to consider screening MERTK thoroughly for larger CNVs in the 
investigation of unsolved arRP cases. 
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Chapter 3.  Novel Mutation Discovered for Weill-Marchesani Syndrome in a 
Newfoundland Family Using Whole Exome Sequencing and Homozygosity 
Mapping. 
 
3.1 Background: Weill-Marchesani Syndrome 
 
As the most abundant tissue of the body, connective tissues play key roles in body 
structure, protecting organs and maintaining homeostasis. Four main categories of 
connective tissues are the connective tissue proper (including loose and dense 
connective tissue), cartilage, bone and blood. The connective tissue proper has three 
core components: ground substance, fibers and cells (Figure 3.1). Ground substance 
is a viscous fluid primarily composed of proteoglycans and cell adhesion proteins, 
which allows the flow of molecules between surrounding cells and capillaries. 
Meanwhile, the connective tissue fibers (i.e. collagen, elastic fibers and reticular 
fibers) provide structural support. Together with the ground substance, these fibers 
make up the extracellular matrix (ECM).  
 Elastic fibers are an important component of the ECM. They are made of 
cross-linked elastin and fibrillin proteins, and are important for load-bearing tissues, 
such as the heart, lungs, kidneys, blood vessels, and components of the eye. Fibrillins 
are large glycoproteins (~350 kDa) that polymerise to form the predominant 
component of microfibrils. The mechanism of microfibril assembly is poorly 
understood. Microfibrils are seen in two forms – in loose association with elastic 
fibers (i.e. in the skin, arteries and lungs), or alternatively, in tightly bound, non-
elastic microfibril bundles (i.e. in ciliary zonules, tendons, glomeruli) (Figure 3.2).   
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Figure 3.1 Basic components of connective tissue. Together, the 
glycosaminoglycans (ground substance) and fibers (i.e. collagen and elastic 
fibers) make up the ECM. Reprinted from Vanakker et al., (2015) with 
copyright permission. 
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Figure 3.2 The structure of connective tissue microfibrils, highlighting the 
complex protein-protein interaction of microfibril bundles. Reprinted from 
Jensen et al., (2012) with copyright permission. 
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Microfibrils confer pliability to the skin as a loose association of fibers and elastin, 
running parallel to the epidermis (Ramirez et al., 2004). Similarly, in the aorta, 
elastin and micofibril bundles provide critical elasticity to a tissue undergoing large 
hydrostatic pressures.  
Meanwhile, non-elastic bundles of micofibrils are dynamic molecules that 
interact with and are re-modelled by a host of proteins within the extracellular 
matrix. They also play a key role in sequestration of latent TGF-β (Zeyer and 
Reinhardt, 2015). In the eye, microfibril bundles play a key structural role in the 
ciliary zonules (i.e. Zonules of Zinn), which are suspensory ligaments connecting the 
ciliary body of the eye to the ocular lens (Figure 3.3). If the ciliary zonules are 
structurally compromised, then the lens can either partially or fully dislocate 
(ectopia lentis) (Figure 3.4).  Bilateral ectopia lentis can be pathognomic for certain 
hereditary connective tissue disorders, for example in Marfan Syndrome and Weill-
Marchesani Syndrome (WMS) when identified with supporting systemic features.  
The critical role of microfibril stability in tissues such as the skin, aorta, long 
bones, and ciliary zonules was demonstrated in Marfan Syndrome. In 1991, shortly 
after fibrillin-1 protein was isolated from microfibrils, the critical role of the FBN1 
gene was demonstrated by Dietz et al., who found a pathogenic variant p.R239P in a 
region of strong genetic linkage (LOD 3.9) (Dietz et al., 1991).  
FBN1 mutations produce substantial phenotypic heterogeneity -- an 
intriguing example of how mutations in a single gene can produce opposite 
phenotypes. Collectively, Mendelian disorders caused by mutations in FBN1 are  
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Figure 3.3 Structure of the eye demonstrating the ciliary zonules which 
regulate diameter of the lens. Reprinted from Ansari & Nadeem, (2016) with 
copyright permission.  
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Figure 3.4 The clinical appearance of ectopia lentis viewed using slit lamp 
microscopy. Reproduced with permission from Sridhar and Chang, (2017), 
copyright Massachusetts Medical Society. 
 
 
 
 
 
 
 
 
 
93 
 
called fibrillinopathies, and they demonstrate the importance of fibrillin-1 proteins 
in connective tissue stability. The fibrillinopathy phenotypes show both key 
differences as well as overlapping features. Broadly, fibrillinoapthies can cause a tall 
stature phenotype or a short stature phenotype (Figure 3.5). Whereas Marfan 
Syndrome is a fibrillinopathy manifesting with increased height and 
disproportionately long limbs or digits (arachnodactyly) and joint laxity, the 
acromelic dysplasias (WMS, Geleophysic dysplasia & Acromicric dysplasia) and 
Myhre syndrome are united by their short stature, joint stiffness, and short stubby 
hands and feet (brachydactyly) (Figure 3.5).  
WMS (formerly spherophakia-brachymorphia syndrome) is a fibrillinopathy 
defined by short stature, muscular build, skin stiffness, brachydactyly, 
microspherophakia, ectopia lentis, severe myopia and risk for glaucoma. WMS was 
initially defined by Georges Weill (Weill, 1932) and later redefined by Oswald 
Marchesani (Marchesani, 1939). The prevalence is estimated to be 1 in 100,000. 
Figure 3.6 demonstrates a 19-year old male WMS patient with the typical muscular 
build, short stature and brachydactyly – joint stiffness is evident by pallor around 
the knuckles while extending the hand. Meanwhile, Figure 3.7 shows the small, 
rounded lens characteristic of microspherophakia. As WMS is inherited in autosomal 
dominant and autosomal recessive forms, Faivre and colleagues studied a cohort of 
WMS patients published in the literature to identify any clinical evidence to 
distinguish between dominant or recessive forms (Faivre et al., 2003). They 
reviewed published literature (from 1932-2001) of 128 WMS patients, consisting of  
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Figure 3.5 The clinical features differentiating several fibrillinpathies and 
their causal genes. Reprinted from  Hubmacher & Apte (2015) with copyright 
permission.  
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Figure 3.6 Clinical manifestations of WMS. A short stature with muscular build 
and brachydactyly seen in this patient with WMS. Reprinted from Evereklioglu 
et al., (1999) with copyright permission. 
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Figure 3.7 Microspherophakia in a lens of a patient with WMS with subluxation 
also seen. Reprinted from (Evereklioglu et al., (1999) with copyright 
permission. 
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30 autosomal recessive, 12 autosomal dominant and 21 sporadic families. The 
cohort included 58 males and 56 females with mean age of 24 years. All autosomal 
dominant WMS patients had short stature (49/49), and nearly all autosomal 
recessive patients (55/56) manifested short stature too.  Similarly, all autosomal 
dominant cases manifested brachydactyly (49/49), as did 96% of autosomal 
recessive cases (54/56). Nearly all autosomal recessive patients 96% (51/53) had 
myopia, while 88% of autosomal dominant (38/43) cases with available data 
suggested myopia. A majority of autosomal recessive and autosomal dominant cases 
developed glaucoma-- 75% and 80% respectively. Meanwhile, cataracts were much 
less common 21% (AR) and 28% (AD) respectively. Neither pattern of inheritance 
could be distinguished by clinical findings alone, but there were some significant 
differences in the data. Faivre and colleagues noted statistically significant 
differences in microspherophakia, ectopia lentis, joint limitation and cardiac 
anomalies in autosomal recessive verses autosomal dominant cases (Table 3.1).  
 In terms of the genetics of WMS, autosomal dominant forms are caused by 
FBN1 mutations, while recessive forms are caused by LTBP2, ADAMTS10 and  
ADAMTS17. FBN1 was the first disease gene mapped causing WMS. Wirtz et al. 
studied two extensive families with three generations of affected individuals, and 
identified linkage to chromosome 15q21.1 (Wirtz et al., 1996). Given the clinical 
similarities between Marfan Syndrome and WMS (ectopia lentis, 
microspherophakia, risk for thoracic aneurysms), they proposed FBN1 was a 
candidate gene for WMS. This prompted Faivre et al. to investigate two autosomal
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Table 3.1 The clinical manifestations of 128 WMS cases published in the literature. Reprinted from Faivre et al., 
(2003)  with copyright permission.
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dominant WMS families – one being the previous family with linkage to 
chromosome 15 – by sequencing all 65 exons of FBN1 (Faivre et al., 2003b). In the 
family with linkage to chromosome 15, the authors identified a heterozygous 24 
nucleotide deletion in exon 41 – an in frame deletion (p. 5074_5097del) affecting the 
latent TGF beta binding domain of fibrillin-1. The next WMS gene identified was 
ADAMTS10. Faivre et al. studied two large families with autosomal recessive WMS 
from Lebanon and Saudi Arabia. They found strong evidence of linkage (LOD 5.99) 
to chromosome 19p13.3-p13.2 – a 12.4 cM interval (Faivre et al., 2002). Dagoneau 
and colleagues examined the over 100 positional candidate genes located within this 
interval (Dagoneau et al., 2004). On the basis of function within the ECM, they 
selected five candidate genes for sequencing – COL5A3, ICAM1, SMARCA4, TUBB5 and 
ADAMTS10. COL5A3 revealed no candidate pathogenic variants, however 
sequencing all 24 exons of ADAMTS10 identified 3 separate variants: two splice site 
variants (c.1190+1G>A and c.810+1G>A) and the nonsense variant (p.R237X). The 
family from Lebanon was homozygous for (p.R237X), while the family from Saudi 
Arabia was homozygous for the c.1190+1G>A spice site variant, predicted to induce 
a frameshift. Finally, the sporadic individual was a compound heterozygote for 
c.810+1G>A and p.R237X.  
In 2012, Haji‐Seyed‐Javadi proposed LTBP2 as a novel candidate gene for 
autosomal recessive WMS (Haji‐Seyed‐Javadi et al., 2012). They screened 30 
unrelated Iranian probands with ectopia lentis – 4 patients attributable to WMS, 13 
to Marfan Syndrome and 13 isolated ectopia lentis cases. They identified candidate 
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pathogenic variants in two unrelated families. One family segregated p.Val1177Met 
in LTBP2 in a manner consistent with autosomal recessive inheritance, while the 
second family segregated a candidate heterozygous variant in LTBP2 (p.Arg548*) 
which was digenically inherited with a FBN1 variant (p.Cys129Gly). The significance 
of this inheritance pattern in the second family is unknown.   
 Finally, pathogenic variants in ADAMTS17 were first described in 2009 
(Morales et al., 2009). Morales et al. investigated 13 patients belonged to seven 
unrelated WMS families – all from Saudi Arabia. Screening ADAMTS10 and FBN1 in 
the cohort identified two different homozygous ADAMTS10 pathogenic variants 
(p.G518D, p.G700C) each in one unrelated family, while no causal FBN1 variants 
were identified. They proceeded with another unsolved autosomal recessive WMS 
family called ‘Family A’. Multipoint linkage analysis identified a disease locus on 
15q26.3 (LOD 3). The critical interval encompassed 2.05 Mb, and the authors 
selected 6 positional candidate genes based on gene function (IGR1R, SYNM, TTC23, 
MEF2A, LYSMD4, ADAMTS17). They identified c.2458_2459insG (p.E820GfsX23), a 
homozygous insertion in exon 18 of ADAMTS17, segregating as expected for an 
autosomal recessive pattern of inheritance. Next they sequenced ADAMTS17 in 
additional cases, and identified a homozygous truncating variant (p.Q254X) in an 
additional family (Family E), and a homozygous splice site variant c.1721+1 G>A, in 
a third family, a sporadic case (WMS-D1). Clinical features and pedigrees for these 
WMS families are shown in Figure 3.8. An interesting observation among these 
families, all from the Saudi Arabian peninsula, was that each had only partial 
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features of WMS – short stature, ectopia lentis and microspherophakia, and they all 
lacked brachydactyly and joint stiffness. This led Morales and colleagues to propose 
that ADAMTS17 variants cause a sub-phenotype which could be referred to as ‘WMS-
like’ syndrome. Other studies then identified other pathogenic ADAMTS17 variants.  
In 2012, Khan and colleagues studied two siblings from one consanguineous family, 
also from Saudi Arabia (Khan et al., 2012). Homozygosity mapping in the two 
siblings identified ADAMTS17 as the most likely shared disease-causing gene. 
Sequencing ADAMTS17 identified a novel homozygous pathogenic variant 
(p.Asp218ThrfsX41) in each sibling. Both siblings were short of stature, had 
spherophakia and no joint stiffness or brachydactyly; consistent with the previous 
findings of Morales et al (2009). Radner et al then investigated 3 Tunisian families 
with WMS features (with brachydactyly and joint stiffness) as well as features of 
congenital ichthyosis (Radner et al., 2013).  Using genotyping and homozygosity 
mapping, they identified a large homozygous genomic deletion encompassing 
100kb. The deletion encompassed all of FLJ42289, and exon 13 of CERS3, while 
deleting all of the 5’UTR and first three exons of ADAMTS17. Finally, Shah and 
colleagues studied one consanguineous autosomal recessive WMS family from India 
(Shah et al., 2014). Whole exome sequencing and a custom filtering protocol for 
homozygous variants identified a homozygous splice variant in ADAMTS17 (c.873+1 
G>T). The pathogenic variant causes skipping of exon 5.  
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Figure 3.8 Family structures and clinical manifestation of WMS-like families 
identified by Morales et al., (2009). Reprinted from (Morales et al., 2009) with 
copyright permission. 
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3.2 Study Aims 
 
In our study, we hypothesized that a pathogenic variant segregated in a family with 
autosomal recessive WMS from Newfoundland. The study aim was to uncover the 
causal pathogenic variant(s) to provide a genetic diagnosis and gain insight into the 
molecular pathogenesis of WMS in this family. The primary study objective, 
therefore, was to explore and interpret whole exome and homozygosity mapping 
data in this family. To prove causality, the next objective was to validate, and test 
segregation of the candidate variant in the family. The final objective was to 
characterize the pathogenic variant, and perform a comprehensive clinical review to 
assist clinicians and researchers in understanding the manifestation of this rare 
disorder.  
3.3 Author Contributions 
 
The following is original research in preparation for submission to an academic 
journal.  As first author of the study, I interpreted candidate variants in the whole 
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and prepared the manuscript.   
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104 
 
Deardorff (MAD) assisted in the measurement and interpretation of radiological 
scans. GJJ and JHW performed ophthalmic examination of individuals and assisted 
with clinical interpretation of disease. Dirk Hubmacher (DH) and Suneel Apte (SA) 
performed cell culture and protein assay of the candidate ADAMTS17 variant. MOW 
participated in the study design, supervised the collection of molecular and genetic 
data, assisted in the analysis of genetic data and helped draft the manuscript. All 
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Centre, Montreal, QC, H3A 0G1 Canada. MAD was affiliated with the Division of 
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Clinic Lerner Research Institute, Cleveland, OH, 44195, USA.  
3.4 Abstract 
 
WMS is a rare hereditary connective tissue disorder manifesting with short stature, 
brachydactyly and limitation of joint movement, as well as ocular features that 
prominently include microspherophakia and ectopia lentis. We identified WMS 
clinically in a large kindred from Newfoundland & Labrador, Canada. Therefore, the 
genetic etiology of WMS in five affected individuals of this apparent autosomal 
recessive family was investigated. Whole exome sequencing and homozygosity 
mapping revealed a novel homozygous missense variant in ADAMTS17 (c. 3068G>A, 
p. C1023Y) which co-segregated with WMS in the family. The pathogenic variant is 
absent in 150 ethnically matched controls, and resides in a Thrombospondin-1 
repeat domain of ADAMTS17. Transfection of mutant ADAMTS17 (p.C1023Y) 
expression plasmids into HEK293T cells revealed significantly reduced secretion of 
ADAMTS17 into the extracellular matrix, supporting pathogenicity of this variant. 
We characterized the clinical presentation in our WMS patients, with longitudinal 
data spanning more than 40 years. Assessment of metacarpophalangeal bones 
demonstrated variable dysmorphia in the hands of two patients examined. This 
work expands and clarifies the phenotype of this rare disorder, further delineating 
the genetic etiology of WMS caused by ADAMTS17 mutations, and exploring the 
subsequent phenotype provided by this unique family.     
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3.5 Introduction 
 
Genetic aberrations in fibrillin-1 (FBN1) (OMIM *134797) demonstrate significant 
clinical heterogeneity, with eight OMIM phenotypes (i.e. fibrillinopathies) currently 
known. Marfan syndrome (OMIM #154700), a well-known example; is a hereditary 
connective tissue disorder involving increased height and disproportionately long 
limbs/digits, as well as other clinical features (Dietz, 1993). Interestingly, WMS is a 
fibrillinopathy that displays the opposite phenotype (i.e. short stature and short 
digits) with overlapping clinical features (i.e ectopia lentis).   
WMS is a rare disorder, as the prevalence is estimated to be about 1 in 
100,000 (Tsilou and MacDonald, 1993). One Danish national survey of congenital 
ectopia lentis (ECL) observed a 6.4 per 100,000 prevalence of ECL, with readily 
identifiable WMS patients accounting for only 0.7% of cases (Fuchs and Rosenberg, 
1998). While there are no absolute diagnostic criteria for WMS, the key 
manifestations are well described. These include systemic features: short stature, 
thick skin, joint stiffness, short digits (brachydactyly); as well as ocular findings: 
microspherophakia, ectopia lentis, severe myopia and glaucoma (Le Goff et al., 
2011). Occasionally, WMS patients develop pulmonary or aortic valve stenosis. 
Typically, an ophthalmologist ascertains WMS patients after noticing early onset 
myopia and a microspherophakic lens and/or ectopia lentis -- in patients with short 
stature. Management focuses on the consequent myopia, glaucoma and cataracts 
that may result. 
As there is risk for secondary angle-closure glaucoma due to subluxation of 
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the lens in WMS patients, management of intraocular pressures is especially 
important in mitigating risk of damage to the optic nerve, and subsequent blindness. 
Certainly, one cohort of patients (N=80) ascertained for microspherophakia 
(including 18 WMS patients) revealed that blindness due to glaucoma approached 
20-30% in this group (Senthil et al., 2014). Measurement of intraocular pressures is 
also complicated by increased corneal thickness in some WMS patients, which 
should be taken into account (Razeghinejad et al., 2009). Medical treatments can be 
ineffective in treating rising intraocular pressure for WMS patients (Taylor, 1996). 
Surgical treatments for WMS patients seek to relieve pupillary block, and have 
included iridectomy, iridotomy, trabeculotomy, anterior vitreotomy and lensectomy 
(Guo et al., 2015; Halpert & BenEzra, 1996; Harasymowycz & Wilson, 2004; Yang et 
al., 2016). 
WMS is inherited in autosomal dominant or autosomal recessive forms. 
Faivre et al. reviewed 128 WMS patients reported in the literature and found that 
the genetic etiology of WMS patients cannot be differentiated based on clinical 
findings alone (Faivre et al., 2003). Variable expressivity of clinical manifestations is 
also seen in siblings or among extended family members with WMS (Evereklioglu et 
al., 1999; Kloepfer and Rosenthal, 1955). Identifying the genetic cause for WMS is a 
critical and worthwhile endeavor. For example, a recent case report highlights the 
diagnostic odyssey of a 30 year old patient, who was being treated for glaucoma, 
when her diagnosis of WMS only became apparent after microspherophakia was 
identified following trabeculotomy (Guo et al., 2015). Securing a diagnosis early is 
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beneficial for these patients, to monitor their intraocular pressures closely and 
hopefully mitigate optic nerve damage, prognosticate on patient outcomes, and to 
facilitate family planning. Investigation of the etiology of WMS is also integral to 
scientific discoveries. Notably, genotype-phenotype correlations of WMS patients 
have previously led to stunning insights into molecular mechanisms of the 
extracellular matrix (Faivre et al., 2003; Hubmacher & Apte, 2011). 
WMS is genetically heterogeneous and caused by highly penetrant pathogenic 
variants. Four genes currently explain WMS. These include FBN1, ADAMTS10, and 
ADAMTS17. LTBP2 has also been identified as a candidate gene based on 
homozygosity mapping. When caused by FBN1, WMS segregates in an autosomal 
dominant pattern (OMIM #608328) (Faivre et al., 2003), while WMS caused by 
ADAMTS10 and ADAMTS17 and LTBP2 segregate in autosomal recessive form (OMIM 
#277600) (Dagoneau et al., 2004; Haji-Seyed-Javadi et al., 2012; Morales et al., 
2009).  
In this study, we investigate the genetic etiology of autosomal recessive WMS 
in a large family from Newfoundland, Canada, which includes five affected siblings 
(Figure 3.9). We explore extensive longitudinal clinical data available for this family, 
and examine variable metacarpophalangeal deformities present in siblings. Finally, 
we detail the discovery of a novel germline pathogenic missense variant, localizing  
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This large family with apparent autosomal recessive inheritance consists of five 
affected individuals with variable presentation of WMS manifestations including 
short stature, myopia, microspherophakia, ectopia lentis, cataracts and variable 
dysmorphic hand features. The majority of affected individuals did not develop joint 
stiffness, while a single individual (II-6) reported limited range of motion in wrists 
and shoulders, and had a winged scapula. 
 
 
 
 
Figure 3.9 The clinical manifestations of an autosomal recessive WMS family 
living in Newfoundland. Figure created by the author. 
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to the thrombospondin-1 repeat domain of ADAMTS17, and have characterized its 
impact on secretion of ADAMTS17 into the extracellular matrix. 
3.6 Materials and Methods 
 
 Patient Ascertainment  3.6.1
 
The family is from a small rural community on the island of Newfoundland, Canada. 
Patients were first seen at an Ophthalmology clinic prior to 1983 by GJJ, and were 
the subject of a case report in 1983 (Johnson and Bosanquet, 1983). Subsequently, 
they were referred to the Ocular Genetics Clinic and were followed by JSG. In 2007, 
family members gave written and informed consent to participate in an ocular 
genetics study. In 2012, they consented to participate in the FORGE Canada 
Consortium study to employ whole exome sequencing to their DNA. 
 Whole Exome Sequencing, Filtering and Homozygosity Mapping 3.6.2
 
Whole blood was drawn and genomic DNA was extracted from peripheral 
leukocytes by standard protocols. Whole exome sequencing (Illumina Hiseq 2000) 
was performed according to protocols at the Genome Quebec Innovation Center, 
Montreal, Canada (Fahiminiya et al., 2014; McDonald-McGinn et al., 2013). Briefly, 3 
µg of genomic DNA from two affected individuals (Figure 3.9: II-3, II-5) was used for 
library preparation, and exome capture and enrichment was accomplished using the 
SureSelect Human Exome Kit V.4 (Agilent Technologies, Inc., Santa Clara, CA). 
Alignment, variant calling, and annotation were performed as per previous FORGE 
projects (Dyment et al., 2013; Smith et al., 2014). Mapping of high quality paired-end 
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reads (100 bp) against the UCSC Genome hg19 was performed using BWA (v. 0.5.9) 
(Li and Durbin, 2010). The Genome Analysis Toolkit (GATK) (McKenna et al., 2010) 
was used for local realignment around indels (short insertions and deletions) and 
coverage assessment. Samtools (v. 0.1.17) mpileup (Li et al., 2009) and ANNOVAR 
(Wang et al., 2010) were then used for variant calling and annotation, respectively. A 
custom filtering protocol was applied to the whole exome data and sequence 
variants were excluded if there were i) < 3 reads supporting the alternative variant 
ii) there was variant allele frequency of > 0.05 in ExAC database and > 30 individuals 
with the variant in our database (~1000 exomes sequenced previously in our 
center), iii) variants were homozygous in ExAC database, iv) variants were 
synonymous, v) variants were within 5’ UTRs or were intronic variants outside of 
splice-site boundaries. 
Finally, homozygosity mapping was performed using in-house scripts written 
in Perl, to identify regions of homozygosity (ROH). An ROH was defined as a span of 
at least 25 SNPs where no more than two were called as heterozygous and the 
remainder were homozygous. 
 Validation of Candidate Variant, Segregation Analysis and Population 3.6.3
Controls 
 
To validate the candidate ADAMTS17 variant, primers were designed using Primer3 
(Untergasser et al., 2012), capturing exon 21 (forward primer: TCCCTTGACCTCA; 
reverse primer: CACCGTCAGGGAG). PCR conditions are available upon request. 
Sanger sequencing of PCR products was accomplished using an ABI 3130XL Genetic 
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Analyzer, and chromatograms were interpreted using Sequencher 5.2.3.  
In this manner, familial segregation was then tested in individuals I-2, II-3, II-
4, II-5 and II-8 (Figure 3.9). Finally, a cohort of 150 geographically matched 
population controls, from a previous study (Green et al., 2007) were then screened 
for the ADAMTS17 variant.  
 Measurement of Metacarpophalangeal Lengths 3.6.4
 
Roentgenograms of both hands of an unaffected sibling (Figure 1: Individual II-4) 
and two affected siblings (Figure 1: II-5, II-3) were obtained in 2016. To examine for 
evidence of dysmorphia, measurements of metacarpal bones, and proximal, middle 
and distal phalanges were taken. These measurements were compared against their 
expected proportions (Poznanski, 1984), taking each person’s age and sex into 
consideration.  
 Cloning 3.6.5
 
The expression plasmids for full-length ADAMTS17 and the proteolytically inactive 
mutant (ADAMTS17-EA) were described previously (Hubmacher et al., 2017). To 
introduce a variant of interest for functional analysis, a synthetic DNA fragment 
spanning nucleotide 2799 – 3352 of ADAMTS17 (Ref.Seq.XM_017021975) was 
ligated with the gel-purified 8335 bp  SrfI x AfeI fragment obtained from ADAMTS17 
and ADAMTS17-EA, using the NEBuilder®  HiFi DNA Assembly Kit (New England 
Biolabs, Ipswich, MA). Positive clones were screened via an additional ScaI 
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restriction site introduced by the mutation and verified by DNA sequencing 
(Cleveland Clinic Lerner Research Institute Genomics Core).  
 
 Cell Culture, Transfection, and Collection of Serum-free Medium and Cell 3.6.6
Lysate 
Human embryonic kidney cells (HEK293T, ATCC, Manassas, VA) were maintained in 
DMEM supplemented with 10% FBS, 100 units/ml penicillin, and 100 μ g/ml 
streptomycin in a 5% CO2 atmosphere in a humidified incubator at 37 °C. HEK293T 
cells were seeded in 12-well plates (BD Bioscience, San Jose, CA) and transfected with 1 μg plasmid DNA using Lipofectamine 3000 according to the manufacturer’s 
protocol, in triplicates. After 16-24h, the medium was removed and cells were rinsed 
with 1 ml PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2KPO4, 1.8 mM KH2PO4) and 
incubated with 600 l serum-free DMEM for 48h. Conditioned medium was 
harvested, cell debris removed by centrifugation, and equal volumes subjected to 
SDS-PAGE under reducing conditions. The cell layer was washed with 1 ml PBS and 
cells were lysed in 0.1% NP40, 0.01% SDS, and 0.05% Na-deoxycholate in PBS. Cell 
lysates were incubated for 5 min with rotation end-over-end and cleared by 
centrifugation (5 min, > 20,000 g, 4 °C) 
 
 Western blotting 3.6.7
 
Equal volumes of conditioned medium and cell lysate were subjected to 7.5% SDS-
PAGE under reducing conditions. Proteins were transferred onto PVDF membranes 
114 
 
(Immobilon F, EMD Millipore, Billerica, MA) for 1.5 h at 70 V at 4 °C in 25 mM Tris, 
192 mM glycine and 20% methanol buffer. The membrane was blocked with 5% 
(w/v) milk in TBS (10 mM Tris-HCl, pH 7.2, 0.15 mM NaCl) for 1 h at room 
temperature, and anti-Myc (9E10, Invitrogen, 1:500) was diluted in 5% (w/v) milk 
in TBS +  0.1% Tween 20 (TBST) and incubated overnight at 4 °C. Membranes were 
washed three times with TBST for 5 min at room temperature and incubated with 
fluorophore-labeled IRDye goat-anti-mouse secondary antibody (1:10,000) (LI-COR 
Biosciences, Lincoln, NE) in 5% milk in TBST + 0.01% SDS for 1 h at room 
temperature. Membranes were washed three times with TBST for 5 min, one time 
with TBS for 5 min at room temperature, and were scanned wet on an Odyssey CLx 
scanner (LI-COR Biosciences, Lincoln, NE). The fluorescent signal was quantified 
using the Image Studio software. 
3.7 Results 
 
WMS in this family segregated in an autosomal recessive pattern, with five of eight 
siblings affected (Figure 3.9). Their unaffected parents are from a small rural 
community and shared the same surname prior to marriage. Clinical features in 
affected patients were first described in a 1983 case report (Johnson and Bosanquet, 
1983). The clinical data encompassing a 40-year period is provided in Table 3.2 and 
is summarized below.  
The oldest affected individual (Figure 3.9: II-2) first presented with myopia at 
13 years of age. He had iridodonesis with lenses displaced nasally and 
microspherophakia. Shallow anterior chambers were noted. Peripheral iridectomies 
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were recommended for this individual, but he died accidentally at age 30 before any 
treatment took place. Other family members were examined. His younger sister 
(Figure 3.9: II-3) had high myopia at age 10 with increasing intraocular pressures 
(IOP). She subsequently received bilateral peripheral iridectomies at age 28. She was 
short of stature and somewhat stocky; her approximate height was 149 cm in her 
early thirties. She did not report any difficulties with range of motion in her fingers 
or wrists. Visually, her hands appeared wider and stubbier than normal, with a 
lateral curvature of both fifth fingers at the distal interphalangeal joints. Like her 
older brother, she had microspherophakia with both lenses positioned only slightly 
nasally (subluxation). At age 48 she had a right retinal tear and detachment repair, 
and at ages 50 and 51 she had cataract extractions with placement of intraocular 
lenses (IOL).  At 58 years old, she had extraction of a dislocated left IOL, pars plana 
vitrectomy and lens replacement with an anterior chamber IOL. Her visual acuity 
returned to R: 20/25+ and L: 20/40- following surgery. There were no cardiac 
abnormalities reported. She did not report any new stiffness in her joints, 
specifically when asked about her ability to make a closed fist. Her younger brother 
(Figure 3.9: II-5) was also assessed. He developed a traumatic cataract from a 
penetrating right eye injury at age 2. He had microspherophakia identified by age 
18, and subsequently had a left peripheral iridectomy due to increasing IOP at age 
26. In his late twenties, his build was short and stocky, with an approximate height 
of 157 cm. He had a normal echocardiogram and no cardiac abnormalities. His hands 
and feet were broad, and fingers and toes appeared short and wide. He had a 
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shortened first metacarpal on his left hand. There was no restriction of joint 
mobility. He had cataract extraction and replacement with an anterior chamber IOL 
(age 49). Coincidentally, at age 53 he had colon cancer with several polyps, as did his 
mother. The next sibling was a brother (Figure 3.9: II-6), who had myopia and 
microspherophakia noted at age 14. Marked iridodonesis was observed, and due to 
increasing IOP, he had bilateral peripheral iridectomies at age 22. His approximate 
height was 161 cm in his early twenties. In 1982, hand x-rays demonstrated bilateral 
shortening of the fourth and fifth metacarpals. He died at age 43. Finally, the 
youngest brother (Figure 3.9: II-8) was first examined at age 10. He had myopia with 
spherical lenses. As his bilateral IOPs increased, he was first treated with timolol, 
and then had bilateral peripheral iridectomies at age 17. He has cognitive 
impairment (thought to be from birth trauma) and had a heart murmur as a child. 
He was diagnosed with pulmonary stenosis by a cardiologist (grade I/VI) at this 
time. A subsequent echocardiogram performed in 1982 indicated the pulmonary 
stenosis was not clinically significant. Roentgenograms in 1982 demonstrated 
shortening of the first, fourth and fifth metacarpals in both hands. He was 156 cm in 
his mid-to late teens. On physical examination, his hands were described as short 
and spade-like with stubby fingers, and with prominent knuckles and knobby 
interphalangeal joints. He had markedly decreased limitation of movement in wrists 
and shoulders, and a winged scapula.  
To further explore evidence of variable hand dysmorphology in this family, 
we obtained new roentgenograms of the hands of two affected family members (II-3, 
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II-5) and compared them against their unaffected sibling (II-4) (Figure 3.10A). 
Visually, both hands of the affected siblings (II-5 and II-3) appear smaller compared 
to their unaffected sibling (II-4). The hands of sibling II-3 are broader and stubbier 
compared to sibling II-5. Metacarpophalangeal measurements were taken to allow 
comparison between affected and unaffected siblings, while adjusting for expected 
lengths given respective sexes and ages (Poznanski, 1984). Analysis of the 
measurements revealed key differences between affected and unaffected siblings 
(Figure 3.10B). For example, in the affected siblings, most metacarpophalangeal 
measurements were 2.0 standard deviations or more below expected values, as 
compared to their unaffected sibling, whose metacarpophalangeal measurements 
were mostly one standard deviation or less. She had relative bilateral shortening of 
the first proximal phalanx, with her right hand 1.5 standard deviations below, and 
left hand 1.8 standard deviations below normal. Hands in the affected siblings were 
overall smaller (2.0 standard deviations) and showed evidence of unilateral 
shortening. In II-5, the first metacarpal bone of the left hand was unilaterally shorter 
than expected by seven standard deviations. Moreover, his affected sister (II-3) also 
showed unilaterally shortened metacarpals, as she had shortening of her right first 
proximal phalanx, measuring 5.3 standard deviations below the mean. These intra-
familial differences were interesting given the shared genetic etiology in this family. 
 
Whole exome sequencing analysis and homozygosity mapping were then 
pursued. Germline DNAs of two affected family members (II-5 and II-3) were 
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Table 3.3 Longitudinal clinical features of autosomal WMS family from 
Newfoundland. Table created by the author. 
Clinical Feature II-2 II-3 II-5 II-6 II-8 
Relationship 
Oldest 
brother 
Sister Brother Brother Youngest Brother 
Early myopia Yes (13) high myopia (10) Yes (glasses in 1972) yes (14) Yes (10) 
Microspherophakia yes (13) yes (10) Yes (18) yes (14) 
spherophakia 
(10) 
Ectopia lentis 
Iridodonesi
s (13), both 
lenses 
displaced 
nasally (13) 
both lenses displaced only 
slightly nasally (10), 
iridodonesis (2000) 
Subluxation of left lens (2003) 
Iridodonesis 
(14) 
None 
Increasing IOPs yes (13) yes (10) yes (26) yes (22) Yes (10) 
Glaucoma No BL (28) (1981) Secondary glaucoma (1981) No No 
Cataracts No Yes. Extractions (50, 51) 
Traumatic cataract right eye (2),  
cataract extraction (L) (49) 
No No 
Other eye features No 
right retinal tear and 
detachment (48), 
Penetrating right eye injury (2) No No 
Height 160cm 149 cm (~30s) 157 cm (late 20s) 161 cm 
155.5 (mid to late 
teens) 
Hand dysmorphia NA 
BL lateral curvature of 5th 
fingers, 2016: unilateral right 
first proximal phalanx 
shortened -5.3 SD 
shortened first metacarpal on his 
left hand (1983? 26?) (2016: L 
first metacarpal shortened -7 SD) 
relative BL 
shortening  
fourth and 
fifth 
metacarpals 
(1982) 
BL shortening of 
the first, fourth 
and fifth 
metacarpals 
Joint stiffness No None (30s) None 
limited 
movement 
wrists, 
shoulders 
None 
Cardiac 
defects 
NR NR Normal echocardiogram No 
Murmur (as 
child), Grade I/IV 
(age), Pulmonary 
stenosis, 
echocardiogram 
reveals no 
significant 
stenosis (1982) 
Treatments 
Advised to have PI 
but died accidentally 
Timolol, BL PI (28), Left 
lensectomy, pars plana 
vitrectomy and lens 
replacement with an anterior 
chamber IOL (58) (Timoptic 
and truspot BID for glaucoma 
2000) 
Timolol (1981), Left peripheral 
irridectomy (26), anterior 
chamber IOL (49) 
BL PI (22) 
(1982) 
Timolol 
ineffective, BL Pis 
(17) (1982) 
Other 
systemic 
features 
No 
Endometriosis 1978-1979, L 
ovarian cystectomy (1979), 
total Hysterectomy (1980), 
BL salpingectomy with L 
oophorectomy 
CRC and polyps (53) 
Winged 
scapula 
None 
Notes d.30 NA NA d. 43 
Cognitive 
impairment (birth 
trauma) 
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Figure 3.10  The variable metacarpophalangeal measurements between affected and unaffected siblings in a 
Newfoundland family with WMS. Figure created by the author. 
Part A: Bilateral hand xray comparison of unaffected sibling (II-4; left panel) with two affected siblings (II-5; center panel, II-3; 
right panel) which demonstrates hands that visually appear small and stubbier compared to their unaffected sibling, which 
also display shortened metacarpal bones. Part B: Metacarpophalangeal measurements identify bilateral shortening of hands in 
affected patients compared to unaffected siblings and demonstrate the metacarpals which are much shorter than expected for 
their relative age and sex.  II-5 displays a left 1st metacarpal bone that is markedly shortened, and while II-3 displayed a 
shorted right 1st proximal phalanx. 
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sequenced and achieved a mean coverage of 140X and 144X, respectively. Our 
variant filtering protocol yielded 262 (II-5) and 234 (II-3) rare coding variants, 
respectively. Of these variants, 120 were shared between both affected individuals. 
Homozygosity mapping revealed a homozygous missense variant (NM_139057.3: 
c.3068G>A: p.C1023Y) in ADAMTS17, being the only variant passing filtering criteria 
and also residing within a region of homozygosity (approximately 2.5 Mb in length), 
common to both affected siblings (Figure 3.11). The global minor allele frequency 
(MAF) of this variant (c.3068G>A: p.C1023Y) was extremely low -- as it has not 
reported in the two largest population databases available (GnomAD and ExAC 
browser), with one hit in the NHLBI Exome Variant Server database. The variant is 
heterozygous in 1 out of 4173 alleles (0.0237%) in an African American population, 
with combined MAF estimated at 0.0081% in the NHLBI database.  
Familial co-segregation analysis corroborated a pathogenic role for this 
variant, as the variant segregated as expected for fully penetrant autosomal 
recessive inheritance (Figure 3.12). This variant was homozygous in affected family 
members (II-3, II-5, II-8), and was not carried in their unaffected sibling (II-4). Their 
mother (I-2) was heterozygous, and their father, now deceased, was an obligate 
carrier. Screening of 300 ethnically matched population control alleles from NL 
demonstrated this variant is not a common in this isolated population, given that no 
additional alleles were detected in controls.  
Bioinformatics analysis identified that the missense ADAMTS17 variant alters 
a cysteine residue in a region predicted to have high evolutionary conservation  
121 
 
 
 
Figure 3.11 Whole exome sequencing and homozygosity mapping of affected 
WMS patients (II-5, II-3) identifies novel ADAMTS17 variant. Figure created by 
the author. 
Part A demonstrates the homozygosity mapping on Chromosome 15. Gray bars 
indicate regions of homozygosity in each patient. Stars indicate the position of the 
homozygous (c. 3068G>A, p. C1023Y) variant in ADAMTS17 in both patients which is 
located within an identical region of approximately 2.5Mb, shared in both patients. 
Part B shows sequence reads of the rare homozygous missense variant in 
ADAMTS17, which was the only variant identified by whole exome sequencing that 
was within the region of homozygosity. 
122 
 
 
Figure 3.12 In silico analysis of the homozygous ADAMTS17 variant (c. 
3068G>A, p. C1023Y) in Newfoundland family and position of the variant 
within the ADAMTS17 gene compared to other previously reported pathogenic 
variants. Figure created by the author. 
Segregation of p.C1023Y is shown in the pedigree at the top of the figure and the 
chromatogram traces on the right. The segregation of the variant fits with an 
autosomal recessive inheritance as all affected individuals are homozygous for the 
variant. Their unaffected sibling (II-4) was a non-carrier, while their unaffected 
mother (I-2) was a heterozygous carrier. Their father (I-1) was deceased at the time 
of the study, but did not manifest WMS features, and is assumed to be an obligate 
carrier. All currently reported ADAMTS17 variants discovered in WMS patients are 
shown in the diagram at the bottom of the figure. The p.C1023Y variant is the first 
disease-causing missense variant identified in this gene date. Alternating colors 
demonstrate different domains in ADAMTS17. The p.C1023Y variant localizes to the 
5th thrombospondin-1 repeat domain. 
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according to the GERP algorithm (score: 5.23). Additional in silico tools predicted 
highly deleterious consequences for this substitution. The SIFT algorithm predicted 
damaging effects (score: 0), as well as PolyPhen-2 (score= 1.0), MutationTaster  
(score: 0.99) and CADD (32) -- each indicating a highly deleterious effect. The 
variant encodes a residue that lies within a thrombospondin type 1 domain of 
ADAMTS17, a domain spanning amino acids 976-1028 of the polypeptide (Figure 
3.12).  
Finally, the impact of ADAMTS17 p.C1023Y mutants on secretion of the 
enzyme into the extracellular matrix was observed in HEK293T cells (Figure 3.13).  
ADAMTS17 fluorescence intensity was measured in cell lysates compared to cell 
media (i.e. secreted protein). Because ADAMTS17 undergoes autoproteolysis, wild 
type constructs with (+) or without (-) the p.C1023Y mutation were compared to 
either wildtype ADAMTS17 or constructs concomittently carrying an active site 
mutation (p. E390A), which decreases autoproteolysis and increases the amount of 
fluorescent protein detectable. Figure 13.3 demonstrates that HEK293T cells (both 
wildtype or p.E390A constructs) with the p.C1023Y mutation (+) or without the 
mutation (-) have comparable expression levels in the cell lysate, as expected. For 
ADAMTS17 p.C1023Y (+) mutants in the cell medium however, there is a significant 
reduction of secreted protein in both wildtype (p= 0.0012) and p.E390A constructs 
(p= 0.00014), indicating that the p.C1023Y mutation results in a significant 
reduction of secretion compared to cells without the mutation.  
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Figure 3.13 Fluorescence intensities of ADAMTS17 p.C1023Y mutants (+) and 
wild type (-) in ADAMTS17 (TS17) and active site mutant (TS17E390A) 
constructs transfected in HEK293T cells. Figure created by the author. 
 
 
Panel A shows fluorescence intensities for each construct in cell media verses lysate. 
There is a noticeable decrease in intensities in cell media in p.C1023Y mutants 
compared to wildtype in both constructs. No difference in intensities are seen in the 
cell lysate. Panel B demonstrates quantification of fluorescence intensities 
normalized to ADAMTS17 in the lysate. The decrease in intensities for ADAMTS17 in 
the p.C1023Y mutants is significant in the media (p=0.0012 in TS17 and p=0.00014 
in TS17E390A). 
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3.8 Discussion 
 
Here, we conducted a clinical and molecular investigation of autosomal recessive 
WMS. The clinical features of this rare disorder in a large family including five 
affected individuals are summarized in Table 3.4. Family members were short of 
stature, with a mean height of 156.5 cm, and heights ranging from 149 cm to 161cm.  
All had myopia within a few years after their first decade of life. There was 
microspherophakia in four siblings, while the eyes of the youngest sibling (II-8) 
appeared spherophakic but not small. Ectopia lentis was seen in 4/5 siblings, with 
iridodonesis or partial subluxation seen in II-2, II-3 and II-6 by their early teens, 
while II-5 experienced a left lens subluxation at age 48. The youngest did not have 
any ectopic lenses when last followed. Intraocular pressures steadily increased in all 
five siblings, who each received treatment in their early teens to mid-twenties. Two 
siblings (II-3, II-5) developed glaucoma while the others did not, and both first 
developed cataracts at age 50 and 49 respectively.  There was no joint stiffness seen 
in four of the affected siblings, while one sibling (II-6) had limited movement of the 
wrists and shoulders, and a winged scapula. No siblings had clinically significant 
cardiovascular defects, although II-8 had a grade I/VI systolic ejection murmur that 
was not significant based on echocardiogram.  
With the exception of II-2, for whom there was no data available, all siblings 
displayed some degree of dysmorphia in their hands. Sibling II-3 had bilateral 
curvature of the fifth fingers and a first proximal phalanx on the right hand that was 
5.3 standard deviations below expected for her age and sex. There was also 
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dysmorphia seen in the hands of II-5, who had shortening of the first metacarpal on 
the left hand (by seven standard deviations). The metacarpophalangeal lengths in 
the hands of these two siblings were noticeably shorter compared to their 
unaffected sibling. Whereas most of the measurements in these two affected siblings 
were between two and three standard deviations below the mean for their age and 
sex, the measurements for their unaffected sibling (II-4) were mostly between zero 
and one standard deviation below the mean ( variant (NM_139057.3: c.3068G>A: 
p.C1023Y) in ADAMTS17, being the only variant passing filtering criteria 
Figure 3.10B). We did not obtain new roetnograms for affected siblings II-6 and 
II-8, but prior roetnograms revealed bilateral shortening of the fourth and fifth 
metacarpals in II-6 and of the first, fourth and fifth metacarpals in II-8. These 
observations reveal that WMS patients with pathogenic ADAMTS17 variants can 
display variable features of hand dysmorphia.  
We next investigated the genetic etiology of WMS in the family. DNA from 
two affected siblings (II-5 and II-3) was examined using whole exome sequencing 
and homozygosity mapping (Figure 3.14), which revealed the missense ADAMTS17 
variant (NM_139057.3: c.3068G>A: p.C1023Y) as the only rare homozygous variant 
present in a shared region of homozygosity in the two siblings. The variant 
segregated as expected for an autosomal recessive disorder, with their other 
affected sibling (II-8) being a homozygous carrier and their unaffected sibling (II-4) 
having two wild type alleles (Figure 3.15). Their mother (I-2) was a heterozygous 
carrier of the p.C1023Y variant, while their deceased unaffected father is an obligate 
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carrier who is presumed to be heterozygous. This variant is rare in the general 
population databases, with 0.0081% MAF in the NHLBI exome variant server, and it 
is predicted to be highly deleterious with a CADD score of 32. The variant was 
absent in a further 300 control alleles from the NL population, demonstrating that it 
is not common to this population. Interestingly, while others have reported 
frameshift, nonsense and splice variants in ADAMTS17, the variant identified in our 
study is the first pathogenic missense variant (Figure 3.16).  
The p.C1023Y point mutation localizes to the fifth thrombospondin repeat-1 
domain of ADAMTS17. To functionally characterize the impact of this variant, we 
introduced p.C1023Y into full-length ADAMTS17 (TS17) and transfected plasmids 
into HEK293T cells (Figure 3.17). Additionally, given that ADAMTS17 is auto 
proteolytic once secreted into cell media, we also introduced the p.C1023Y variant 
into a proteolytically inactive ADAMTS17 construct (ADAMTS17E390A) to prevent 
degradation of ADAMTS17. Compared to wildtype, the p.C1023Y mutants are 
significantly reduced in both the full length ADAMTS17 (p= 0.0012) and TS17E390A 
constructs (p= 0.00014) in the cell media. There were no differences seen in the cell 
lysate between wild type and ADAMTS17, indicating that the protein is expressed 
but not secreted. It is likely that the change from cysteine to tyrosine causes 
instability in conformation of the protein. 
Taken together, we have identified and characterized a novel rare 
homozygous missense mutation (p.C1023Y) in ADAMTS17, which segregates in a 
large family from an isolated region of NL. The clinical information demonstrated 
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here shows the variable and intrafamilial variability in the phenotypic 
manifestations of this rare disorder, with dysmorphic hand features prominent in 
family members, who for the most part lack joint stiffness. The finding of this 
pathogenic variant may provide others with a genetic diagnosis for WMS, and our 
investigation provides unique insights into the molecular pathogenesis of 
ADAMTS17, identifying a key residue within the fifth thrombospondin-1 repeat 
domain. 
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Chapter 4.  Candidate Gene Screening Reveals Evidence GALNT12 is a Moderate 
Penetrance Gene for Colorectal Cancer within the Newfoundland & Labrador 
Population. 
 
4.1 Background: Hereditary Colorectal Cancer 
 
Neoplasia of the large intestine or rectum (i.e. colorectal cancer), also known as CRC, 
is a common malignancy affecting 1 in 13 Canadians (Canadian Cancer Society’s 
Advisory Committee on Cancer Statistics, 2015). CRC is the second leading cause of 
cancer death among Canadian men and the third leading cause among Canadian 
women. NL has the highest age and sex-standardized incidence of CRC reported in 
Canada, with 435.8 new cases per 100,000. NL has the highest familial incidence of 
CRC reported anywhere in the world (Green et al., 2007).  
Three molecular pathways define the pathogenesis of CRC (Colussi et al., 
2013). These are the chromosomal instability (CIN), DNA mismatch repair (MMR) 
and CpG island methylator phenotype (CIMP) pathways. CRC evolves through the 
adenoma-to-carcinoma sequence, whereby premalignant lesions (i.e. polyps) 
acquire somatic mutations and eventually progress to invasive malignancy over a 
period of 5-10 years (Kuipers et al., 2015) (Figure 4.1). This growth phase is often 
subclinical, with as few as only 39% of CRCs detected early (Hudson et al., 2012). As 
the second most commonly diagnosed cancer in Canada, the five-year survival rate is 
64% (Canadian Cancer Society’s Advisory Committee on Cancer Statistics, 2015).  
Despite this, CRC is highly preventable. Early detection and polypectomy is 
effective in reducing CRC incidence. For example, colonoscopic surveillance has been 
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Figure 4.1 The adenoma to carcinoma sequence and common genetic 
abberations in each respective CRC molecular pathway. Reprinted from Ahnen 
(2011) with copyright permission. 
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shown to decrease CRC-related mortality by up to 33% (Pan et al., 2016; Stanesby 
and Jenkins, 2017). Therefore, CRC screening programs are effective to prevent this 
disease. The Canadian Task Force on Preventative Health Care therefore 
recommends individuals at population-level risk begin CRC screening at age 50 
(Canadian Task Force on Preventive Health Care, 2016). Preventative initiatives 
such as screening colonoscopies can therefore offer patients options including 
prophylactic bowel resection. Individuals with strong genetic predisposition for CRC 
may develop CRC earlier than age 50. For this reason, discovery of genetic markers 
is useful to prioritize these patients for targeted CRC screening (Lech et al., 2016). 
Identification of novel genetic markers is therefore a high priority within the 
scientific community (Gonzalez-Pons and Cruz-Correa, 2015).  The heritability of 
CRC can be up to 35% based on twin studies (Jiao et al., 2014). CRC is a genetically 
heterogeneous disease, which demonstrates both multifactorial and monogenic 
etiology. Up to 30% of CRC cases have a familial component (i.e. more than one first 
degree relative affected), caused by a number of genetic and environmental factors 
(Jasperson et al., 2010) (Figure 4.2). Hahn and others describe the model of genetic 
heterogeneity in CRC, which examines relative risk against allele frequency (Hahn et 
al., 2016; Manolio et al., 2009) (Figure 4.3). Under this model, there are rare and 
highly penetrant risk factors, as well as common low penetrance risk factors. 
Experimental methodologies such as whole exome sequencing have been beneficial 
in studying and identification of several highly penetrant monogenic disorders, 
while genome wide association studies have been successful in identifying 
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Figure 4.2 The overall proportion of hereditary, sporadic and familial CRC 
cases. Reprinted from Hahn et al., (2016) with copyright permission. 
 
Abbreviations: MUTYH-associated polyposis (MAP), polymerase proofreading-
associated polyposis (PPAP), NTHL1-associated polyposis (NAP), Peutz-Jeghers 
Syndrome (PJS), juvenile polyposis coli (JPC).  
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Figure 4.3 A model of the genetic heterogeneity of CRC, with variant 
penetrance as a function of allele frequency. Reprinted from Hahn et al. (2016) 
with copyright permission. 
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common low penetrance risk factors. Meanwhile, the rare-to-low frequency 
moderate penetrance risk factors have been largely unexplored in CRC. 
In terms of the highly penetrant genes, about 5-10% of CRC cases are 
ascribed to the monogenic hereditary CRC disorders (Brandão and Lage, 2015).  FAP 
is a hereditary CRC syndrome accounting for less than 1% of all cases (Half et al., 
2009). CRC is inherited in an autosomal dominant manner in FAP. Mutations in 
Adenomatous Polyposis Coli (APC) are responsible for FAP. Moreover, there is 
significant allelic heterogeneity, with more than 1000 pathogenic APC variants 
described (Rivera et al., 2011). In FAP, CRC arises through the CIN pathway, due to 
disrupted signalling of the WNT pathway.  APC is a tumor suppressor gene that 
regulates WNT signalling. The APC protein regulates degradation of β-catenin -- a 
transcription factor that induces proliferation of intestinal cell crypts (Benchabane 
and Ahmed, 2009). Clinically, FAP manifests with hundreds to thousands of polyps 
throughout the gastrointestinal tract by the second decade of life. The extracolonic 
manifestations of FAP include papillary thyroid carcinoma, hepatoblastoma, 
congenital hypertrophy of the retinal pigment epithelium, osteomas and desmoids, 
the occurance and frequency of these being correlated with mutations position along 
the APC gene (Groen et al., 2008). FAP is almost fully penetrant, with CRC by age 40 
if no screening and management is in place (Malloy & Smith, 2015). Finally, 
pathogenic variants in APC can also cause a clinical variant known as attenuated 
FAP, which is characterized by fewer adenomatous polyps in the gastrointestinal 
tract (i.e. 10-100).  
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Juvenile Polyposis Syndrome (JPS) is another autosomal dominant hereditary 
CRC syndrome caused by mutations affecting WNT signalling. JPS accounts for a 
small fraction of CRC cases (<1%) and arises by pathogenic variants in SMAD4 and 
BMPR1a (Larsen Haidle & Howe, 1993). The term juvenile refers to the histological 
appearance of the polyps. The diagnostic criteria for JPS are satisfied if a proband is 
found with any of the following: 5 or more juvenile polyps in colon or rectum or any 
number of juvenile polyps with positive family history; multiple juvenile polyps in 
both upper and lower gastrointestinal tract; or a known pathogenic variant in 
SMAD4 or BMPR1a. As the above indicates, JPS can manifest with juvenile polyps as 
part of JPS, however it may also manifest as JPS with hereditary hemorrhagic 
telangactasia (HHT) (i.e. extracolonic features). These extracolonic manifestations in 
JPS with HHT include epistaxis, arteriovenous malformations, digital clubbing and 
telangiectases (Williams et al., 2012). There is a significantly increased risk for CRC 
in JPS patients, having a cumulative lifetime risk of 38.7% and mean age of CRC 
diagnosis at 43.9 years (Brosens et al., 2007).  While JPS with HHT is limited to 
patients with SMAD4 variants, a separate syndrome from JPS is also seen in some 
patients with BMPR1a variants – called hereditary mixed polyposis syndrome 
(O’Riordan et al., 2010). The latter is characterized by different polyp types with 
mixed adenomatous, hyperplastic, and atypical juvenile histologies -- and can also be 
caused by the GREM1 gene (Lieberman et al., 2017). 
Peutz-Jeghers syndrome (PJS) is another rare autosomal dominant disorder 
characterized by pathogenic variants in STK11 and characterized by polyps of 
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hamartomatous histology. STK11 acts as a tumor suppressor gene restricting cell 
division. Hamartomatous polyps develop in 90% of PJS patients, and are found 
throughout the gastrointestinal tract – predominantly in the small and large 
intestine, but are also found in the stomach and urinary tract (Anaya et al., 2008). 
PJS patients are at a high lifetime risk (93%) for developing CRC and extracolonic 
cancers, including pancreatic, gastric, esophageal, uterine, ovarian, lung, testicular 
and breast cancers. The presence of mucocutaneous pigmentations seen around the 
buccal mucosa and anus can help establish the diagnosis of PJS.   
Another autosomal dominant CRC disorder is Serrated Polyposis Syndrome, 
again accounting for a small fraction of overall CRC cases. Polyps in this syndrome 
are of the hyperplastic histological type. The genetic basis for this syndrome is not 
yet known (Hassan et al., 2016). Several criteria exist according to the WHO and can 
include 1.) at least 5 serrated polyps (two of which are >1 cm) located proximal to 
the sigmoid colon or 2.) any type of serrated polyp proximal to the sigmoid colon if 
there is family history of this disorder in a first degree relative, or 3.) twenty or more 
serrated polyps throughout the colon (Snover et al., 2010). The risk for CRC in 
Serrated Polyposis Syndrome is lower than for other hereditary CRCs (IJspeert et al., 
2017).  
MUTYH-associated polyposis (MAP) is the only autosomal recessive CRC 
syndrome and is a highly penetrant, but rare cause of CRC (Poulsen & Bisgaard, 
2008). Biallelic mutations in this base-excision repair gene predispose to CRC and a 
number of extracolonic manifestations including: duodenal adenomas, osteoma, 
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desmoid cysts, esophageal cancer, thyroid cancer, breast cancer, uterine cancer, 
leukemia, dental cysts, tooth agenesis, basal cell carcinoma and congenital 
hypertrophy of the retinal pigment epithelium and leukemia and uterine cancer, 
among others. Patients may develop tens to hundreds or even thousands of 
adenomas in the gastrointestinal tract, and therefore the clinic manifestation can 
mirror attenuated FAP or FAP. MAP is highly penetrant, with 80% of biallelic 
carriers developing CRC by age 70, and mean diagnosis of CRC being age 48 (Kantor 
et al., 2017). 
 HNPCC is a large umbrella term and accounts for the largest percentage of 
hereditary CRC cases (10%) (Kohlmann and Gruber, 1993). In HNPCC, patients 
develop markedly fewer adenomas than the polyposis colon cancers, but have 
significant risk for CRC. Most individuals with HNPCC fulfill the Amsterdam Criteria 
1 (AC-1): which requires that there are three or more CRC cases in a family, with at 
least one being a first degree relative of the others. The age of diagnosis in one 
patient must be under age 50, and CRC cases must be histologically confirmed where 
possible. Finally, CRC must be found in two or more successive generations. The AC-
1 provides a starting point to identify families suspicious for a genetic predisposition 
to CRC. From there, two possibilities exist: either patients have inherited defects in 
MMR genes (i.e. Lynch Syndrome or LS) or they meet AC-1 but have no detectable 
MMR defects (i.e. FCCTX).  
LS is an autosomal dominant hereditary CRC disorder accounting for a 
relatively large percentage of CRC cases overall (~10%). Four genes are implicated 
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in LS and these are all involved in the MMR pathway. These genes are MLH1, MSH2, 
MSH6 and PMS2. In addition to sequencing these genes, suggestive deficits in MMR 
genes can be identified by testing tumors for microsatellite instability (MSI) and for 
intact MMR proteins tested by immunohistochemistry. High MSI (MSH-H) indicates 
defective DNA repair processes; thus the tumors of LS patients have MSI and MMR 
defects, which will usually prompt sequencing of the MMR genes in patient DNA. LS 
patients have a high risk for CRC (52-82% of patients, with mean diagnosis between 
44-61 years) in addition to a high risk of extracolonic cancers, most notably 
endometrial and ovarian cancers. Other extracolonic malignancies include gastric, 
urogenital, brain, biliary tract, pancreatic, skin and small bowel cancers (Bansidhar, 
2012).  
 Families that meet AC-1, but have microsatellite stable (MSS) tumors, and 
intact MMR proteins by immunohistochemistry, with no germline mutations in 
either APC or MMR genes, are grouped into the heterogeneous classification called 
FCCTX. The mean age of CRC in FCCTX patients is later then for LS (i.e. 57 years 
compared to 43-45 for LS) (Dominguez-Valentin et al., 2015). It is likely that 
numerous genes are responsible for this heterogeneous cluster of families with a 
strong predisposition of unknown etiology, and therefore FCCTX families are an 
ideal group for investigation of novel genetic causes for CRC. Several putative FCCTX 
genes have been identified over the years, including BMPR1a (Nieminen et al., 2011), 
SEMA4A (Schulz et al., 2014), RPS20 (Nieminen et al., 2014) and POLE/POLD1 (Palles 
et al., 2013). Among these candidates (and numerous others identified in early onset 
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non-FCCTX families), only mutations in the POLE gene have been widely replicated 
and classified into a new category (polymerase proofreading associated polyposis) 
(Church, 2014).  Thus, while the investigation of FCCTX families has yielded a 
number of putative candidate genes -- many have not been globally replicated and 
therefore represent CRC syndromes for a very limited number of families or are 
false assertions. An FCCTX study of the NL population (N=30 unrelated FCCTX 
probands) screened BMPR1a for pathogenic variants, and did not identify any 
mutations of this gene in FCCTX (Evans et al., 2017). Furthermore, whole exome 
sequencing of 30 NL FCCTX probands has not identified pathogenic variants in any 
of the aforementioned candidate FCCTX genes (Woods & Evans, unpublished data).  
The paucity of novel CRC genes that describe CRC in the way that APC or the 
MMR genes do has led some to hypothesize that the highest impact genes or those 
that are easiest to find (i.e. the low hanging fruit) have all been discovered. 
Furthermore, what remain of any highly penetrant CRC predisposition genes are 
likely to explain only a small proportion of families within geographically restricted 
regions. Indeed, a key article by Chubb et al., studied 8000 early onset familial CRCs 
(one of the largest early onset CRC cohorts assembled to date), and demonstrated 
that no highly penetrant CRC genes could be found (Chubb et al., 2016). As well, the 
authors found that at most only 16% of familial CRCs could be ascribed to the known  
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Figure 4.4 Contribution of rare variants in known CRC predisposition genes in 
a cohort of early onset familial CRCs. Reprinted from Chubb et al., (2016) with 
copyright permission. 
 
Variants were considered under different categories. Class 1 indicates disruptive 
variants (nonsense and frameshift). Class 2 indicates variants predicted to be 
damaging using in silico tools. Class 3+ indicates all non-synonymous variants and 
previously reported pathogenic splice variants according to InSight or Clinvar. 
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highly penetrant genes in this cohort of early onset familial CRC cases (Figure 4.4). 
Given that their study had over 80% statistical power to detect a novel highly 
penetrant CRC predisposition gene, the authors hypothesized that the likelihood of 
finding a global novel high penetrance predisposition gene is becoming increasingly 
unlikely. 
As we appear to be confronted with a paucity of global high penetrance CRC 
predisposition genes, the research community has identified a significant knowledge 
gap in our understanding of rare moderate penetrance alleles, which could 
represent a significant fraction of the missing heritability (Valle, 2017). In recent 
years, limited examples of moderate penetrance variants have been recognized in 
the typically highly penetrant known CRC genes, reflecting the increasing reality that 
clinicians face with respect to CRC variant interpretation (Tung et al., 2016).  
To that end, GALNT12 is a candidate CRC gene which has been investigated 
for several years. Several genetic linkage and association studies demonstrated the 
existence of a CRC-susceptibility locus spanning 9q22.32-31.1(Gray-McGuire et al., 
2010; Skoglund et al., 2006; Wiesner et al., 2003) and GALNT12 resides in the 6.5cM 
critical interval (markers D9S1851-D9S277) within this region (Kemp et al., 2006).  
Guda et al. first studied GALNT12 as a candidate CRC predisposition gene (Guda et 
al., 2009). Sequencing 30 MSS CRC cell lines, they identified two somatic variants in 
GALNT12, which showed significantly reduced enzyme activity compared to 
wildtype protein (Figure 4.5).  Further sequencing in germline DNAs of 272 CRC  
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Figure 4.5 Somatic GALNT12 variants identified in 30 MSS CRC cell lines. 
Reprinted from Guda et al., (2009) with copyright permission. 
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Figure 4.6 Functional assay of germline GALNT12 variants in CRC cases and 
controls. Reprinted from Guda et al., (2009) with copyright permission. 
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patients compared to 192 controls revealed six additional GALNT12 variants 
exclusive to CRC cases – which all had significantly impaired GALNT12 enzyme 
activity compared to wildtype, and variants that were exclusive to controls (Figure 
4.6).  
Following this discovery of inactivating somatic and germline GALNT12 
variants in MSS CRC cells and patient germline DNAs, Clarke and colleagues then 
investigated GALNT12 in a clinic-based discovery cohort of 118 probands from NL 
with strong CRC predisposition (Clarke et al., 2012).  Clarke and colleagues 
identified four instances of rare and deleterious GALNT12 variants in germline DNA 
of probands from high risk CRC families (Table 4.1). They found three unrelated 
families harboring the p.D303N variant (also previously seen in the Guda et al. 
study), and one family harboring the p.Y396C variant. The p.D303N segregated in 
two CRC families, with a SISA prediction that suggested a 1.56% probability that co-
segregation occurred by chance (Figure 4.7). Following the Clarke et al. study, Seguí 
and coauthors screened 103 FCCTX cases for GALNT12 variants but did not identify 
any candidates for further pursuit (Seguí et al., 2014). There remains continued 
clinical uncertainty as to the relevance of GALNT12. Previously, this was considered 
a moderate penetrance CRC predisposition gene in early versions of the National 
Comprehensive Cancer Network (NCCN) guidelines, however this status was 
removed in the 2017 edition over uncertainty and paucity in the highly penetrant 
FCCTX families (Benson et al., 2017) . Additional analyses are required to further 
understand the impact of rare variation in this gene. 
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Table 4.1 Rare GALNT12 Variants in clinic-based cohort of 118 high-risk NL CRC cases. Reprinted from Clarke et al., 
(2012) with copyright permission. 
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Figure 4.7 Segregation of GALNT12 p.D303N variant in two NL families from high risk CRC cohort. Reprinted from 
Clarke et al., (2012) with copyright permission. 
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4.2 Study Aims & Objectives 
 
GALNT12 is a strong candidate for CRC susceptibility based on prior genetic and 
functional studies. In this study, it was hypothesized GALNT12 is a moderate 
penetrance gene for CRC susceptibility, explained by rare and deleterious variants. 
The aim of the study was to examine a large population-based cohort (N=479) of 
cases from NL (i.e. Newfoundland Colorectal Cancer Registry – NFCCR), to identify 
rare GALNT12 variants, and replicate the findings of the prior Clarke et al. study.  
 Therein, the main study objective was to screen all coding and splice regions 
of GALNT12 (i.e. 10 exons and intronic boundaries) using Sanger sequencing on 479 
germline DNA samples. After annotating and interpreting rare genetic variants, the 
second objective was to identify the frequency of these variants in population-
matched NL controls (N=400). The final objective was to characterize the functional 
consequence of the rare variants identified in this study.  
 
4.3 Author Contributions 
 
The following is an original research article peer-reviewed and published in Human 
Mutation (Evans DR et al., 2018).  As first author of the study, I was responsible for 
identification and interpretation of GALNT12 variants via sequencing of NFCCR cases 
and NL controls. I prepared the manuscript and interpreted key study findings. The 
Sanger DNA sequencing was a large-scale endeavor that required clean sequence 
traces of the entire length of the GALNT12 coding region and splice junctions. 
Therefore, among cases and controls, the effort encompassed sequencing across all 
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coding bases and splice boundaries of N=5500 exons. Amanda T. Dohey and Erica C. 
Clarke assisted in primary data collection and sequenced approximately one third of 
exons in the NFCCR cases. Amy E. Powell and Julia J. Pennell assisted in primary data 
collection of 150 control samples (N=150 exons) in the G-C rich exon 1. JSG assisted 
in manuscript review and provided clinical data for GALNT12 carriers. MOW 
conceived of the study and assisted in all aspects of genetic, molecular and clinical 
interpretation during the study. MOW supervised and revised the manuscript, and is 
the corresponding author.  
Functional characterization of GALNT12 candidate variants (i.e. enzyme 
assay) was achieved through collaboration with investigators at the Case Western 
Reserve University Comprehensive Cancer Center (Ohio, United States). In this 
regard, Srividya Venkitachalam (SV) was a key contributor and co-first author of the 
study.  SV, Lakshmeswari Ravi (LaR) and Erina Quinn (EQ) performed cloning, 
mutagenesis and recombinant protein purification. SV and Leslie Reveredo (LeR) 
performed functional assays. SV assisted in the methods section and later critically 
reviewed the manuscript. Thomas A. Gerkin (TAG) and Kishore Guda (KG) 
supervised all enzyme assays. KG supervised the collection of molecular and genetic 
data, contributed to study design and assisted in preparation and review of the 
manuscript. All authors read and approved the final manuscript.  
 Co-authors had the following academic affiliations during the work described 
in this chapter. MOW, JSG, JJP and ATD were affiliated with the Discipline of Genetics, 
Faculty of Medicine, Memorial University of Newfoundland, St. John’s, NL A1B 3V6 
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Canada. SV, KG, EQ and LaR were affiliated with Division of General Medical 
Sciences-Oncology, Case Comprehensive Cancer Center, Case Western Reserve 
University School of Medicine, Cleveland OH 44106, U.S.A. LeR was affiliated with 
Department of Chemistry, Case Western Reserve University, Cleveland OH 44106, 
U.S.A. TAG was affiliated with Department of Chemistry, Case Western Reserve 
University, Cleveland OH 44106, U.S.A as well as the Departments of Pediatrics & 
Biochemistry, Case Western Reserve University, School of Medicine, Cleveland OH 
44106, U.S.A. 
4.4 Abstract 
 
Characterizing moderate penetrance susceptibility genes is an emerging frontier in 
CRC research. GALNT12 is a strong candidate CRC-susceptibility gene given previous 
linkage and association studies, and inactivating somatic and germline alleles in CRC 
patients. Previously, we found rare segregating germline GALNT12 variants in a 
clinic-based cohort (N=118) with predisposition for CRC. Here, we screened a new 
population-based cohort of incident CRC cases (N=479) for rare (MAF ≤1%) 
deleterious germline GALNT12 variants. GALNT12 screening revealed 8 rare 
variants. Two variants were previously described (p.Asp303Asn, p.Arg297Trp), and 
additionally, we found 6 other rare variants: five missense (p.His101Gln, 
p.Ile142Thr, p.Glu239Gln, p.Thr286Met, p.Val290Phe) and one putative splice-
altering variant (c.732-8 G>T). Sequencing of population-matched controls (N=400) 
revealed higher burden of these variants in CRC cases compared to healthy controls 
(P=0.0381). We then functionally characterized the impact of these substitutions on 
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GALNT12 enzyme activity using in vitro-derived peptide substrates. Three of the 
newly identified GALNT12 missense variants (p.His101Gln, p.Ile142Thr, 
p.Val290Phe) demonstrated a marked loss (>2-fold reduction) of enzymatic activity 
compared to wild-type (P≤0.05), while p.Glu239Gln exhibited a ~2-fold reduction in 
activity (P=0.077). These findings provide strong, independent evidence for the 
association of GALNT12 defects with CRC-susceptibility; underscoring implications 
for glycosylation pathway defects in CRC.  
4.5 Introduction 
 
Unraveling the genetic predisposition to CRC is a subject of global significance  
(Rafiemanesh et al., 2016; Valle, 2014). Since the elucidation of MMR genes in 
hereditary CRC, the search for new and highly penetrant CRC-susceptibility genes 
has yielded diminishing returns. Indeed, recent studies now postulate that the 
existence of any major high penetrance susceptibility genes, of similar caliber as the 
MMR genes and APC, is unlikely (Chubb et al., 2016). This emphasizes the increasing 
relevance of CRC-susceptibility models that recognize the impact of rare alleles with 
modest effect sizes; which are difficult to detect by classic approaches such as 
genome-wide association and family-based linkage studies, yet could explain a 
sizeable fraction of the missing heritability in CRC (Hahn et al., 2016; Manolio et al., 
2009). The genetic investigation of large and well-characterized patient cohorts is a 
useful way to identify moderate penetrance variants. While high penetrance variants 
are often the most clinically actionable, CRC screening guidelines now recognize 
moderate penetrance alleles in APC, CHEK2 and MUTYH (Tung et al., 2016). With the 
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genetic architecture of CRC becoming increasingly apparent, and the role of 
moderate penetrance genes becoming a new focus, this study explores GALNT12 
(MIM #610290, RefSeq: NM_024642.4) as a moderate penetrance gene for CRC 
susceptibility.   
The initiation of mucin-type O-linked glycosylation is governed by the GALNT 
family of enzymes (Brockhausen et al., 2009), and glycosylation plays a vital role in 
regulating key cellular functions including adhesion, migration and immune 
surveillance (Ohtsubo and Marth, 2006). PpGalNAc-T12 (encoded by GALNT12), is 
highly expressed in normal colon tissue and downregulated in colonic cancers (J.M. 
Guo, Chen, Wang, Zhang, & Narimatsu, 2004; J.M. Guo et al., 2002). Aberrant 
glycosylation can impair the normal functioning of lipids and proteins by affecting 
cellular glycan structure (Pinho and Reis, 2015; Stowell et al., 2015) and is a 
hallmark of several different cancers; including CRC (Bergstrom & Xia, 2013; 
Brockhausen, 2006). It is unsurprising, therefore, that genetic and epigenetic defects 
underlying the O-linked pathway are proposed to contribute to CRC pathogenesis 
(Brockhausen, 2006; Brockhausen et al., 2009; Tran and Ten Hagen, 2013).  
Genetic evidence demonstrates that GALNT12 is a candidate CRC-
susceptibility gene; as we and others have identified a CRC-susceptibility locus 
spanning 9q22.32-31.1 (Gray-McGuire et al., 2010; Skoglund et al., 2006; Wiesner et 
al., 2003) and GALNT12 resides in the 6.5cM critical interval (markers D9S1851-
D9S277) within this region (Kemp et al., 2006). Bolstered by functional evidence 
showing that inactivating GALNT12 alleles are over-represented in CRC cell lines 
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(Guda et al., 2009), we previously characterized GALNT12 in a clinic-based discovery 
cohort (N=118) with predilection for CRC, and identified rare and segregating 
GALNT12 alleles in high-risk CRC families (Clarke et al., 2012).  
Here, our aim was to expand the investigation of GALNT12 by screening for 
rare and deleterious alleles in a larger and well-characterized population-based 
cohort of incident CRC cases (N=479) from the province of Newfoundland & 
Labrador (NL). This island of Atlantic Canada harbors unique founder populations of 
predominantly English and Irish descent, and is well-suited for genetic research; 
given geographic and historical isolation (Mannion, 1977), and willingness to 
participate in research studies. With one of the highest reported incidence rates of 
familial CRC in the world (Green et al., 2007), and the highest incidence rate of CRC 
reported in Canada (Canadian Cancer Society’s Advisory Committee on Cancer 
Statistics, 2015), the NL population offers an invaluable opportunity to study the 
genetic etiology of CRC (Rahman et al., 2003; Zhai et al., 2016). This was most 
significantly demonstrated by ‘Family C’, an NL kindred that helped elucidate the 
role of MSH2 in hereditary CRC (Leach et al., 1993).  
To further our investigation into the putative association of GALNT12 defects 
and CRC susceptibility, and leveraging the unique attributes of the NL population, 
we examined the germline DNAs of 479 incident CRC cases from the Newfoundland 
Colorectal Cancer Registry (NFCCR) (Green et al., 2007). Herein, we describe novel 
findings of rare and deleterious GALNT12 alleles in CRC patients, which cluster 
around the glycosyl-transferase domain, and functionally impair this enzyme.   
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4.6 Methods 
 
 Newfoundland Colorectal Cancer Registry and Population-matched 4.6.1
Controls 
 
During the prior NFCCR study, all pathologically confirmed incident CRC cases that 
occurred over a 5-year period (January 1st, 1999- December 31st, 2003), with 
diagnosis under the age of 75, were identified through provincial tumor registries  
(Green et al., 2007). After providing written and informed consent, study 
participants completed family history and risk factor questionnaires and provided 
access to blood samples, tumor tissues, medical records and gave permission for kin 
contact. As well, a cohort of CRC-free population controls was ascertained through 
random digit dialing (Raptis et al., 2007; Wang et al., 2009). After providing written 
and informed consent, population control participants provided family history, 
personal history and diet questionnaires, as well as blood samples for DNA 
extraction.  
Patients of the NFCCR cohort have previously been screened for MMR gene 
variants and MSI status (Woods et al., 2010). MMR gene variants were assessed for 
pathogenicity using the InSiGHT variant database (Thompson et al., 2014). We 
assigned familial CRC risk criteria based on relationship to the proband of each 
family. Risk criteria included in this study were the Amsterdam Criteria-1 (AC-1) 
(Vasen et al., 1991), the Age and Cancer Modified Amsterdam Criteria (ACMAC) 
(Woods et al., 2005), the Revised Bethesda Criteria (Umar et al., 2004), and criteria 
for FCCTX (Lindor, 2009). 
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During the current study, we chose germline DNAs of 479 NFCCR cases and 
400 population-matched CRC-free controls, which then underwent GALNT12 
screening. We were blind to both MMR variant and  microsatellite status during the 
study.  The Health Research Ethics Authority of Newfoundland & Labrador granted 
approval for this study (HREB # 2010.035).  
 
 Sanger DNA Sequencing and Variant Interpretation 4.6.2
 
CRC cases and population controls were sequenced using Sanger sequencing. Primer 
design was followed as per previous studies (Guda et al., 2009) and PCR 
amplification was performed for all 10 exons and intronic boundaries of GALNT12 
(conditions available upon request). The GALNT12 RefSeq (NM_024642.4) and the 
canonical transcript (ENST00000375011.3) were selected using Ensembl genome 
browser, with the GRCh38.p10 reference genome assembly (Zerbino et al., 2018). 
Standard sequencing protocols for automated sequencing on an ABI 3130XL Genetic 
Analyzer (Applied Biosystems by Life Technologies, CA, USA) were followed. 
Sequencing data was then analyzed and interpreted using Sequencing Analysis 5.2 
(Applied Biosystems by Life Technologies, CA, USA) and Sequencher 4.9 (Gene Codes 
Corporation, Michigan, USA).  
 Minor allele frequency (MAF) was assessed using publically available 
databases including: dbSNP (Sherry et al., 2001), the NHLBI exome variant server 
(NHLBI GO Exome Sequencing Project, Seattle, WA; URL 
http://evs.gs.washington.edu/EVS), the ExAC browser and the GnomAD browser 
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(Lek et al., 2016). We calculated the maximum credible allele frequency of a CRC 
variant, and variant penetrance, using GnomAD frequencies (Whiffin et al., 2017) 
(Supp. Methods). A GALNT12 variant MAF threshold of ≤1% in more than one 
population database was used to identify high impact variants. 
For each variant, bioinformatics tools including SIFT (Sim et al., 2012), 
Polyphen-2 (Adzhubei et al., 2013), CADD (Kircher et al., 2014) and REVEL 
(Ioannidis et al., 2016) were used to predict functional consequences of rare 
variants. The putative splice-altering variant was assessed using three programs 
including Spliceman (http://fairbrother.biomed.brown.edu/spliceman/index.cgi), 
Human Splicing Finder (http://www.umd.be/HSF/), and SpliceView 
(http://bioinfo.itb.cnr.it/~webgene/wwwspliceview.html). Further details about 
these tools, including program inputs and settings are provided in Supplementary 
Methods section. We submitted rare GALNT12 variants to the Leiden Open Variation 
Database (LOVD) (www.lovd.nl/GALNT12).  
 Generation of Secreted pIHV Constructs 4.6.3
 
A GALNT12 cDNA fragment excluding the N-terminal transmembrane domain, 
corresponding to amino acids 38-581, was amplified by RT-PCR from RNA of a 
normal control as described previously (Guda et al., 2009). The resulting PCR 
fragments were cloned into pIHV, a modified SV40 promoter-driven pZeoSV2 vector 
(Life Technologies, Carlsbad, CA, USA) that contains an insulin secretion signal to 
direct the secretion of the recombinant protein into the cell culture medium and an 
N-terminal His6 and V5 epitope tags to facilitate purification and detection of the 
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recombinant protein. cDNA fragments encoding mutant GALNT12 (p.His101Gln, 
p.Ile142Thr, p.Glu239Gln, p.Thr286Met, p.Val290Phe, p.Arg297Trp, p.Asp303Asn 
and p.Tyr396Cys) were generated by site directed mutagenesis (QuikChange 
Lightning, Agilent Technologies, Santa Clara, CA, USA). 
 Cell lines and DNA Transfection  4.6.4
 
SW480 cells were obtained from American Type Culture Collection (ATCC) in 2012, 
tested for authenticity using short tandem repeat genotyping at least 3 months prior 
to experimental assessments, and screened periodically for mycoplasma 
contamination using the MycoAlert mycoplasma detection kit (Lonza, Basel, 
Switzerland). Transfection was performed using Lipofectamine 2000 (Life 
Technologies, Carlsbad, CA, USA) according to standard protocol. Briefly, 106 SW480 
cells were plated per 100-mm dish 24 hours before transfection, and incubated in 
5% CO2 at 37 °C overnight. 4 g of plasmid DNA was used per 100-mm dish.  
 Recombinant Protein Purification 4.6.5
 
The cell monolayers were washed twice with ice-cold PBS and incubated with lysis 
buffer (50mMTris, pH 7.5/150mMNaCl/1mMCaCl2/1mM MnCl2/EDTA-free 
protease inhibitor pellets/ 0.3% CHAPS) for 15 min on ice. After scraping, the lysates 
were clarified by centrifugation for 15 min at maximal speed. The recombinant 
protein was immunoprecipitated from the lysates using anti-V5 agarose beads 
(Sigma-Aldrich, St Louis, MO, USA), and subsequently washed with wash buffer 
(50mMTris, pH 7.5/150mMNaCl/1mMCaCl2/1mM MnCl2/EDTA-free protease 
164 
 
inhibitor pellets).   
 Western Blot Analysis 4.6.6
 
After immunoprecipitation, 1/10 fraction of the recombinant protein was mixed 
with equal volume of Laemmli sample buffer (Bio-Rad, Hercules, CA, USA) at 95 °C 
for 5 min, and loaded onto a Bis-Tris SDS/4–12% polyacrylamide gel (Life 
Technologies, Carlsbad, CA, USA).  After SDS/PAGE, proteins were transferred onto 
Immobilon-P PVDF membranes (EMD Millipore, Billerica, MA).  Membranes were 
blocked for 1 hr with 5% nonfat milk, and incubated with appropriate dilution of 
mouse anti-V5 antibody conjugated to horseradish peroxidase (Life Technologies, 
Carlsbad, CA, USA) to detect the V5-tagged proteins. Enhanced Chemiluminescence 
Plus (GE Healthcare-BioSciences, Pittsburg, PA, USA) and ImageJ software (NIH, 
Bethesda, MA, USA) were used to detect and quantitate respective protein bands. 
 Enzymatic Assay for GALNT12 Variants 4.6.7
 
Negative control (empty vector), positive control (wild-type GALNT12), and 
missense mutant versions of GALNT12-bound beads were added to transferase-
specific reaction mixtures in 1.5mL Eppendorf microcentrifuge tubes. Transferase-
specific reaction mixtures contained 40 mM sodium cacodylate pH 6.8, 0.32 mM 2-
mercaptoethanol, 0.03% Triton-X 100, 10 mM MnCl2, 1 mM UDP-GalNAc containing 
0.1 uCi of [3H] UDP-GalNAc (American Radiolabeled Chemicals Inc., St. Louis, MO, 
USA), protease inhibitors A and B (Sigma-Aldrich, St Louis, MO, USA) and 1 mM (0.5 
mg/mL) OPT-T12 substrate GAGAYYITPRPGAGA (RS Synthesis, Louisville, KY). Of 
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note, OPT-T12 is an optimal peptide substrate specifically determined for ppGalNAc 
T12 by the Gerken Lab (Gerken et al., 2011) and custom synthesized by RS Synthesis. 
A 10 mmol stock solution of OPT-T12 substrate was prepared by lyophilizing from 
water several times and adjusting to pH 7.4 with dilute NaOH/HCL. Reagent reaction 
mixtures were combined with 100 µL transferase-bound beads to a final reaction 
volume of 250 µL. The pH of the total reaction was adjusted to 6.8 and the mixture 
was agitated at 37°C in a TAITEC shaking Microincubator M-36 to maintain the 
beads in suspension. Following an overnight incubation, reaction mixtures were 
quenched with an equal volume of 250 mM EDTA and frozen for later processing. 
UDP and non-hydrolyzed UDP-GalNAc were removed by passing the sample through 
a column of ~3mL of Dowex 1x8 anion exchange resin (Acros Organics, Thermo 
Fisher Scientific, Pittsburg, PA). Subsequently, eluents were lyophilized, 
reconstituted with water to a final volume of 1ml and passed through G10 columns. 
[3H]-GalNAc incorporation onto the OPT-T12 substrate was determined by 
scintillation counting on a Beckman LS5801 scintillation counter while absorbance 
at 220 nm and 280 nm was measured using a spectrophotometer. Transferase 
activity at each time point was calculated as a ratio of the post-G10 counts to the 
absorbance at 220 nm. Mutant transferase-specific activities were then normalized 
to the WT transferase to yield an approximate relative specific activity of each 
mutant. The specific activities of the wild-type, and each of the GALNT12 mutants, 
were assayed and expressed as the average activity derived from 3 independent 
biological replicates per experimental arm.  
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 Statistical Analyses 4.6.8
 
 Transferase activities of wild-type and mutant GALNT12 proteins were compared 
using a Student’s t-test, with a P value ≤0.05 being considered statistically 
significant. A one-sided Fisher’s exact test was used to compare the frequency of 
GALNT12 variants in CRC cases and population-matched controls, with a P value 
of ≤0.05 considered statistically significant. 
4.7 Results 
 
Germline DNA sequencing of 479 NFCCR cases revealed 21 polymorphisms in 
GALNT12 (Supp. Table S1). Analysis of rare (MAF ≤1%) GALNT12 variants identified 
8 candidates for further study (Table 4.1). Among these were 7 missense variants 
(c.303C>G, p.His101Gln; c.425T>C, p. Ile142Thr; c.715G>C, p.Glu239Gln; c.857C>T, 
p.Thr286Met; c.868G>T, p.Val290Phe; c.889C>T, p.Arg297Trp; c.907G>A, 
p.Asp303Asn) and 1 putative splice-altering variant (c.732-8G>T) ( Figure 4.8) 
GnomAD MAFs ranged from 0.1244% (p.Asp303Asn) (344 alleles) to 0.0004061% 
(p.Glu239Gln) (1 allele). Maximum credible allele frequency was calculated under 
several penetrance models to explore potential disease allele frequency thresholds 
(Appendix Supp Table 6). The 8 candidate GALNT12 variants were sequenced in a 
population-matched CRC-free control cohort (N=400).  Control sequencing revealed 
these 8 variants were over-represented in CRC cases compared to population-
matched CRC-free controls (P = 0.03814), with the p.Asp303Asn and p.Arg297Trp 
variants each found in a single control, respectively (Table 4.1, Appendix 
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Table 4.2 Rare GALNT12 variants identified in a population-based cohort of 479 incident CRC cases from NL. 
Reprinted from Evans et al., (2018) with copyright permission. 
 
 
 
 
 
 
 
 
 
 
 
Legend Abbreviations: SNV (single nucleotide variant); nSNV (nonsynonymous single nucleotide variant); UTR (untranslated region); NFCCR 
(Newfoundland Colorectal Cancer Registry); NL (Newfoundland & Labrador); SIFT (sorting tolerant from intolerant); T (tolerated); D (damaging); 
B (benign); POD (possibly damaging); PRD (probably damaging); NA (not applicable); MAF (minor allele frequency); AC (allele count); dbSNP (the 
single nucleotide polymorphism database) (available at https://www.ncbi.nlm.nih.gov/SNP/) (Assembly GRCh38.p7); rsID (reference SNP cluster 
ID); GnomAD (Genome Aggregation Database) (available at http://gnomad.broadinstitute.org/) (version r2.0.2); CADD (Combined Annotation 
Dependent Depletion); REVEL (Rare Exome Variant Ensemble Learner). Note: RefSeqs used included NM_024642.4; NP_078918.3; NC_000009.12. 
GALNT12 
Variant 
Type 
dbSNP  
rsID 
NFCCR 
Cohort 
GnomAD 
(MAF/AC/Total 
Alleles) 
SIFT  
Polyphen-2 
HumVar  
REVEL CADD 
NL 
Controls 
(CRC-free) 
c.303C>G 
(p.His101Gln) 
SNV rs201926457 1/479 0.0001516/27/178098 0.01 (D) 
0.979 
(PRD) 
0.3301 28.1 0/400 
c.425T>C 
(p.Ile142Thr) 
SNV rs757214097 1/479 NA 0 (D) 
0.998 
(PRD) 
0.76 27.5 0/400 
c.715G>C  
(p.Glu239Gln) 
SNV rs777144221 1/479 0.00008728/17/194766 0.05 (D) 0.99 (PRD) 0.5701 29.6 0/400 
g.98831764G>T 
(c.732-8 G>T) 
intronic/splice 
variant 
rs763682300 1/479 0.000004061/1/246220 NA NA NA 12.18 0/400 
c.857C>T 
(p.Thr286Met) 
SNV rs548915885 1/479 0.00002844/7/246124 0.01 (D) 
0.999 (PR 
D) 
0.36 34 0/400 
c.868G>T 
(p.Val290Phe) 
SNV rs371949942 1/479 0.00009383/26/277090 0 (D) 0.94 (PRD) 0.36 25 0/400 
c.889C>T 
(p.Arg297Trp) 
SNV rs149726976 1/479 0.0002744/76/276924 0 (D) 
0.908 
(POD) 
0.3000 27.3 1/400 
c.907G>A 
(p.Asp303Asn) 
SNV rs145236923 3/479 0.001244/344/276526 0.47 (T) 
0.999 
(PRD) 
0.4000 24.8 1/400 
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 Figure 4.8 Families from the Newfoundland Colorectal Cancer Registry with rare GALNT12 variants. Reprinted from Evans et al., (2018) with copyright permission.  
Ten unrelated families harboring rare GALNT12 alleles were identified in this study. Three families (1220, 1148, 1117) harbored the p.Asp303Asn allele, while the remaining variants 
were each present in probands of a single family. Eight families were MMR proficient and MSS, while two families (1575 and 1595) carried pathogenic MMR gene variants. Symbols: 
squares (males), circles (females), upper quadrant shaded (CRC), lower quadrant shaded (other cancer), grey shaded circle (polyps), diagonal line (deceased), arrow (proband), +/- 
(heterozygous variant). Age of cancer diagnoses are indicated in brackets. RefSeqs: NM_024642.4; NP_078918.3; NC_000009.12.
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Supp Figure 2). Using multiple in silico tools (SIFT, Polyphen, CADD, REVEL), 
consequences of GALNT12 variants were predicted (Table 4.1). Missense variants 
scored deleterious according to CADD, SIFT and Polyphen-2. CADD scores were 
highly deleterious, ranging from 24.8 (p.Asp303Asn) to 34.0 (p.Thr286Met).  
GALNT12 variants clustered within or near the glycosyl-transferase domain 
encoded by GALNT12 (Figure 4.9). Transferase activity of missense variants was 
characterized using an in vitro-derived peptide substrate assay (Figure 4.10). Three 
of the newly identified GALNT12 missense variants (p.His101Gln, p.Ile142Thr, 
p.Val290Phe) demonstrated a marked loss (>2-fold reduction) of enzymatic activity 
compared to the wild-type protein (P ≤ 0.05), while the p.Glu239Gln variant 
exhibited a ~2-fold reduction in enzymatic activity (P =0.077). Additionally, we 
tested the p.Tyr396Cys allele identified in our previous study (Clarke et al., 2012), 
which demonstrated a significant loss in GALNT12 activity (P ≤ 0.05).  
In silico tools (Spliceman, Human Splicing Finder, Spliceview) were used to 
predict consequences of the putative splice-altering variant (c.732-8G>T), as RNA 
was not accessible for this kindred living in a rural and remote area (Appendix 
Section 0 Supplementary Methods). Predictions were discordant, as Spliceman 
predicted high probability of disrupted splicing (L1 81%), whereas Human Splicing 
Finder predicted alteration of an exonic splice silencing site or alternatively no 
effect, while Spliceview predicted no influence on splicing. 
 The 8 rare GALNT12 variants were derived from probands of 10 unrelated 
families, with p.Asp303Asn represented in 3 unrelated families (Figure 4.8). We  
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Figure 4.9 Rare germline variants of GALNT12 identified in CRC patients 
cluster within and around the glycosyl-transferase domain of the protein. 
Reprinted from Evans et al., (2018) with copyright permission. 
Eight rare candidate GALNT12 variants were identified in CRC cases in this study. Six 
out of the eight variants were situated within the glycosyl-transferase domain, while 
two (p.His101Gln, p.Ile142Thr) were located upstream. RefSeqs: NM_024642.4; 
NP_078918.3; NC_000009.12. Reprinted from Evans et al., 2018 with Copyright 
permission. 
 
 
171 
 
 
Figure 4.10 Biochemical characterization of wild-type and mutant GALNT12 
proteins. Reprinted from Evans et al. (2018) with copyright permission. 
Y-axis depicts the enzyme activities of mutant versions of GALNT12, relative to the wild-
type (WT) protein (X-axis).  Error bars represent standard error of the means derived from 
3 independent replicate experiments.  (*) indicates significant difference (P≤0.05) in 
enzyme activity of respective mutant GALNT12 as compared to the WT protein, estimated 
by one-tailed Student’s t-test.  Shown below the graph is a representative Western blot 
image demonstrating protein expression of wild-type and mutant versions of GALNT12 in 
SW480 cells transfected with respective cDNA constructs. The p.Tyr396Cys GALNT12 
variant was identified in our previous clinical cohort-based study (Clarke et al., 2012) and 
was included in this in vitro enzyme assay to test its enzymatic potential. 
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proceeded with familial co-segregation analysis to assess penetrance. DNA was not 
available for segregation analysis in 9 out of 10 families, and many relatives were 
deceased at the time of study. Segregation was tested in Family 1117 (Figure 4.8), as 
DNA was available for two distant CRC-affected relatives of the proband (first 
cousins once removed). Neither carried the p.Asp303Asn variant, and it is unclear 
whether the proband’s risk for CRC derives from the paternal or maternal lineages. 
Our limited co-segregation analysis was therefore inconclusive, but not supportive 
of p.Asp303Asn segregation (Appendix Supp Figure 3). Given the limited DNA 
available for segregation analysis, we estimated the penetrance (Minikel et al., 2016; 
Whiffin et al., 2017) under different assumptions for the NL population (Appendix 
Section 0 Supplementary Methods). We observed evidence of moderate penetrance 
for these GALNT12 variants (Appendix Section Supp Table 7).  
Table 2 shows the clinical and molecular characteristics of CRC probands 
carrying the rare GALNT12 variants. The age of proband CRC diagnosis ranged from 
43-72 years. Patients of the NFCCR cohort were screened for MMR defects or MSI 
during prior studies (Woods et al., 2010), and during this study, we had no a priori 
knowledge of patient MMR status. We found that the majority of probands with rare 
GALNT12 variants (8 out of 10) were MSS and MMR proficient. Probands from two 
families (Figure 4.8: 1575, 1595) harbored pathogenic (InSiGHT class 5) MMR gene 
variants with high tumor MSI-H (Table 4.3). Finally, we assessed risk of genetic 
predisposition for CRC in all families using established risk criteria. Two families 
(Figure 1: 1595, 1541) fulfilled the AC-1 (Vasen et al., 1991). Of these two AC-1 
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Table 4.3 Clinical and pathological characteristics of Newfoundland Colorectal Cancer Registry patients 
harboring rare candidate GALNT12 variants. Reprinted from Evans et al., (2018) with copyright permission. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend: High microsatellite instability (MSI-H), microsatellite stable (MSS), immunohistochemistry (IHC), mismatch repair (MMR). Risk Criteria: Familial 
colorectal cancer type X (FCCTX), Revised Bethesda Criteria (Bethesda), Age and Cancer Modified Amsterdam Criteria (ACMAC). RefSeqs used include 
NM_024642.4; NP_078918.3; NC_000009.12.
Patient Family Variant 
Age of 
diagnosis 
Tumor location 
Microsatellite 
stability 
MMR protein 
IHC 
MMR variants Risk criteria 
III-1 1575 
c.303C>G; 
p.His101Gln 
43 Rectum MSI-H 
MSH6 
deficient 
MSH6:  
c.3514dupA;  
Arg1172Lysfs*5 
Bethesda 
II-1 1769 
c.425T>C; 
p.Ile142Thr 
58 Transverse MSS Intact Negative NA 
III-5 1863 
c.715G>C; 
p.Glu239Gln 
59 Rectum MSS Intact Negative Bethesda 
III-2 1541 
g.98831764G>T; 
c.732-8 G>T 
51 Transverse MSS Intact Negative 
AC-1,FCCTX, 
ACMAC, 
Bethesda 
III-1 1595 
c.857C>T; 
p.Thr286Met 
60 Descending MSI-H 
MLH1 
deficient 
MLH1: c.793C>T; 
p.His264Leufs*2 
AC-1, ACMAC, 
Bethesda 
II-1 2287 
c.868G>T; 
p.Val290Phe 
64 Rectum MSS Intact Negative NA 
III-2 1543 
c.889C>T; 
Arg297Trp 
72 Ascending MSS Intact Negative NA 
III-1 1148 
c.907G>A; 
p.Asp303Asn 
72 Cecum MSS Intact Negative NA 
IV-1 1220 
c.907G>A; 
p.Asp303Asn 
59 Descending MSS Intact Negative NA 
III-12 1148 
c.907G>A; 
p.Asp303Asn 
60 Sigmoid MSS Intact Negative Bethesda 
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families, the proband of Family 1595 was MSI-H with MLH1 deficient, whereas the 
proband of Family 1541 was MSS and MMR proficient; meeting criteria for FCCTX. A 
total of five families met the Revised Bethesda Criteria (Umar et al., 2004). Two were 
the AC-1 families described above, and of the remaining three, one was MSI-H and 
MSH6 deficient, while two families were MSS and MMR intact. 
 
4.8 Discussion 
 
Here, we screened a population-based cohort of 479 incident CRC cases, identifying 
8 rare GALNT12 variants (Table 4.1). We observed a higher burden of these variants 
in CRC cases compared to population-matched CRC-free controls (P ≤ 0.05). Multiple 
in silico tools (CADD, SIFT and Polyphen-2) predicted these missense variants are 
deleterious (Table 4.1), and variants clustered within or near the functionally 
relevant glycosyl-transferase domain (Figure 4.9). Transferase assays revealed 
GALNT12 mutants demonstrate a marked reduction of enzyme activity compared to 
wild-type (Figure 4.10).   
To explore GALNT12 variation in this study, we chose a rare variant MAF 
threshold of ≤1%. This allowed us to assess rare variants under reduced penetrance, 
and consider potential for NL founder effects. Recently, Whiffin et al proposed a 
strategy that leverages allele frequencies available in large population databases to 
assess ‘maximum credible allele frequencies’ (Whiffin et al., 2017). Predicted 
maximum credible allele frequencies for CRC variants in NL are shown under 
different models of penetrance in Appendix Supp Table 6. For example, under 50% 
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penetrance, we estimated a MAF of no greater than 0.00997%, or 37 GnomAD alleles 
(See Appendix B, Supplementary Methods). This analysis however, does not 
consider the potential for genetic drift in our founder population. During the 
analysis, we also noted a limitation, as the most common known pathogenic CRC 
variant in NL, a founder variant in MSH2 (p.Val265_Gln314del), greatly exceeds our 
calculated maximum credible allele frequencies, with a GnomAD MAF of 1.125% 
(330 alleles out of 29,332 total alleles; 18 homozygotes). This pathogenic variant is 
known to cause CRC in multiple families around the world, and explains up to 71% 
of CRC caused by MSH2 in NL (Woods et al., 2010). This finding likely arises from a 
very high number of false positive calls, due to low sequence complexity in this 
region; highlighting a confounding variable in using these large databases, which 
rely on next-generation DNA sequencing technology. We advocate for a cautious 
approach to relying on expected frequencies as a sole indicator of pathogenicity. 
Ultimately, we observed that a majority of GALNT12 variants identified in this study 
were well below 0.02% global MAF.  
Bioinformatic tools (SIFT, Polyphen-2) are well-established for predicting 
consequences of genetic variation (Dong et al., 2015). SIFT assumes variation within 
evolutionarily conserved regions is more likely to impact protein function (Sim et al., 
2012), while Polyphen-2 considers sequence-based, phylogenetic and structural 
features to predict consequences (Adzhubei et al., 2013). We observed agreement 
between SIFT and Polyphen-2 in predicting deleterious consequences for GALNT12 
missense variants (Table 4.1). The sole exception was p.Asp303Asn; which SIFT 
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predicted ‘tolerated’ while Polyphen-2 predicted ‘probably damaging’. A limitation 
of these tools is that they cannot predict intronic variation. Newer ensemble 
prediction tools such as CADD and REVEL are gaining favor since they incorporate 
weighted estimates using multiple in silico tools, trained on machine-learning 
algorithms, to assist in variant interpretation (Ioannidis et al., 2016; Kircher et al., 
2014). CADD scores have demonstrated clinical utility for interpreting MMR variants 
in a manually-curated dataset from InSiGHT (van der Velde et al., 2015).  We 
observed highly deleterious CADD scores (24.8-34.0) for all GALNT12 missense 
variants (Table 4.2). REVEL scores predicted two GALNT12 variants (p.Ile142Thr, 
p.Glu239Gln) are deleterious (score >0.5); thus CADD and REVEL were not 
concordant. Though both tools have merits, they are limited by circular errors that 
arise from benchmarking datasets (Grimm et al., 2015). Overall, rare missense 
GALNT12 variants were predicted deleterious according to three programs -- CADD, 
SIFT and Polyphen-2. Since these deleterious variants clustered around the glycosyl-
transferase domain (Figure 4.9), we postulated that assaying enzyme activity might 
further delineate any consequences of these variants.  
Accordingly, we characterized mutant enzyme activities using an in-vitro 
peptide derived assay (Figure 4.10). We observed that GALNT12 mutants showed a ≥ 2-fold reduction of enzyme activity in 7 of the variants (including the previously 
identified p.Tyr396Cys), with five mutants (p.His101Gln, p.Ile142Thr, p.Val290Phe, 
p.Arg297Trp, p.Tyr396Cys) reaching the threshold for statistical significance (P≤0.05). Moreover, GALNT12 expression was consistently higher in mutants 
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compared to wild-type, which demonstrated the lowest protein expression (Figure 
4.10). This observation suggests our assay is likely to underestimate the reduction of 
enzyme activity in seen in mutants. The consistent differences in GALNT12 
expression could result from a compensatory mechanism arising from altered 
protein stability. Taken together, our enzymatic assays provided corroborating 
evidence for the deleterious effects of GALNT12 variants.  
Due to our ascertainment method (incident cases), were not able to pursue 
familial co-segregation analysis for most GALNT12 variants in this study; given that 
additional DNAs were not available for 9 out of 10 families. We tested segregation of 
p.Asp303Asn in Family 1117 (Figure 4.8). The results did not support segregation, 
though pedigree structure and limited DNA sample numbers rendered the analysis 
inconclusive (Appendix Supp Figure 3). Recently, Whiffin et al.  proposed a strategy 
to estimate variant penetrance using allele frequencies in large population 
databases (Minikel et al., 2016; Whiffin et al., 2017). Using prevalence of CRC in NL 
and lifetime CRC risk in Canada (See Appendix B, Supplementary Methods), we 
estimated penetrance of GALNT12 variants (Appendix Supp Table 7), and found in 
silico evidence for moderate penetrance. While these in silico estimates provide a 
broad estimate of penetrance (orders of magnitude), confounding factors include 
population stratification and sampling variance, especially for very low frequency 
alleles in the databases. While encouraging, a formal assessment of penetrance for 
GALNT12 variants remains an important avenue for future work, and argues for 
pursuing these variants in CRC families from diverse populations. 
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The tumor characteristics and molecular profiles of probands harboring 
GALNT12 variants are shown in  Table 4.3. Without a priori knowledge of MMR or 
MSI status, we observed most probands with a rare GALNT12 variant (8 out of 10) 
were MSS with MMR stable. Two probands (Figure 4.8: 1575, 1595) concomitantly 
carried one GALNT12 variant (p.His101Gln or p.Thr286Met) with a pathogenic 
(InSiGHT class 5) MMR variant (MSH6; NM_000179.2: p.Arg1172Lysfs*5 or MLH1 
NM_000249.3: p.His264Leufs*2) respectively. GALNT12 p.His101Gln mutants 
demonstrated significant reduction in enzyme activity, while p.Thr286Met mutants 
did not (Figure 4.10). It is difficult to assess the role of these particular GALNT12 
variants, as the concomitant pathogenic MMR variants undoubtedly contributed to 
CRC predisposition in these LS families. One advantage to our population-based 
approach is that we did not exclude these patients with prior known causes of CRC, 
which is an exclusionary bias often present in studies exploring novel genes. 
Regardless, the concomitant MMR variants should not prompt exclusion of these 
GALNT12 variants from further consideration, since this reasoning would overlook 
the influence of ascertainment bias and more importantly, population genetics. For 
example, there are previously documented cases of bilineal inheritance and trans-
heterozygotes for autosomal dominant polycystic kidney disease segregating in the 
NL population (Pei et al., 2001). Likewise, an NL family with autosomal dominant 
sensorineural hearing loss harbors a pathogenic KCNQ4 deletion, with a likely 
second, undiscovered deafness gene in 10 other affected relatives (Abdelfatah et al., 
2013). Thus, two pathogenic variants for a monogenic disease can, and do co-occur 
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within NL families. Further study encompassing a broader array of populations will 
be useful to delineate the role of these GALNT12 variants. Review of the CBioPortal 
database (www.cbioportal.org), an online database for somatic mutations in cancer 
tissues, did not identify these candidate variants in any colon tumors.  
In total, three non-LS families met the Revised Bethesda Criteria, with one 
family meeting criteria for FCCTX (Table 4.3). Recently, germline DNA sequencing of 
GALNT12 in a Spanish cohort of 103 FCCTX families failed to identify any rare 
candidate variants in this gene (Seguí et al., 2014). While only 45.6% of families in 
the Seguí et al. (2014) study met AC-1 and were truly FCCTX, the differences 
between this study and ours underscore the importance in recognizing the influence 
of population genetics as well as ascertainment criteria. A negative screening study 
in one population does not refute a role for GALNT12 in CRC.  
Strong arguments exist for a role for GALNT12 in CRC pathogenesis. Genetic 
evidence demonstrates that GALNT12 resides within a CRC susceptibility locus, with 
both rare and functionally deleterious somatic and germline GALNT12 variants 
found in CRC patients (Clarke et al., 2012; Guda et al., 2009). Moreover, GALNT12 is 
selectively expressed in intestinal epithelia and frequently downregulated in CRCs 
(Guo et al., 2002, Guo et al., 2004). Moreover, GALNT12 has been identified as one of 
the key genes facilitating normal morphology and polarization in colon epithelial 
cells (Li et al., 2017). GALNT12 is a key enzyme catalyzing the initiation of mucin 
type O-glycosylation (Bennett et al., 2012); a pathway shown to play a critical role in 
CRC progression (Pinho and Reis, 2015; Stowell et al., 2015). Mice deficient in 
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intestinal mucin-type O-glycans spontaneously develop colitis-associated colon 
cancer due to inflammation resulting from impaired mucin barrier function 
(Bergstrom et al., 2016). Moreover, mice lacking Muc2 spontaneously develop 
adenomas and CRC (Velcich et al., 2002). Finally, recent studies of human 
glycosylation-associated genes from CRC-cell lines have identified candidates that 
are significantly mutated in CRC (Venkitachalam et al., 2016). 
Taken together, our findings suggest a thorough investigation for any 
putative link between GALNT12 and CRC progression is necessary. A broader 
approach for testing rare GALNT12 alleles in diverse populations, and characterizing 
their biological function in pre-clinical animal models may help decipher a role of 
GALNT12 in CRC pathogenesis. The discovery of moderate penetrance genes is an 
important avenue to explain the missing heritability in CRC. Although challenging, 
the characterization of these genes is poised to impart novel insights for interpreting 
cancer risk moving forward. Screening large and well-characterized cohorts, in 
unique populations, represents an important strategy moving forward.   
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Chapter 5.  Summary 
 
Both collectively and individually, Mendelian disorders place substantial burden on 
human populations (Section 1.5). Genetic discovery of these disorders not only 
unlocks fundamental understanding into pathophysiology, but it imparts clinical 
knowledge that can have substantial impacts on patients, their families, their loved 
ones and even whole communities. The unique architecture of the NL population, a 
culturally and geographically diverse clustering of individuals (Sections 1.7), has 
played a pivotal role in the exploration and genetic discovery of many Mendelian 
disorders (Section 1.8).    
In this work, I employed modern strategies to discover genetic variants for 
three Mendelian disorders in the genetically heterogeneous NL founder populations. 
These disorders included arRP (Chapter 2), WMS (Chapter 3) and CRC (Chapter 4). 
For arRP and WMS, family-based studies using whole exome sequencing 
supplemented by either linkage (arRP) or homozygosity mapping (WMS) were 
employed. Meanwhile, I employed a candidate gene study to investigate GALNT12 in 
a cohort of CRC patients.   
For the WMS and arRP studies, I hypothesized the existence of a highly 
penetrant monogenic cause underlying each disorder, given strong family histories 
and previous genetic knowledge for these conditions. The FORGE Canada 
Consortium provided whole exome sequencing infrastructure and bioinformatic 
support. In both studies, a novel and highly penetrant pathogenic variant not 
previously reported was identified in a causative gene known for each disorder.   
199 
 
With respect to the CRC study, I instead employed a candidate gene approach 
based on emerging evidence surrounding the genetic architecture of CRC (Section 
4.1). Particularly of interest to me was exploring the role of moderate penetrance 
variants in candidate genes for CRC; given the decreasing likelihood that novel 
highly penetrant genes explain familial CRC inheritance, which was eloquently 
described by Chubb and colleagues (Chubb et al., 2016). In addition, a separate 
investigation for novel highly penetrant genes in 30 NL FCCTX probands has not 
identified any obvious candidate CRC genes to date (Woods & Evans, unpublished 
data). The strength of the candidate gene approach in the GALNT12 study rested on 
the unique attributes of the NFCCR cohort.  The candidate gene approach allowed 
me to screen a relatively large series of cases (N=479) as compared to a whole 
exome approach, which would have limited the total number of samples sequenced 
due to financial constraints imposed by the technology.   
While the GALNT12 study differed from the arRP and WMS studies in 
methodology – they each faced similar challenges that highlight the shifting 
paradigm of modern genetic discovery (Section 1.3). Whereas historically, gene 
mapping and Sanger DNA sequencing were the central focus of discovery studies, 
the new paradigm focuses on management of vast quantities of data and 
interpreting variants (Section 1.4). Indeed, assessing variant pathogenicity from a 
plethora of candidates remains a central challenge moving forward. 
 With respect to the arRP study, multiple lines of evidence corroborate the 
pathogenicity of the MERTK deletion (Section 2.8). First, the deletion has never been 
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previously reported worldwide and is thus extremely rare. Second, the effect of the 
deletion is large: it is multi-exonic and removes 201 amino acids from the encoded 
protein, thereby having large impact on the 3D protein structure as compared to the 
effect of a missense variant. Third, prior animal and human studies have indicated a 
role for MERTK in photoreceptor viability. Finally, pedigree structure and 
segregation analysis corroborates pathogenicity in the family, as there was strong 
evidence of genetic linkage to this locus (LOD 4.89) and the deletion segregated as 
expected for autosomal recessive inheritance.  
Likewise, for the WMS study, evidence for pathogenicity of the ADAMTS17 
variant is strong (Section 3.8). Although the variant is previously reported in 
population databases, the frequency is exceedingly rare (0.0081% in NHLBI and 
unreported in GnomAD). As compared to the MERTK deletion, the pathogenicity of 
p.C1023Y in ADAMTS17 was initially more difficult to assess, as it is a missense 
variant. While multiple in silico tools corroborate a likely deleterious effect for the 
variant, further functional assays were necessary to demonstrate pathogenicity. 
Shown in Figure 3.13, these assays demonstrate a marked reduction of ADAMTS17 
secreted to the ECM in cells with p.C1023Y compared to wildtype. This is 
functionally consistent with haploinsufficiency seen in previous studies, given that a 
genotype-phenotype correlation already exists between ADAMTS17 and WMS.  
Taken together, in addition to the homozygosity mapping indicating the shared 2.5 
Mb region in these patients, the evidence for pathogenicity for p.C1023Y is strong.  
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Meanwhile, variant interpretation in the CRC study faced unique challenges. 
Guidelines for interpreting moderate penetrance variants do not yet exist, as few 
studies have attempted to explore this area. Nevertheless, GALNT12 variants were 
assessed with the same rigor as variants for high penetrance. For example, variants 
with very low MAF were pursued for investigation. Next, there was strong a priori 
evidence indicating GALNT12 is implicated in CRC. Furthermore, we predicted 
deleterious consequences for the missense variants using similar tools for high 
penetrance variants, and we bolstered evidence for pathogenicity using functional in 
vitro assays. Familial segregation was not assessed in this study and is therefore a 
missing piece of evidence for assessment of pathogenicity, although segregation for 
a moderate penetrance variant would surely be more nuanced compared to 
segregation for a high penetrance variant. Overall, and in light of the limitations in 
our understanding with respect to moderate penetrance variants, the evidence 
regarding of the rare GALNT12 variants is likely to be moderately supportive for 
pathogenicity as compared to the arRP and WMS studies. Despite this, the impacts of 
the GALNT12 study, if further replicated globally, will be much greater moving 
forward.    
The role of moderately penetrant variants is a largely unexplored area of 
genetics. In hereditary CRC research, and other areas, emphasis has always been on 
the highly penetrant variants -- given that these have the largest clinical impact and 
the associated risks are more easily interpreted for patients. In hereditary CRC, 
Chubb and colleagues demonstrated that although many of the highly penetrant 
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variants are now described (i.e. the “low-hanging fruit”), a large familial fraction of 
CRC remains that is unexplained by the highly penetrant variants. This emphasizes 
the importance of exploring moderate penetrance variants. Both polygenic and 
environmental factors likely contribute to the phenotypic expression of these 
variants. For example, polymorphisms in modifier genes as well as gene-
environment interactions are already known to influence highly penetrant 
pathogenic mutations (Cooper et al., 2013).  
Exploring moderate penetrance variants has been hindered by current 
dogma, which often requires strong familial inheritance patterns to suggest 
causality. It will likely be challenging to demonstrate convincing patterns of 
inheritance for moderate penetrance variants; a problem that will be exacerbated 
for late-onset disorders. Moderate penetrance variants will require higher degrees 
of investigation into molecular and functional mechanisms of pathogenicity, which 
can be resource intensive given the hundreds to thousands of candidate rare 
variants to be explored in a given family. Moreover, the role of genetic background 
on moderate penetrance variants could be a complicating factor. Finally, return of 
results to patients with these variants will remain a significant challenge to 
clinicians until such a time as they are better understood, particularly given the 
uncertainties surrounding prediction of risk for an individual patient and how that 
will influence their health care decisions. Ultimately, our advancing understanding 
of rare genetic variants is poised to dramatically alter the way we manage patients 
in the future, as further insights are gained. 
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5.1 Conclusion 
 
In conclusion, my investigation of three Mendelian disorders expands the collective 
understanding of Mendelian genetics in the NL founder population. From these 
studies, I conclude that the MERTK deletion is a new founder mutation, which 
explains RP in three families from the Northern Peninsula with a shared complex 
ancestry. The pathogenic ADAMTS17 variant explains an exceedingly rare connective 
tissue disorder, and is not carried at high frequency among the healthy NL 
population, but demonstrates the aggregation of rare disorders in the province. The 
high incidence of rare GALNT12 variants in the province could explain a fraction of 
CRC in NL. Further studies will be needed to bolster assessments of pathogenicity 
for GALNT12 variants in other populations. 
5.2 Future Directions  
 
The widespread accessibily of whole exome sequencing has created new 
possibilities for exploring Mendelian disorders. There are likely to be many more 
discoveries on the horizon, given our limited understanding of the genome. Indeed, 
there are still many Mendelian disorders to explore by genetic investigation moving 
forward. Success rates of clinical diagnostic tests are one metric to shed light on our 
collective knowledge of Mendelian disorders, and to highlight how much there 
remains remains unsolved. 
 In 2014, a retrospective study found that traditional approaches (i.e. genetic 
testing) provided a diagnosis for only 46% of patients suspected of having a 
monogenic disorder, while another 53% had clinical findings consistent with a
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Figure 5.1 Estimating the fraction of unexplored candidate genes implicated in Mendelian disorders. Reprinted 
from Chong et al., (2015) with copyright permission. 
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genetic disorder, but no known pathogenic variant detected (Shashi et al., 2014). 
Chong et al. (2015) summarize the work remaining to characterize Mendelian 
disorders with an intuitive analysis of the protein-coding genes in humans (Figure 
5.1). Of their approximated 19,000 genes, at least 15% (2,937 genes in 2014) are 
known to underlie at least 4,163 Mendelian phenotypes. A further 3% (643) of genes 
map to disease regions, but have not yet been identified as causative in Mendelian 
disease. Studies of loss-of-function mutations in mice indicate that up to 30% of 
analogous genes produce embryonic lethality -- and are therefore candidates for 
lethal genetic disorders (Ayadi et al., 2012). What remains is some 52% of genes 
with an unknown impact.  This exemplifies our relatively poor understanding of the 
function of each of these coding genes and of their basic science, as well that 
Mendelian genetics has a strong role to play in this area. Furthermore, this example 
discusses only the genes in protein coding regions, but it is also likely that Mendelian 
disorders are influenced by non-coding and regulatory elements in much more 
complex, poorly understood ways. Therefore, it is likely that many genes remain to 
be studied, with an expanding pool of phenotypes to be characterized.  Advances and 
increasing cost-effectiveness of other MPS technologies, such as whole genome 
sequencing will therefore also be integral to future genetic discoveries. Leveraging 
whole genome sequencing to its maximum potential will first require a broader 
understanding of the non-coding and regulatory elements of the genome.   
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Appendix 
Appendix A: Supporting Materials for arRP Study 
 
Supplementary Methods 
 
The detect this deletion, a custom PCR protocol was optimized using the QIAGEN 
HotStarTaq Plus DNA polymerase assay kit (cat. no. 203605) and dNTPs from the 
QIAGEN PCR grade dNTP set (cat. no. 201913). dNTPs were diluted to a working 
concentration of 2 mM. Primers were diluted to a working concentration of 5 μM. The 25 
μl PCR reaction consisted of 5 μl of Q solution, 2.5 μl of 10x buffer, 2.5 μl of dNTPs, 2.5 
μl of forward primer, 2.5 μl of reverse primer, 0.15 μl of HotStarTaq, 8.85 μl of dH2O and 
1 μl of template DNA at 100 ng/μl. The thermocycler protocol began with a denaturation 
stage of 95 °C for 5 minutes, and was followed by 40 cycles of 95 °C for 5 minutes, 60 
°C for 30 seconds and 72 °C for 2.5 minutes, with a final elongation phase at 72 °C for 10 
minutes. PCR products were purified using an Exo-Sap protocol following 
manufacturer’s specifications (Affimetrix, Santa Clara, CA, USA) with exonuclease I 
(cat. no. 70073Z) and shrimp alkaline phosphatase (cat. no. 78390). Sanger sequencing 
was performed using the BigDye Terminator v.3.1 sequencing kit (cat. no. 4337454) 
under standard protocols for ABI automated direct sequencing on an ABI 3130xl genetic 
analyzer. Raw sequence data was processed using Sequencing Analysis version 5.2 
(Applied Biosystems Inc., Foster City, CA, USA) and sequence chromatograms were 
visualized using Sequencher version 5.0 (Gene Codes Corporation, Ann Arbor, MI, USA. 
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Supplementary Tables & Figures 
 
 
 
Supp Figure 2 Primer design for PCR experiment used to detect wildtype 
individuals from carriers and non-carriers of the MERTK deletion. Reprinted 
from Evans et al., (2017) with copyright permission.  
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Supp Table 1 Summary of clinical features in an arRP family, segregating a large MERTK deletion.Reprinted from 
Evans et al., (2017) with copyright permission. 
Legend: Abbreviations used in this table indicate the following: visual acuity (VA), visual fields (VF), blood vessel (BV), not available 
(NA), features not present (N), features present (Y), left eye (OS), right eye (OD), both eyes (OU), counting fingers (CF), hand 
movements only (HM), light perception only (LP). 
Pedigre
e ID 
Earliest 
VA 
(age) 
Earliest 
VF 
(age) 
First VA 
decline 
(age) 
First VF 
decline 
(age) 
Final 
VA 
(age) 
Final 
VF 
(age) 
Nyctalop
ia (age of 
onset) 
Bone 
spicul
es 
Optic 
disc 
pallor 
BV 
thinnin
g 
Color 
defects 
(age) 
Cataracts 
(age) 
Fundus  
(age) 
V-11 
20/120 
OU (28) 
Central 
field 
loss  
(28) 
HM OU 
(30) 
NA 
HM OU 
(30) 
NA NA Y N N NA 
posterior 
capsular 
OS (35) 
Bronze beaten with granular 
grey-white flecks in 
midperiphery (35). 
VI-10 
20/20 
OU (11) 
tempora
l 
constric
tion OS, 
full field 
OD (11) 
20/25 
OU (12) 
Large 
central 
scotoma 
with 
periphe
ral 
islands 
of vision 
nasally 
(19) 
HM OU 
(37) 
Central 
scotoma
s to 30-
40 
degrees 
OU (37) 
Y 
(always) 
N NA NA 
10/20 
Ishihar
a (11), 
19/20 
ishihar
a (16) 
N 
Albinoid  with marked decrease 
in chorioretinal pigmentation 
(11), salt and pepper appearance 
(12), extensive chorioretinal 
degeneration (37) 
VI-3 NA (7) 
central 
field 
constric
tion (7) 
NA (7) 
legally 
blind 
(12) 
LP OU 
(35) 
LP OU 
(35) 
Y(7) Y Y Y Y(12) N 
Dense bone spicules at equator, 
atrophic area in mid-periphery 
with greyish spots. Macular 
degeneration with small atrophic 
area of choroidal sclerosis. 
VI-9 
20/20 
OD (14) 
full 
fields 
OU (14) 
20/80 
OD, 
20/40 
OS (17) 
Significa
nt 
central 
loss OU, 
periphe
ral 
islands 
nasally 
(20) 
CF OU 
(30) 
CF OU 
(30) 
Y 
(always) 
Y Y Y N N 
Decreased chorioretinal 
pigmentation and stippling  (14) 
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Supp Table 2 Exact linkage analysis of sub-pedigrees, displaying regions with LOD scores > 
1.5 under recessive model of inheritance with 99% penetrance and disease allele 
frequency of 0.1. Reprinted from Evans et al., (2017) with copyright permission. 
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Supp Table 3 Refinement of six linked regions using approximate linkage analysis of the full 
family pedigree. Reprinted from Evans et al., (2017) with copyright permission. 
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Supp Figure 3 The five chromosomes displaying genetic linkage in an arRP 
family. Dashed lines indicate exact calculation using two sub-pedigrees while 
solid lines indicate subsequent approximate linkage calculation using the full 
pedigree. Reprinted from Evans et al., (2017) with copyright permission. 
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Supp Table 4 Candidate CNVs from whole exome data of patient VI-9, 
identified using FishingCNV. Reprinted from (Evans et al., (2017) with 
copyright permission. 
Chromosome Start (bp) End (bp) Log2 fold change p (Holm-Bonferroni) Gene 
16 72821063 72822747 4.0528 4.67E-49 ZFHX3 
2 1.13E+08 1.13E+08 -5.1555 8.67E-29 MERTK 
2 69723117 69723212 0.6295 0.006970274 AAK1 
2 2.17E+08 2.17E+08 0.3469 0.016480077 SMARCAL1 
10 32807344 32832313 0.5602 0.024287399 CCDC7 
12 1.1E+08 1.1E+08 0.7673 0.024453384 GIT2 
11 89914788 89914869 0.5903 0.02890554 NAALAD2 
9 40784477 40784603 0.7005 0.029094809 ZNF658 
1 60106952 60107023 -0.9596 0.036795731 FGGY 
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Appendix B: Supporting Materials for CRC study 
 
Supplementary Methods 
Splice Site Prediction 
 
Three in silico tools were used (Spliceman, Human Splicing Finder and SpliceView) 
to predict consequences for the intronic GALNT12 variant (NM_024642.4: c.732-8 
G>T). Spliceman predicts the likelihood that distant mutations around splice sites 
disrupt splicing. Spliceman was accessed online 
(http://fairbrother.biomed.brown.edu/spliceman/index.cgi) on March 22nd 2018. 
The ‘species’ chosen from the input menu was Human (hg19). Additional options 
(reverse complement, masked splice site positions) were unselected (i.e. per default 
settings). The GALNT12 c.732-8 G>T variant input sequence (tgggt(g/t)ctttc) was 
entered in FASTA format. Spliceman calculates an L1 percentile rank, which predicts 
higher likelihood that a variant disrupts splicing. Using these parameters, Spliceman 
predicts an 83% percentile for the c.732-8 G>T variant disrupting splicing.  
 Next, we calculated splice consequences of c.732-8 G>T using Human Splicing 
Finder (version 3.1, using Ensembl database release 75 of February 2014). We 
accessed the online application (http://www.umd.be/HSF/) on March 22nd 
2018.The ‘automatically select the longest transcript’ option was selected, with the ‘search for SNPs related to the analyzed sequence’ option unselected. Under ‘more 
database options’, the ‘Display all’ and ‘all’ options were selected (as per default) for 
ESE/ESS, gene status and transcript status. For the number of nucleotides 
surrounding the exon (both 5’ and 3’ introns), a value of 100 nucleotides was 
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chosen, with no specifications for 5’ intron or 3’ introns (default settings). For the 
analysis type, we selected ‘splice site analysis’ and chose to identify sequence by 
Ensembl Gene ID. The GALNT12 gene ID was used (ENSG00000119514). From the 
dropdown menu, ‘Exon 4 (186bp) was selected for GALNT12 with 100 nucleotides 
surrounding the exon. A test nucleotide sequence of 386 nucleotides; corresponding 
to exon 4 of GALNT12 with 200 intronic nucleotides on 5’ and 3’ ends, was 
automatically generated. The position of the intronic variant was nucleotide 308, 
with a substitution to ‘T’ selected. Under these conditions, Human Splicing Finder 
predicts two possibilities: alteration of an intronic splice silencer site or, 
alternatively, no impact on splicing.  
SpliceView was then used to assess the intronic variant. The online web 
application (http://bioinfo.itb.cnr.it/~webgene/wwwspliceview.html) was accessed 
on March 22nd 2018. ‘Homo sapiens’ was selected as the organism, with the direct 
strand option selected (default). The input sequence for the GALNT12 variant used 
was: 
ttattggaaggaagacaagaattcacccttgaatttcccaattgtcttcctgctgcccgtctgcataggagagacggatgga
tgtcttgggt(g/t)ctttcagGATCCATGAAGAGGAGTCGGCAGTGGTGTGCCCGGTGATTGATG
TGATCGACTGGAACACCTTCGAATACCTGGGGAACTCCGGGGAGCCCCAGATCGGCGGTT
TCGACTGGAGGCTGGTGTTCACGTGGCACACAGTTCCTGAGAGGGAGAGGATACGGATGC
AATCCCCCGTCGATGTCATCAG. In this sequence, the variant is the 93rd nucleotide. 
No donor splice sites were reported under these conditions. Two splice acceptor 
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sites were predicted for position 69 (score 82) and position 102 (score 83). Thus, 
the variant was not predicted to influence splicing using SpliceView.  
In Silico Variant Prediction 
 
SIFT (v1.03) predictions we assessed using the online tool (http://sift.jcvi.org/) on 
March 22nd 2018. The ‘SIFT Human SNPs’ option was selected, with Homo Sapiens 
GRC37 Ensembl 63 version. Genomic coordinates (GRCh37.p13, annotation release 
105) were entered into the tool for prediction. Polyphen-2 (v2.2.2r398) predictions 
(http://genetics.bwh.harvard.edu/pph2/dokuwiki/start) were performed on March 
22nd 2018. An individual query was ran for each variant, using the Ensembl protein 
identifier (ENST00000375011), with amino acid position and substitution inputs. 
Advanced query options were as per default parameters (hits sorted by identity, no 
mapping to mismatch, structural parameters calculated for first hit only, contacts 
calculated for first hit only, minimum alignment length of 100, minimal identity 
length of 0.5, maximal gap length in alignment of 20, 6 Å threshold for contacts). 
CADD scores (v1.3) were calculated online on March 22nd 2018 
(http://cadd.gs.washington.edu/score). GALNT12 variants were uploaded to the tool 
in VCF format according to dbSNP genomic positions using GRCh37.p13 annotation 
release 105. REVEL scores were obtained from 
(https://sites.google.com/site/revelgenomics/) on March 22nd 2018. The hg19 
GRCh37 human genome build is used for this dataset. The pre-calculated REVEL 
scores were downloaded from 
(https://rothsj06.u.hpc.mssm.edu/revel/revel_segments/) and the region encoding 
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the rare GALNT12 variants was selected (file name: revel_chrom_09_097062310-
115422054.csv.zip).  
Using SIFT, a variant was considered deleterious if it scored below 0.05. For 
Polyphen-2, variants scoring 0.15-0.85 were considered ‘possibly damaging’, and 
variants above 0.85 were considered ‘probably damaging’. CADD scores above 15 
were considered deleterious. Finally, we considered a REVEL score above 0.5 
indicated a deleterious variant, which corresponds to a sensitivity of 0.754 and 
specificity of 0.891. We obtained sensitivity and specificity data from the website 
provided by program authors (https://sites.google.com/site/revelgenomics/). 
Scores were rounded up to the nearest 0.005 to obtain these sensitivity and 
specificity values.   
Variant Penetrance and Maximum Credible Allele Frequencies 
 
We estimated penetrance on March 22nd 2018 using the online application provided 
(http://cardiodb.org/allelefrequencyapp/). The incidence rate of CRC in NL is 112.2 
cases (per 100,000), based on Canadian Cancer Statistics (2013). The population 
size of NL was 526,702 in 2013. To calculate total prevalence of CRC in NL we 
multiplied incidence by average CRC survival rates in NL (6 years). Dividing the total 
population by this value gave an estimated prevalence for CRC in NL of 1 in 148.5 
people. Given that CRC is a late onset disease, we also used estimated lifetime CRC 
risk to estimate penetrance for comparison. Canadian lifetime risk for CRC was used 
as no data for NL lifetime risk was available. Under these assumptions, a total 
prevalence of 1 in 148.5 (estimated NL prevalance) or 1 in 13 (Canadian lifetime risk 
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for CRC) was the input value to estimate variant penetrance using the online 
application. The number of GALNT12 case alleles (from NFCCR screening) was 1 for 
all variants except p.Asp303Asn  (with 3 alleles detected). The total number of case 
alleles was 958. GALNT12 population control allele frequencies were obtained from 
the gnomAD browser (gnomAD r2.0.2) (http://gnomad.broadinstitute.org/).  
To calculate maximum credible allele frequency, we accessed the online 
application (http://cardiodb.org/allelefrequencyapp/) on March 22nd 2018. For 
input values, we used our estimated NL CRC prevalence (1 in 148.5) or the Canadian 
CRC lifetime risk (1 in 13). A previous population-based study (Woods et al., 2010) 
identified MSH2 as the most commonly mutated gene, accounting for 2% of cases 
incident cases sequenced (genetic heterogeneity). The MSH2 p.Val265_Gln314del 
accounted for 71% of cases with MSH2 mutations (10 out of 14 MSH2 mutations). 
Accordingly, genetic ‘heterogeneity’ was set to 0.2 and allelic heterogeneity was set 
to 0.71. We used 0.95 for confidence intervals, and a reference population size of 
277264 (total possible coverage in GnomAD). We tested maximum credible allele 
frequencies under 0.1, 0.5 and 1.0 for prevalence (Supp Table 6).  
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Supp Figure 4 Probands from control families 40994 and 40794 are positive 
for GALNT12 p.Asp303Asn and p.Arg297Trp variants, respectively. CRC-free 
control families are negative for personal and family history of CRC, but can 
include other types. Reprinted from Evans et al., (2018) with copyright 
permission. 
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Supp Figure 5 Segregation testing for the p.Asp303Asn allele in Family 1117. 
Reprinted from Evans et al., (2018) with copyright permission. Additional 
DNAs were only available for family members on an extended branch of this 
family. The p.Asp303Asn allele was not present in extended relatives of the 
proband (first cousins once-removed). RefSeqs: NM_024642.4; NP_078918.3; 
NC_000009.12. 
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Supp Table 5 All GALNT12 variants identified in a cohort of colorectal cancer patients from the Newfoundland 
Colorectal Cancer Registry. Reprinted from Evans et al., (2018) with copyright permission. 
 
Legend 
The RefSeq (NM_024642.4) represents GALNT12 (ENSG00000119514, ENST00000375011.3) nucleotide coding annotation, while NP_078918.3 represents protein annotation for coding variants. Genomic 
coordinates (NC_000009.12) describe intronic and untranslated region (UTR) variants. Abbreviations: SNV (single nucleotide variant); nSNV (nonsynonymous single nucleotide variant); NFCCR 
(Newfoundland Colorectal Cancer Registry); NL (Newfoundland & Labrador); SIFT (sorting tolerant from intolerant); T (tolerated); D (damaging); B (benign); POD (possibly damaging); PRD (probably 
damaging); NA (not applicable); MAF (minor allele frequency); AC (allele count); dbSNP (the single nucleotide polymorphism database) (available at https://www.ncbi.nlm.nih.gov/SNP/) (Assembly 
GRCh38.p7); rsID (reference SNP cluster ID); NHLBI ESP (National Heart, Lung, Blood Institute Exome Sequencing Project) (available at http://evs.gs.washington.edu/EVS/); ExAC (Exome Aggregation 
Consortium) (available at http://exac.broadinstitute.org/) (Version 0.3.1); GnomAD (Genome Aggregation Database) (available at http://gnomad.broadinstitute.org/) (version r2.0.2). Symbols: † (potential 
low quality site in ExAC as coverage fewer than 80% of individuals). Note: allele counts represent total alleles detected among all sub-populations within databases. 
GALNT12  variant Variant Type dbSNP rsID Patients of NFCCR Cohort
dbSNP 1000 
genomes 
(MAF/AC)
NHLBI 
ESP6500 
(MAF/AC)
ExAc (MAF/AC/total 
alleles)
GnomAD 
(MAF/AC/total alleles)
SIFT 
(prediction/median 
information 
content)
Polyphen-2 HumDiv 
(prediction/sensitivity
/specificity)
Polyphen-2 HumVar 
(prediction/sensitivity/
specificity)
c.136G>A (p.Gly46Arg) SNV rs10987768  17/479 0.0781/391 NA 0.0/1/2† 0.03608/923/25584 0.43 (T/2.59) 0.002 (B/0.99/0.30) 0.001 (B/0.99/0.09)
c.303C>G (p.His101Gln) SNV rs201926457 1/479 NA 0.000315/4 0.0005469/8/14628† 0.0001516/27/178098 0.01 (D/2.37) 0.995 (PRD,0.99/0.30) 0.979 (PRD/0.57/0.94)
c.356A>T (p.Glu119Val) SNV rs1137654 68/479 0.0286/143 0.057856/732 0.1102/3334/30262† 0.06002/12993/216482 0 (D/2.37) 0.791 (POD,0.68/0.97) 0.198 (B/0.88/0.73)
g.98823249T>G (c.372-7T>A) intronic/splice 
variant
rs2295923  1/479 0.0156/78 0.000461/6 0.006583/799/121366 0.006497/1801/277198 NA NA NA
c.425T>C (p.Ile142Thr) SNV rs757214097 1/479 NA NA 0.000008237/1/121404 NA 0 (D/2.37) 1 (PRD,0.85/0.93) 0.998 (PRD/0.18/0.98)
c.715G>C  (p.Glu239Gln) SNV rs777144221 1/479 NA NA 0.0000727/2/27512† 0.00008728/17/194766 0.05 (D/2.37) 1 (PRD/0/1) 0.99 (PRD/0.51/0.95)
g.98831764G>T (c.732-8 G>T) intronic/splice 
variant
rs763682300 1/479 NA NA 0.000008252/1/121182 0.000004061/1/246220 NA NA NA
c.781G>A (p.Asp261Asn) SNV rs41306504  3/479 0.0068/34 0.008073/105 0.01142/1385/121322 0.01188/3294/277212 0.18 (T/2.37) 1 (PRD/0/1) 0.968 (PRD/0.61/0.93)
c.857C>T (p.Thr286Met) SNV rs548915885 1/479 0.0004/2 NA 0.0000416/5/120196 0.00002844/7/246124 0.01 (D/2.37) 1 (PRD/0/1) 0.999 (PRD/0.09/0.99)
c.868G>T (p.Val290Phe) SNV rs371949942 1/479 NA 0.000154/2 0.0001003/12/119656 0.00009383/26/277090 0 (D/2.37) 0.991 (PRD/0/1) 0.94 (PRD/0.66/0.91)
c.889C>T (p.Arg297Trp) SNV rs149726976  1/479 0.0004/2 0.000308/4 0.0002725/32/117444 0.0002744/76/276924 0 (D/2.37) 0.999 (PRD/0.71/0.97) 0.908 (POD/0.69/0.9)
c.907G>A (p.Asp303Asn) SNV rs145236923 3/479 0.0008/4 0.000923/12 0.001233/138/111936 0.001244/344/276526 0.47 (T/2.37) 1 (PRD/0/1) 0.999 (PRD/0.09/0.99)
g.98835391G>T intronic variant rs377266726 1/441 NA 0.000077/1 0.00006592/8/121356 0.00007942/22/277012 NA NA NA
c.1131 G>A (p.Leu377=) nSNV rs148125332 1/455 NA 0.000077/1 0.0003047/37/121412 0.0003932/109/277232 NA NA NA
g.98840194G>T intronic variant rs3824516   34/473 0.0543/272 NA NA 0.04641/1436/30942 NA NA NA
c.1392C>G (p.Pro464=) nSNV rs35616709 4/473 0.0018/9 0.004152/54 0.00299/363/121386 0.003071/851/277152 NA NA NA
g.98844267G>T intronic variant  rs1885608     381/473 0.2244/1124 NA NA 0.7413/22920/30918 NA NA NA
c.1497C>T (p.Asn499=) nSNV  rs35632007  1/435 0.0010/5 NA 0.001822/221/121278 0.001786/495/277166 NA NA NA
c.1563C>T (p.Cys521=) nSNV rs143860974     1/435 NA 0.000077/1 0.00005766/7/121408 0.00006856/19/277118 NA NA NA
c.1707G>C (p.Ser569=) nSNV rs2273846  42/470 0.1416/709 0.083192/1082 0.08826/10713/121384 0.08736/24211/277142 NA NA NA
g.98849263A>G 3' UTR rs2273847 39/470 0.1424/713 NA NA 0.09733/3014/30968 NA NA NA
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Supp Table 6. Estimates of maximum credible allele frequencies for a putative CRC variant of variable 
penetrance using NL CRC prevalence or Canadian lifetime CRC risk. Reprinted from Evans et al., (2018) with 
copyright permission. 
 
 
Legend. 
Maximal credible allele frequency estimates as per Whiffin et al. (2017) (available online at http://cardiodb.org/allelefrequencyapp/). 
Abbreviations: NL (Newfoundland & Labrador); CRC (colorectal cancer); GnomAD (Genome Aggregation Database). Further information (genetic 
and allelic heterogeneity estimation) available in Supp. Methods. 
Program Parameters 
Maximum Credible 
Allele 
Frequency/Allele 
Count (Penetrance 
0.1) 
Maximum Credible 
Allele 
Frequency/Allele 
Count (Penetrance 
0.5) 
Maximum Credible 
Allele 
Frequency/Allele 
Count (Penetrance 
1.0) 
NL Prevalence (1 in 148.5) 
0.000478/152 0.0000956/35 0.0000478/20 
Genetic Heterogeneity (0.02) 
Allelic Heterogeneity (0.71) 
Total Possible GnomAD 
alleles (277264) 
Canadian Lifetime Risk (1 in 
13) 
0.00546/1579 0.00109/332 0.000546/172 
Genetic Heterogeneity (0.02) 
Allelic Heterogeneity (0.71) 
Total Possible GnomAD 
alleles (277264) 
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Supp Table 7 Estimated penetrance of GALNT12 variants using GnomAD database. Reprinted from Evans et al., 
(2018) with copyright permission. 
GALNT12 Variant 
NFCCR 
AC 
NFCCR 
total 
alleles 
Population 
database AC 
Population 
database 
total alleles 
Penetrance 
under NL CRC 
prevalence (95% 
CI) 
Penetrance 
under 
Canadian 
lifetime CRC 
risk (95% CI) 
Reduction 
of GALNT12 
transferase 
activity 
c.303C>G (p.His101Gln) 1 958 27 178098 
0.046 (0.0056-
0.38) 
0.53 (0.064-1) S 
c.425T>C (p.Ile142Thr) 1 958 1 121404 0.85 (0.027-1) 1 (0.3-1) S 
c.715G>C (p.Glu239Gln) 1 958 17 194766 
0.081 (0.0089-
0.73) 
0.92 (0.1-1) NS 
g.98831764G>T (c.732-8 G>T) 1 958 1 246220 1 (0.054-1) 1 (0.62-1) S 
c.857C>T (p.Thr286Met) 1 958 7 246124 0.25 (0.021-1) 1 (0.24-1) S 
c.868G>T (p.Val290Phe) 1 958 26 277090 
0.075 (0.009-
0.62) 
0.86 (0.1-1) S 
c.889C>T (p.Arg297Trp) 1 958 76 276924 
0.026 (0.0036-
0.18) 
0.29 (0.041-1) NS 
c.907G>A (p.Asp303Asn) 3 958 344 276526 
0.017 (0.0052-
0.055) 
0.19 (0.059-
0.63) 
NS 
 
Legend 
Penetrance estimates as per Whiffin et al (2017) (available online at http://cardiodb.org/allelefrequencyapp/), and modelled under different the projected NL 
CRC prevalence (1 in 148.5) as well as the Canadian lifetime CRC risk (1 in 13). Population database allele counts and total alleles represent aggregate allele 
frequencies from the gnomAD browser (http://gnomad.broadinstitute.org/), with exception to allele frequencies for the p.Ile142Thr variant (not covered in 
GnomAD), for which ExAC (http://exac.broadinstitute.org/) was used. Abbreviations: NFCCR (Newfoundland Colorectal Cancer Registry); NL (Newfoundland & 
Labrador); CI (Confidence Intervals); S (significant P<0.05); N (not significant, P >0.05); AC (allele count); MAF (minor allele frequency); CRC (colorectal cancer); 
GnomAD (Genome Aggregation Database); ExAC (Exome Aggregation Consortium); RefSeqs: NM_024642.4; NP_078918.3; NC_000009.12. Further information is 
available in Supplementary Methods.
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